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ABSTRACT 
  
Concern with potential toxicity due to the widespread use of unlicensed and 
off label drugs in children has led to regulatory changes aimed to strengthen the 
evidence base for paediatric drugs. This thesis examines paediatric randomised 
controlled trials (RCTs), the highest level of evidence, and assesses them in relation to 
global child health.  
A systematic review was performed using validated methods to search three 
major databases for paediatric RCTs published in 2007. More than 600 RCTs were 
identified involving more than 100,000 children. The RCTs appear to study the 
appropriate clinical areas however few studies involved neonates. The RCTs also 
seem to be of good methodological quality with a mean Jadad score of 3.22.   
The reporting of RCTs that involve both adults and children needs to be 
improved to add to the evidence base of paediatric medicines. More attention is also 
needed on the reporting of safety information from the RCTs to provide useful 
toxicity data. Although severe and moderate ADRs were seen in 25% of the RCTs, 
few RCTs (12%) established safety monitoring committees (SMCs). SMCs are vital 
to ensure patients in paediatric RCTs are protected from toxicity.  
The burden of childhood disease is heaviest in low and middle income 
countries (LMIC). A minority of the RCTs were performed in LMIC, although they 
are increasingly globalised. RCTs conducted in LMIC appear to have lower 
methodological quality, and reported less well on ethical approval and adverse events. 
In conclusion high quality, ethical paediatric RCTs should add to the evidence 
base for paediatric medicines. However they should correspond with the health needs 
of children on a global basis. 
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CHAPTER ONE: INTRODUCTION 
 
 In this thesis I aim to describe drug toxicity experienced by paediatric patients, 
specifically within randomised controlled trials (RCTs). RCTs compare two or more 
treatments in a group of patients differentiated only by chance; thereby allowing any 
arising adverse events to be assessed while having to exclude the minimum amount of 
other (confounding) factors apart from the treatment. The toxicity data has been 
gained from a sample of paediatric RCTs acquired from a broad systematic review of 
RCTs involving children published in 2007.  
The primary goal of this thesis is to contribute to the body of knowledge so 
that toxicity can be reduced in paediatric clinical trials as well as children in general 
who use medicines. To do this, I explore the epidemiological, methodological and 
reporting characteristics of paediatric RCTs in my sample to identify areas where 
improvements can be made. I also aim to relate paediatric RCTs to the burden of 
disease experienced by children worldwide, considering that the burden of childhood 
disease lies overwhelmingly in poor or developing countries.  
 In this chapter, I provide the context of my thesis by reviewing the broader 
scientific literature regarding medicines in children. 
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1. BACKGROUND 
 
 The background for this thesis is that medicines given to children are 
inadequately studied in their own paediatric population groups (Bonati et al. 1999, 
Choonara 2000, Smyth 1999). Clinicians, policy-makers and parents have long 
allowed children to be given medicines based on research conducted in adults and in 
certain cases, on no research at all (Smyth 2001). This situation is now 
overwhelmingly regarded as untenable. Arguments against this extrapolation or 
generalisation have been made on many occasions previously. Essentially children 
cannot be regarded as small adults; they are afflicted with many conditions and 
disease processes that are different to those in adults, particularly in the neonatal or 
infantile period. Drugs may behave differently within children (different 
pharmacokinetics) compared to adults and also cause different effects (different 
pharmacodynamics) in children (Klassen et al. 2008). Paediatric patients require 
specific formulations of drugs and may experience specific adverse effects not 
suffered by adults.  
Thus paediatric patients are in a disadvantaged situation. On one hand, 
insufficient information on the efficacy of drugs can lead to suboptimal treatment. On 
the other hand, without safety data gained from clinical trials, children may be 
exposed to serious unintended harms arising from drug toxicity (Choonara et al. 
1996). 
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µ7KHUDSHXWLF2USKDQV¶ 
This is not a recent concern. In 1968, Shirkey described children as 
µWKHUDSHXWLFRUSKDQV¶DIWHUREVHUYLQJWKDWPDQ\GUXJs carry disclaimers such as  
"Not to be used in children´ 
³ ... is not recommended for use in infants and young children since few 
studies have been conducted in this age group´ 
³ ... clinical studies have been insufficient to establish any recommendations 
for use in infants and children ... should not be given to children". 
Children at the time were deprived of the use of many medications and yet 
many doctors continued to prescribe the restricted medications to children in spite of 
the disclaimers. Shirkey argued that testing of these drugs in the situation of use or 
³E\ RUGHDO´ UDWKHU WKDQ WKH FRQWUROOHG VLWXDWLRQ RI D FOLQLFDO WULDO LV XQODZIXO DQG
would expose children to the risk of toxicity. He noted that drug companies were 
reluctant to bear the costs of clinical trials for the smaller and less profitable paediatric 
market. The regulatory climate discouraged clinicians to pursue clinical drug trials in 
the paediatric population, for example written consent of the participant was required 
by law but in the absence of clear guidelines for studies in children. He called for a 
much greater amount of activity in testing drugs in infants and children, with greater 
involvement from three main groups; the drug industry, paediatricians and the 
government especially the US FDA (Shirkey, 1999).  
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In response, the FDA stated their regulatory position clearly that drugs for use 
in children must be tested in children (Wilson, 1999). Unfortunately little changed in 
the next two decades. Wilson also noted that 78% GUXJVLQWKH863K\VLFLDQV¶
Desk Reference lacked information for use in children, and that this was unchanged 
almost 20 years later according to another report in 1991 (Gilman and Gal, 1991) that 
IRXQG WKDW  RI WKH GUXJV LQ WKH 3K\VLFLDQV¶ 'HVN 5Hference lacked paediatric 
information.  
The same situation was also seen in Europe. Turner et al. (1998) found that a 
quarter of prescriptions to children in a paediatric hospital were either unlicensed or 
off-label. In more than a third of all admissions, children received unlicensed or off-
ODEHO PHGLFLQHV &RQUR\ HW DO¶V  UHSRUW RI WKH SDUWLFXODUO\ KHDY\ XVH RI
unlicensed or off-label drugs in neonates received great attention and provoked 
serious discussions in the United Kingdom. A further study by Conroy et al. (2000a) 
showed that the problem was widespread across Europe. 
Subsequently in the late 1990s, there were significant changes to the US drug 
regulatory framework to address the continuing problem of inadequate drug testing in 
children.  
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2. DEVELOPMENT OF DRUG REGULATION 
 
 It is ironic that significant regulatory changes meant to improve the situation 
for children took such a long time to be put in place, considering that prominent 
events of drug toxicity affecting children were the catalysts for major developments in 
drug regulation in the 20th century. 
 In 1938, the US Congress passed the Federal Food, Drug and Cosmetic Act 
requiring new drugs to be proven safe before marketing, thereby initiating a new 
system of drug regulation. This act was put in place following a major therapeutic 
disaster caused by an untested drug. Once sulfanilamide became available in the 
1930s, a liquid preparation was needed to administer the drug to small children. As 
the drug dissolved poorly in water, the Massengill pharmaceutical company 
developed an elixir of sulfanilamide using diethylene glycol as the solvent. 107 deaths 
were directly associated with diethylene glycol poisoning after ingesting the Elixir. At 
the time, the safety of drugs was not required to be established prior to clinical use 
(Steinbrook, 2000). 
 The thalidomide tragedy involving thousands of children born with congenital 
deformities particularly phocomelia in the 1960s led to another major revision of drug 
regulation. The Kefauver-Harris drug amendments passed by the US Congress in 
1962 required, for the first time, that drug companies prove the efficacy of a drug 
prior to marketing. Therefore, drug manufacturers would now need to show evidence 
of both safety (1938 Act) and efficacy (1962 amendments) of drugs before receiving 
marketing approval. Thus, the authority of the US FDA in regulating drugs and 
clinical trials was now firmly established (Steinbrook, 2000). 
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 The United Kingdom parliament enacted the Medicines Act in 1968 in 
response to the thalidomide catastrophe. The Medicines Control Agency (now known 
as the Medicines and Healthcare products Regulatory Agency, MHRA) was conferred 
the authority to regulate drugs in much the same way as the FDA; drug companies are 
required to show evidence of efficacy, safety and quality of drugs before they can be 
marketed (Choonara and Dunne, 1998).  
 The situation with medicines for children as highlighted by Shirkey (1968, 
1999) persisted after the major developments of the 1960s. The FDA passed several 
minor policies (Federal Register 1978, 1983) largely meant to develop clearer 
guidelines on protecting children participating in research and to review information 
on labels of drugs used in children. The US Pharmacopoiea established a Paediatric 
Advisory panel in 1975 with Shirkey as the first chairperson (Wilson, 1999). 
Nonetheless, no real incentive existed to encourage clinical trials of drugs in the 
paediatric population. Furthermore, the many (perceived) barriers to undertake these 
clinical trials remained. 
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3. CHALLENGES TO CONDUCTING CLINICAL TRIALS IN CHILDREN    
 There is a fundamental dilemma in conducting clinical drug trials in children. 
Clinicians and parents are hesitant to expose children to the potential risks, or at the 
very least the inconvenience, of being a subject in a clinical trial. Yet by giving them 
medicines that are not supported by sufficient knowledge, children are exposed to 
risks of therapeutic failure and unintended harms. Unlike the situation in adults where 
clinical drug trials underwent significant progress post-1960s, trials in children were 
hampered by major challenges contained within two broad categories ± ethical and 
methodological ± which often overlap with each other (Kauffman, 2000, Caldwell et 
al., 2004, Smyth, 2001).  
3.1 Ethical Challenges 
The Nuremberg Code of 1947 (Shuster, 1997) and the Declaration of Helsinki 
of 1964, latest amended form 2008 (World Medical Association, 2009) established 
the principles of protecting research participants in clinical trials. Consent must be 
obtained from participants while the researchers must ensure that there is no undue 
risk, putting the wellbeing of the participant above all other interests. Although 
guidelines for ethical issues surrounding paediatric clinical trials have existed for 
some time, for instance from the American Academy of Paediatrics, AAP (1977, 
revised 1995, Committee on Drugs, 1995) and from the British Paediatric 
Association, BPA later known as Royal College of Paediatrics and Child Health, 
RCPCH (RCPCH, 2000) the involvement of children in clinical trials present many 
ethical challenges. 
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The overarching ethical requirement of clinical trials is that participants give 
their informed and freely volunteered consent to take part, documented in writing. 
Children are considered to have a limited capacity to understand the implications and 
risks of clinical trials, or to make independent decisions for their inclusion or 
withdrawal from trials, although this is variable across the paediatric age groups 
(Kauffman, 2000).  
Thus the process of obtaining consent which is not straightforward even in 
purely adult trials brings another layer of complexity to paediatric clinical trials.  The 
Declaration of Helsinki has provisions allowing for proxy consent from the legal 
representative for children, in most cases the parents. Despite this, Shirkey (1999) 
observed difficulties obtaining this consent unless a particularly good relationship 
existed between doctor and parents. Both parents (Caldwell et al., 2002) and doctors 
(Caldwell et al., 2003, Sammons et al., 2007) would often place the concerns 
regarding the individual child for instance, risk of adverse effect, likelihood to be 
given an ineffective treatment or placebo and inconvenience, above the benefit to the 
general paediatric population (perhaps rightly so). Therefore consent may not be 
easily forthcoming.  
Parents require information that is clearly presented and enough time to 
consider and understand the information (Tait et al., 2003). This is often difficult to 
achieve, for example when the child is acutely ill especially in neonates (Levene et 
al., 1996, Mason and Allmark, 2000, McKechnie and Gill, 2006) or when the severity 
of illness is particularly distressing for instance in paediatric cancer (Kupst et al., 
2003, Eden, 1994). Previous studies have shown that even when consent has been 
obtained, many parents report that they felt obliged to participate (van Stuijvenberg et 
al., 1999) rather than giving it voluntarily.  
9 
 
In addition to the practical challenges of obtaining consent from parents, there 
is the conceptual challenge of obtaining informed consent for paediatric trials. 
Because the consent is obtained from a surrogate, it may be less morally robust; in 
keeping with the ultimate bioethical principle of autonomy. Kodish (2003) believes 
WKDW LQIRUPHG FRQVHQW ³PD\ QRW EH SRVVLEOH LQ WKH VWULFW SKLORVRSKLFDO VHQVH
[paediatric] investigators, parents and older children have an important obligation to 
approximate truly informed consent to the JUHDWHVW H[WHQW SRVVLEOH´ +H SURSRVHV
XVLQJWKHWHUPµSDUHQWDOSHUPLVVLRQ¶LQFRPELQDWLRQZLWKFKLOGDVVHQWLQDQ\VLWXDWLRQ
where it is possible. 
There is increasing recognition and requirement that assent from the paediatric 
patient should be obtained from clinical trials (AAP, Committee on Drugs, 1995, 
5&3&+  $VVHQW LV GHILQHG DV µDFWLYH DJUHHPHQW¶ E\ WKH $$3 DQG
µDFTXLHVFHQFH¶E\WKH5&3&+RIWKHSDHGLDWULFSDUWLFLSDQWZKRLVEHORZWKHOHJDODJH
of being able to consent. This presents further challenges to investigators as it is not a 
simple task to apply the concept universally to the heterogeneous mix of paediatric 
patients. In many instances assent is not needed, for example, when neonates, sedated 
or unconscious children are studied or in certain studies of therapies used in 
emergency situations. 
 Further questions remain - for example, at what age does a child become 
capable of understanding the procedures, risks and benefits of research, how much 
does the child understand, what counts as dissent (John et al., 2008) and who can 
RYHUULGH GLVVHQW KRZ DQG ZKHQ 2QGUXVHN HW DO¶V  ZRUN VXJJHVWV WKDW PRVW
children under the age of 9 cannot be expected to provide meaningful assent.  
 
10 
 
For children who are expected to be able to meaningfully assent, additional 
issues need to be addressed including how to present information to them adequately 
and how to document the assent; whether a signature is required or not (Ungar et al., 
2006). Nevertheless despite the many challenges presented to investigators by the 
consent and assent processes, both are essential to protect the autonomy of the 
paediatric patient in a clinical trial. 
 Another ethical challenge is seen in the assessment of risks and benefits of the 
clinical trial to the paediatric patient. The benefits of clinical trials are now well-
established both to the wider group of children as well as to the participants 
themselves. Children in general stand to benefit from safer and more efficacious 
therapies, contributed by scientific testing in their age groups (Choonara, 2006).  
The direct benefits to the participants themselves may be considerable. 
$FFRUGLQJWR6P\WK³LIWKHK\SRWKHVLVRQZKLFKWKHUDSHXWLFUHVHDUFKLVEDVHG
is well founded, at least half the patients in a randomised controlled trial may benefit 
while those in the control arm will be no worse off than if the research has not been 
GRQH´ )XUWKHUPRUH D QXPEHU RI VWXGLHV VXJJHVW WKDW SDUWLFLSDQWV LQ FOLQLFDO WULDOV
have better outcomes compared to non-participants (Vist et al., 2005). Schmidt et al. 
(1999) found that neonates participating in a RCT of antithrombin therapy assigned to 
placebo needed significantly shorter ventilation periods compared to non-participants, 
seemed to suffer fewer and less severe intraventricular haemorrhages and had a lower 
mortality rate. All the non-participating neonates were eligible to participate but were 
not randomised and all neonates received the same care otherwise. 
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 To evaluate the risks for paediatric patients participating in a clinical trial, 
broadly similar guidelines are provided by the AAP (Committee on Drugs, 1995) and 
5&3&+  LQ ZKLFK ULVN DVVHVVPHQW LV EDVHG RQ WKH FRQFHSW RI µPLQLPDO ULVN¶
.DXIIPDQ  0LQLPDO ULVN LV GHILQHG DV ³D OHYHO RI ULVN VLPLODU WR WKH ULVN
eQFRXQWHUHGLQWKHFKLOG¶VXVXDOGDLO\DFWLYLW\´$$3, 1995RU³DSUREDELOLW\RIKDUP
or discomfort not greater than that ordinarily encountered in daily life or during the 
SHUIRUPDQFHRIURXWLQH>WHVWV@´7KHJXLGHOLQHVIXUWKHUVWDWHWKDWDQ\VWXGLHVH[SRsing 
paediatric participants to more than minimal risk require close ethical scrutiny before 
it can be performed.  
 ,I WKH GHILQLWLRQ RI µPLQLPDO ULVN¶ ZHUH VWULFWO\ IROORZHG LW ZRXOG EH YHU\
difficult to justify conducting a clinical trial involving children. Thus, the wordings 
UHTXLUHDZLGHVFRSHRILQWHUSUHWDWLRQLQGHFLGLQJRQZKDWFRQVWLWXWHVµPLQLPDOULVN¶ 
The guidelines may be a reflection of the prevailing attitudes prior to the major 
developments occurring following the turn of the new millennium, and probably are 
in need of updating. For example, a study by Shah et al. (2004) found that institutional 
review board chairs in the US varied in their application of risk and benefit categories 
in paediatric research. The decision is probably more challenging in paediatric trials 
compared to adults since adult participants can play an active role in risk-benefit 
assessments, while in paediatric trials, a surrogate decision is made, as seen in the 
consent process as well. 
In conclusion, conducting clinical trials in the paediatric population pose 
multiple ethical challenges that are not found in adult trials. The significant amounts 
of time, effort and thought required to address these challenges have likely 
contributed to the dearth of clinical trials underpinning evidence based medicines use 
in paediatrics.    
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3.2 Methodological Challenges 
 Conducting a paediatric clinical trial requires many study design 
characteristics that are different from adults. Transferring a study protocol from an 
adult trial and simply adjusting the age range would often lead to an undoable study 
or a study with inappropriate requirements such as pregnancy testing in preschoolers 
(Kauffman, 2000). Thus in addition to the unique ethical requirements of paediatric 
clinical trials, investigators are presented with methodological challenges. 
 One of the biggest methodological hurdles in conducting a paediatric clinical 
trial is recruitment. Paediatric patient populations are much smaller, more 
heterogeneous and are undergoing different stages of physiological development 
(Steinbrook, 2000, Smyth, 1999). Many childhood diseases are rare compared to the 
adult form, for example juvenile arthritis or diabetes, or are heterogeneous in their 
presentation such as cerebral palsy and Down syndrome. For relatively prevalent 
diseases such as asthma, developing selection criteria and measuring differences in 
treatment effect can be challenging due to the inherent heterogeneity and development 
processes of children. The resulting small sample populations would mean that the 
trial would have inadequate statistical power to detect small or moderate differences 
in treatment outcomes (Smyth, 2001).  
Other practical issues exist, for instance straightforward sampling procedures 
in adult trials present challenges to investigators in paediatric trials. Venepuncture in 
children requires specific justification, strategies and expertise. The small blood 
circulating volume of neonates and infants necessitates the use of sensitive assay 
methods to analyse minute sample volumes such as the dried blood spot technique 
(Patel et al., 2010).  
13 
 
Less invasive sampling procedures such as urine and breath assays, population 
pharmacokinetic approaches and microanalytical methods can be used but require 
further effort to develop and adapt them to paediatric patients (Conroy et al., 2000b).  
Paediatric drug trials also require specific age-appropriate formulations for 
example liquid preparations or granules, especially for younger children. Frequently, 
these formulations are not readily available (Mulla et al., 2007), thus requiring 
additional costs and time to develop them. For clinical trials using extemporaneous 
drug formulations, it would be difficult to generalise the results to clinical practice as 
the study validity depends on being able to replicate the formulation aside from the 
design, execution and analysis of the trial (Schreiner and Greeley, 2002). Developing 
appropriate paediatric formulations requires sufficient knowledge of pharmacokinetic  
parameters that needs to be obtained from pharmacokinetic studies, thereby 
presenting an additional encumbrance prior to comparative trials to evaluate efficacy 
and safety. 
The various unique challenges presented by paediatric clinical trials would 
need highly trained and experienced researchers to address the issues. Unfortunately, 
there are few experienced investigators in paediatric clinical pharmacology 
worldwide. This shortage of expertise has been previously highlighted both in the 
United States (Wilson, 1999) and also in Europe. It was noted in 2000 that there were 
only 2 paediatric clinical pharmacologists in the United Kingdom (Conroy et al., 
2000b). In 2004, there were 3 paediatric clinical pharmacologists and 3 trainees when 
a formal training programme was established by the Royal College of Paediatrics and 
Child Health (Choonara et al., 2004).  
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In 2005, a survey of the European Society of Developmental, Perinatal and 
Paediatric Pharmacology (ESDP) revealed only 18 paediatric clinical pharmacologists 
and 23 trainees throughout Europe (Bonati et al., 2006). Efforts are on-going to 
increase the capacity in the field of paediatric clinical pharmacology (Gazarian, 
2009). 
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3.3 The Example of Paediatric Oncology 
 With such myriad barriers to performing paediatric clinical trials, the 
reluctance to study medicines in the paediatric population was perhaps reasonable. 
However the experience in paediatric oncology with clinical trials provided evidence 
to the contrary. According to Mitchell (2007), RCTs KDYH ³EHen the mainstay of 
SDHGLDWULF RQFRORJLFDO SUDFWLFH IRU GHFDGHV´ /DUJH PXOWLFHQWUH FRRSHUDWLYH JURXSV
VXFK DV WKH 8. &KLOGUHQ¶V &DQFHU 6WXG\ 8.&&6* 86 FKLOGUHQ¶V &DQFHU *URXS
(CCG) and the International Society of Paediatric Oncology (SIOP) were formed and 
the majority of paediatric oncology patients were recruited into clinical trials. The 
resulting treatment regimens contributed to a remarkable change in the prognosis for 
paediatric cancer.  
From a situation where virtually all children with malignancy died, currently 
more than 75% will survive long term (Mitchell, 2007). Hargrave et al. (2001) has 
shown that treatment-related deaths in children with leukaemia progressively 
decreased from 9% to 2% within the large clinical trials between 1980 and 1997, 
indicating the value of scientific information gained from clinical trials conducted in 
FKLOGUHQ )XUWKHUPRUH WKH VXFFHVVIXO GHYHORSPHQW RI WKHUDS\ IRU :LOP¶V WXPRXU
(Pritchard-Jones and Pritchard, 2004) exemplified the benefit of conducting RCTs, 
even for very rare diseases in children.   
 Thus the success of paediatric oncology in utilising clinical trials demonstrates 
two major points; firstly barriers to involving paediatric patients in clinical trials are 
not insurmountable and secondly, the knowledge gained from the studies can be 
invaluable in improving treatment outcomes in children as well as reducing the risk of 
unwanted effects of the drugs.   
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3.4 The Economic Reason 
 An important distinction to make is that paediatric oncological trials are 
mostly driven by the cooperative groups and are non-commercial while drug 
development is largely the domain of the pharmaceutical industry. Children represent 
a smaller commercial market for drugs and therefore provide less financial incentive 
for drug companies to pursue research in the paediatric population compared to adults 
(Conroy et al., 2000b, Budetti, 2003). Considering that on average to develop a drug 
to reach the market would cost roughly USD 800 million (DiMasi et al., 2000), it is 
no surprise that the pharmaceutical industry would be reluctant to invest in paediatric 
studies for a new drug when the financial return is questionable. This holds true to an 
even greater degree in drugs that are out of patent or approaching the end of their 
patent. There are considerable costs and probably no financial incentive in studying 
older medicines in children.  
 To summarise, there are numerous barriers to clinical trials being conducted in 
the paediatric patient population despite the oft-highlighted need for adequate 
scientific evaluation of medicines being used in them. These challenges can be 
addressed and the knowledge gained from conducting such studies can be invaluable 
in improving treatment outcomes, as has been demonstrated in paediatric oncology. 
Unfortunately without significant financial incentive, the pharmaceutical industry will 
remain reluctant to pursue paediatric clinical research of medicines. 
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4. UNLICENSED AND OFF-LABEL MEDICINES 
 As earlier mentioned, drug licensing authorities will not grant a license unless 
there is sufficient evidence for the efficacy, safety and quality of a drug. Therefore the 
end result of the many obstacles to performing paediatric clinical trials as commented 
above is that many drugs are not licensed for use in children. The use of these 
µXQOLFHQVHG¶GUXJVLVFRPPRQSODFHLQSDHGLDWULFSUDFWLFH)XUWKHUPRUHOLFHQVHGGUXJV
are frequently prescribed outside the established labelling information that 
accompanies the license, for example they are used in a different dosage, age, 
LQGLFDWLRQ URXWH RU IRUPXODWLRQ WKDW LV VWDWHG RQ WKH ODEHO 7KLV LV FDOOHG µRII-ODEHO¶
use. 
 There has been considerable interest in the prevalence of unlicensed and off-
label prescription in paediatric departments in the past decade. According to 
Pandolfini and Bonati (2005) there were at least 30 studies investigating unlicensed 
and off-label drug prescribing in paediatric patients. More studies were published in 
WKHIROORZLQJ\HDUV'L3DRORHWDO'HOO¶DUHDHWDO.XPDUHWDO 2008). 
The results show that the use of unlicensed or off-label drugs was widespread in 
paediatrics. Overall, 11% to 80% of all drugs prescribed in paediatrics were either 
unlicensed or off label.  
 Primary care appear to have the lowest rates of unlicensed or off-label 
prescribing (Pandolfini and Bonati, 2005) ranging between 11-37%. In the United 
Kingdom, McIntyre et al. (2000) observed that for children under 12, around 11% 
received an off-label prescription but very few (0.3%) received an unlicensed drug. A 
study of GP prescriptions throughout Scotland found that paediatric patients received 
off-label drugs at a rate of 26% (Ekins-Daukes et al., 2004).  
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Various rates are seen in primary care in other countries, for example France (33%, 
Chalumeau et al., 2000), Holland (29%, T Jong et al., 2002) and Germany (13% 
Bucheler et al., 2002).     
 Higher rates of unlicensed or off-label prescribing were seen in paediatric 
LQSDWLHQWV7XUQHUHWDOIRXQGWKDWRIDOOSUHVFULSWLRQVLQD8.FKLOGUHQ¶V
hospital were unlicensed or off-label. A large study involving paediatric wards in five 
European countries found even higher rates; 46% of all the prescriptions were either 
unlicensed or off-label (Conroy et al., 2000a). Of 11 studies of off-label or unlicensed 
medicines in paediatric wards, 16% to 62% of prescriptions were off-label or 
unlicensed (Pandolfini and Bonati, 2005). 
 The highest rates of unlicensed or off-label prescriptions are seen in neonates. 
Between 80 and 97% of neonates in 7 studies were prescribed unlicensed or off-label 
drugs and off-label or unlicensed prescriptions constituted between 55% and 80% of 
all prescriptions (Pandolfini and Bonati, 2005). When different paediatric units in a 
single hospital were compared directly, neonatal wards showed the highest rates of 
unlicensed or off-label prescriptions (Conroy et al., 1999, W¶-RQJHWDO). Slightly 
ORZHU UDWHV ZHUH VHHQ LQ PRUH UHFHQW VWXGLHV 'HOO¶DUHD  HW DO  UHSRUWHG WKDW
35% of prescriptions in an Italian neonatal unit and Kumar et al. (2008) reported that 
45% of parenteral prescriptions in an American neonatal intensive care unit were 
unlicensed or off-label. 
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 The different definitions and classification methods used by these studies 
made the results difficult to compare and generalise among different paediatric 
centres or countries. There is a growing concensus on a common definition of 
unlicensed or off-label medicines especially in Europe (Neubert et al., 2008). 
Nonetheless, methodological issues do not detract from the fact that the use of 
unlicensed or off-label drugs is widespread in paediatric patients up to the present 
time. 
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5. ADVERSE DRUG REACTIONS  
 Adverse drug reactions (ADRs) include any noxious, unintended or undesired 
effect of a drug which occurs at doses used for prophylaxis, diagnosis or therapy. This 
definition excludes therapeutic failures, poisonings, drug abuse and adverse events 
due to administration or medication errors as well as non-compliance (WHO, 2007). 
Lazarou et al. (1998) estimated that ADRs were the cause of around 5% of hospital 
admissions and that approximately 11% of hospital inpatients experience them. This 
very large systematic review of  39 studies from the United States suggest that  ADRs 
account for in excess of 100,000 deaths per year, making it between the fourth and 
sixth most common cause of death in the United States. In the United Kingdom, a 
large prospective study found that 6.3% of admissions were related to an ADR and 
that the admissions accounted for 4% of hospital bed capacity although only adults 
above 16 years old were included in this study (Pirmohamed et al, 2004). 
 It is important to differentiate ADRs from another commonly used term, 
adverse drug events (ADEs) which is a more inclusive definition. ADEs involve any 
injury resulting from administration of a drug. Thus ADRs are detected in a situation 
where the drug has been used in proper doses, administered correctly and for 
approved indications.  However the situation is less well delineated in paediatric 
patients since the commonplace use of unlicensed or off label medicines means that 
doses, administration as well as indications often lie outside of approved guidelines. 
This leads to a greater imperative to study ADRs in children. 
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Impicciatore et al. (2001) performed a meta analysis of 17 ADR studies in the 
paediatric population published from 1973 to 2000. The authors estimated that 9.5% 
of hospitalised children experienced ADRs; ADR incidence rates ranged from 4.4% to 
16.8% in the studies. Admissions due to ADRs appeared to be lower compared to 
adults, accounting for 2% of all hospital admissions. In outpatients, the incidence rate 
of ADRs was 1.5%. There were studies from 7 different countries included in the 
analysis. 
 Clavenna and Bonati (2009) conducted an updated analysis involving studies 
published after the review by Impicciatore et al. They used the same meta analytic 
procedures and found 8 studies from 6 different countries. The results showed similar 
ADR rates in children with the incidence of ADRs in hospitalised children estimated 
to be 10.9%. ADRs accounted for 1.8% of admissions to hospital while paediatric 
outpatients experienced ADRs at a rate of 1%. The data suggest that hospitalised 
children suffer similar ADR rates with hospitalised adults although ADRs accounted 
for a lower percentage of admissions for the paediatric populations. 
 Recent studies in the United States that looked at ADEs provided further 
information on prevalence rates. A nationwide active surveillance program estimated 
that almost 160,000 children and adolescents were treated in emergency departments 
across the US for ADEs annually. Roughly half (49%) consisted of young children 1 
to 4 years old. Unintentional overdoses led to about 45% of the presentations while 
the remainder were primarily ADRs; 35% caused by allergic reactions, 13% by 
adverse effects and 6% by vaccine reactions (Cohen et al., 2008). 
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Another study analysed 11 years of data from paediatric presentations to all 
health care facilities in the United States. The authors found that almost 600,000 visits 
annually were attributed to ADEs, the majority (78%) to outpatient clinics. There 
were sizable numbers of ADRs including allergic reactions in younger children and 
adverse effects in adolescents (Bourgeois et al., 2009). 
 In paediatric patients, the correlation of unlicensed or off-label drug use with 
the rate of adverse events has been investigated (Choonara and Conroy, 2002). 
Although many studies have described the prevalence of unlicensed or off-label 
prescriptions in paediatric patients, there have been relatively few studies that have 
explored the relationship of such prescriptions to the rates of adverse events. Turner et 
al. (1999) performed a prospective study evaluating the relative risk of an adverse 
drug reaction (ADR) occurring associated with the use of an unlicensed or off-label 
medicine. They found that the use of unlicensed or off-label drugs was associated 
with an increased risk of an adverse drug reaction occurring (RR 1.74, 95% CI 0.89-
3.41), although this was confounded by the fact that the presence of polypharmacy 
was the greatest contributory factor to the development of an ADR. 
Another prospective study by Neubert et al. (2004) in a German paediatric unit 
found that unlicensed or off-label drugs did not cause significantly more ADRs 
compared to licensed prescriptions. However, patients who received unlicensed or 
off-label drugs had a significantly higher incidence of ADRs compared to those who 
had received only licensed drugs (28% vs 8%, p<0.05). 
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 Although the evidence that unlicensed or off-label drugs can cause a higher 
risk of toxicity is limited, their widespread use in paediatric practice is widely 
regarded as untenable. The risk of ADRs can be disguised by under-reporting (Waller, 
2007). Prescribing a medicine without sufficient clinical evidence of their efficacy 
and safety is using it in an uncontrolled, unsystematic and ultimately unscientific 
manner (Budetti, 2003). 
In summary, adverse drug reactions are a significant public health issue in 
children. They appear to suffer similar rates of ADRs with adults, particularly among 
hospitalised patients. The large numbers of children affected emphasise the 
importance of further research into drug toxicity occurring in children, in view of the 
previously highlighted deficiency in scientific evaluation underlying many of the 
medicines used in the paediatric population.  
5.1 Prominent occurrences of drug toxicity in children 
 Prominent episodes of drug toxicity suffered by children underline the need 
for paediatric medicines to be based on adequate evaluation of their efficacy, safety 
and quality. As discussed earlier, two major episodes of drug toxicity mainly affecting 
children played a vital role in the development of drug regulation, namely the 
sulphanilamide-diethylene glycol and the thalidomide tragedies. 
 Tragically, diethylene glycol has been repeatedly used as a solvent especially 
for paediatric formulations of paracetamol, even up to the present time. This has 
caused many fatalities in children; 47 children in Nigeria in 1992, 51 children in 
Bangladesh in 1995, 85 children in Haiti in 1998 (Choonara and Rieder, 2002) and as 
recently as 2008 where 84 children died (Bonati, 2009).  
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Around the period of the thalidomide saga, another prominent occurrence of 
drug toxicity came to light. Several neonates died after being administered 
chloramphenicol. The grey baby syndrome was identified after the causative 
relationship was discovered (Weiss et al., 1960). The immature metabolic pathways in 
the neonate led to a accumulation of chloramphenicol in plasma causing severe 
toxicity which ultimately caused the death of several neonates. According to 
Choonara and Rieder (2002), appropriate clinical studies to design age-appropriate 
dosing could have averted the tragedy. 
 The mechanism of valproate hepatotoxicity in young children is also thought 
to be related to abnormal metabolism The majority of fatalities were children under 3 
years of age (Brown, 1988, Choonara et al., 1996). These episodes demonstrate the 
danger of extrapolating dosing regimes of paediatric medicines from adult data. 
 Another prominent case of drug toxicity involving children is the development 
RI 5H\H¶V V\QGURPH ZLWK DVSLULQ XVH 5H\H¶V V\QGURPH LV DQ DFXWH HQFHSKDORSDthy 
occurring in children and adolescents that has been linked to aspirin use during a 
febrile illness. The association with aspirin is sufficiently strong that aspirin is no 
longer used in the paediatric population (Glasgow, 2006). The dramatic decline in the 
incidence of the syndrome following public health warnings in the 1980s support the 
case for a causal link (Belay et al., 1999).  
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The propofol infusion syndrome as reviewed by Kam and Cardone (2007) 
caused at least 20 paediatric deaths. Several case reports of paediatric deaths appeared 
with the use of propofol infusions, before an unpublished randomised controlled trial 
of the use of propofol infusions was conducted in 2001 involving patients in a 
paediatric intensive care unit in the US (Felmet et al., 2003). The trial was terminated 
when a dose-effect relationship was seen in relation to mortality rate in the children. 
As a result, the US FDA issued a warning against the use of propofol for long term 
sedation in children.  This episode of drug toxicity provided an important lesson on 
the potentially severe risks, while at the same time demonstrating the life-saving 
information that can be provided by clinical trials in children. 
 In conclusion, prominent cases of drug toxicity involving children have been 
the catalyst for major developments in regulatory activities. Many lessons can be 
learnt from these episodes; particularly the importance of sound scientific evaluation 
of medicines used in children as well as the need to be vigilant on any adverse effects 
that are experienced by children when using the medicines. 
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6. NEW LEGISLATION TO ENSURE BETTER MEDICINES FOR CHILDREN 
 The mounting awareness that drug therapies for children require studies with 
the same level of scientific rigor in their own population led to major regulatory 
efforts in the 1990s. The first changes were seen in 1994, when the FDA issued the 
first paediatric labelling rule. This regulation requested manufacturers of marketed 
drugs to alter the labels of the product to include paediatric information where 
available. The rule allowed efficacy information to be extrapolated from adults to a 
paediatric population provided the condition and therapeutic response is similar; with 
paediatric dosage (pharmacokinetic) information included. When paediatric 
information was not available (as is commonly the case), manufacturers are allowed 
to include a disclaimer stating paediatric safety and efficacy has not been established 
(FDA, 1994). Although intended to encourage clinical studies in the paediatric 
population, the availability of a disclaimer meant that pharmaceutical companies did 
not see any incentive to pursue clinical studies in children. 
 In response, the FDA introduced a set of regulatory measures including both a 
voluntary incentive and a mandatory requirement, to motivate drug company sponsors 
WR SXUVXH SDHGLDWULF FOLQLFDO UHVHDUFK 7KLV ZDV WHUPHG WKH µFDUURW DQG VWLFN¶
(Steinbrook, 2000). The voluntary incentive provision was contained within the FDA 
Modernization Act enacted in 1997. For the first time an exclusivity incentive was 
introduced, where drug companies that complied with a written request by the FDA to 
conduct clinical studies in the paediatric population would be awarded a 6-month 
extension to the marketing exclusivity of their product. 
 7KH µVWLFN¶ ZDV )'$¶V SDHGLDWULF UXOH HQDFWHG LQ  )'$  7KLV
legislation gave the FDA a mandate to require paediatric clinical studies for any new 
or marketed drug where a significant use or benefit to children is expected. 
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As expected, the rule encountered heavy opposition from the pharmaceutical 
industry since it conferred the FDA with considerable regulatory power to actively 
require paediatric clinical studies from sponsors. Several pharmaceutical lobby groups 
managed to successfully apply for the rule to be struck down in a federal court in 
2002. Nevertheless, considerable efforts led by the FDA managed to persuade the US 
Congress to uphold the rule in 2003 and it was codified as the Pediatric Research 
Equity Act. Similarly, the FDA Modernization Act was renewed in 2002 as the Best 
Pharmaceuticals for Children Act (Cooper, 2002, Federal Register, 2002, 2003). 
 These legislative changes drastically altered the landscape for medicines in 
children. The FDA has now gained the authority to firstly incentivise pharmaceutical 
companies to pursue clinical studies of medicines in children but also to require 
mandatory research involving paediatric populations when necessary. 
 Across the Atlantic, regulatory developments did not take long to follow 
American developments. Following tri-party discussions between the United States, 
Japan and the EU states, the International Conference on Harmonisation (ICH) 
developed a guideline to harmonise pharmaceutical regulation between the three 
sectors in 1998. This ICH guideline was then adopted by the European Medicines 
Agency (EMEA) in 2002 and EHFDPHD(XURSHDQJXLGHOLQHWLWOHGµ1RWHIRU*XLGDQFH
RQ&OLQLFDO,QYHVWLJDWLRQRI0HGLFLQDO3URGXFWVLQWKH3DHGLDWULF3RSXODWLRQ¶ 
However there is a suggestion that the voluntary nature of the guidance  meant 
that it was largely ineffective in stimulating paediatric studies by drug companies     (t 
Jong et al. 2002). Finally the Regulation on Medicinal Products for Paediatric Use 
was passed in the European Parliament in 2007 (Choonara and Bonati, 2007). This 
regulation conferred the EMEA with authority similar to the FDA in regard to 
paediatric studies.  
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Pharmaceutical companies are now required to submit a Paediatric 
Investigation Plan (PIP) or an application for a waiver, for any drug seeking 
marketing approval. For drugs already marketed, a PIP is also required for any 
alterations in indication, formulation or route of administration. Furthermore, there is 
also a voluntary provision within the regulation for a paediatric use marketing 
authorisation (PUMA) that would award a 10-year data and marketing protection for 
off-patent drug therapies that are developed specifically for paediatric populations .  
Another component within the regulation is the formation of an expert 
Paediatric Committee. The task of this committee is to advise the EMEA on the 
development of medicines for use in children, in accordance with the legislation. Also 
contained within the regulation is the stipulation that all paediatric clinical trials must 
be registered on a database that is accessible to the public (EudraCT). Further, all 
details of the results of paediatric clinical trials, including those terminated 
prematurely, must be accessible to the public (Choonara, 2007).  
Thus, the many legislative changes on both sides of the Atlantic have provided 
a very stimulating environment for paediatric clinical studies to be conducted, in the 
effort to provide rigorous scientific evidence on the safety, efficacy and quality of 
paediatric medicines thereby ensuring more rational use of medicines in children 
(Hoppu, 2008). 
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7. THE GLOBAL SITUATION: HEALTH RESEARCH DISCREPANCY 
 On a global scale, clinical research is concentrated in high income countries. 
This situation is expected, since clinical research requires considerable resources, 
expertise, commitment from multiple levels including academia, health authorities 
and especially an invested healthcare industry. On the other hand, in this era of rapid 
globalisation coupled with a higher awareness of bioethical awareness, there is 
growing recognition that this discrepancy in clinical research needs to be addressed. 
Essentially the idea is that clinical research should benefit the whole of mankind. 
  The Commission on Health Research for Development (1990) published a 
landmark report that found a large discrepancy in global health research. Overall, only 
5% of the total funding spent on health research were directed towards addressing the 
health issues in developing countries, whose population accounted for 93% of the 
global burden of preventable diseases. Several years later the Global Health Forum, a 
non-profit organisation in partnership with the World Health Organization (WHO) 
developed the term 10-90 gap to describe this imbalance between the lack of 
resources for health research in poor countries and the size of health problems 
suffered by their populations.   
 Although health research encompasses a very wide range of topics and 
activities, research on medicines is clearly an important area within health research. 
)LUVWO\ WKHUH LV FRQFHUQ RQ WKH µPRUDOO\ XQFRPIRUWDEOH GUXJ JDS¶ &RKHQ-Kohler, 
2007) which indicates that millions of the global population are denied the basic 
human right of essential medicines due to the economic paradigm where medicines 
are regarded as a product to be used only by those who can pay for them. Secondly, 
there is evidence that drug development is geared almost exclusively for financial 
profit alone.  
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For example, Trouiller (2004) reported that only 13 out of 1393 of new drugs 
approved between 1975 and 1999 were for tropical diseases that affect vast 
populations in LMIC. 
 Further evidence is seen in published clinical trials. Horton (2003) highlighted 
the significant underrepresentation of diseases affecting the developing world in 
leading medical journals and called for a greater exposure of research to address 
global health needs. Rochon et al. (2004) found that the majority of RCTs published 
in 6 leading medical journals was not relevant to global health needs and that more 
than half of the 40 leading causes of the global disease burden was not represented by 
any RCT. Isaakidis et al. (2002) found that few RCTs are conducted in sub-saharan 
Africa in contrast to the enormous burden of disease suffered by the human 
population living in the area. In an overview of systematic reviews contained within 
two major databases namely the Cochrane Database and the Database of Abstracts of 
Reviews of Effects (DARE), Swingler et al.  (2003) suggested that systematic reviews 
were more responsive to disease burden in high income countries rather than to the 
global burden of disease. 
 There have been a dearth of research looking at whether paediatric clinical 
research is related to the global burden of disease suffered by children. What is clear 
is that the global burden of childhood disease lies overwhelmingly in poor or 
developing countries. According to UNICEF (2009) 99% of under-5 mortality occur 
in low and middle income countries, nearly half occurring in sub-saharan Africa.  
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There is growing opinion that drug toxicity in children living in LMIC are 
being overlooked. There is also a conspicuous absence of research looking at this 
topic in the medical literature. Recognising the situation, WHO produced a 
publLFDWLRQ WLWOHG µ3URPRWLQJ 6DIHW\ RI 0HGLFLQHV LQ &KLOGUHQ¶ LQ  WR GUDZ
attention to the issue of safety of medicines in all children but also with emphasis on 
children in developing countries (Watts 2007, Choonara 2008). This report estimates 
that less than 10% of ADRs are reported globally and that many developing countries 
lack safety monitoring and reporting mechanisms. 
 -XVWDIHZPRQWKVODWHU:+2ODXQFKHGDPDMRUZRUOGZLGHFDPSDLJQµ0DNH
0HGLFLQHV &KLOG 6L]H¶ WR DGGUHVV WKH QHHG IRU DFFHVV WR VDIH and child-specific 
medicines globally. This campaign, endorsed by multiple agencies including 
UNICEF, aims to encourage research to develop medicines specifically for children as 
well as promoting improved measures to ensure that children can access essential 
medicines, particularly in poor countries. Major targets by the campaign include 
tackling priority research gaps where medicines do not exist or safety and efficacy is 
unknown, tackling development gaps where medicines are known but require 
adapting for children and finally addressing the access gaps to allow medicines to 
reach children that need them. The campaign has a 5 year time frame and publishes 
regular progress reports. 
 Thus, efforts are now underway to address the health research disparity 
between rich and poor countries. WHO is spearheading a large movement to address 
the need for paediatric medicines with emphasis on children in poor countries who 
form the majority of unwell children globally.  
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8. SUMMARY 
 The situation in paediatric medicines has developed through several stages. It 
was ironic that although drug toxicity suffered largely by children led to the 
development of drug regulation, the paediatric population were mostly neglected in 
clinical drug research. Although the problem was recognised, the situation persisted 
for an extended period. The numerous perceived challenges meant that few clinical 
drug trials were conducted in the paediatric population. Ethical and methodological 
challenges were often cited, but perhaps the main obstacle was the lack of financial 
incentive to pursue clinical research where the market for the paediatric drugs was 
much smaller compared to adults. Nonetheless, the experience in paediatric oncology 
demonstrated the challenges were surmountable and that clinical drug trials provided 
invaluable returns in respect to treatment outcome.  
 The resulting scenario was that paediatric patients were frequently given 
medicines that lacked marketing approval (unlicensed) or differently from the way 
described by the label (off label). Subsequent studies showed that unlicensed and off 
label use was widespread. There is data to support that unlicensed and off label 
medicines predispose to a higher risk of adverse drug reactions in children. The 
growing concern with using unlicensed and off label medicines in children led to a 
growing demand for a change in the situation. 
 High profile changes in drug regulation on both sides of the Atlantic signalled 
a potential improvement to the situation. There now exists a stimulatory environment 
for paediatric clinical trials of medicines with the pharmaceutical industry 
incentivised by a 6 month exclusivity provision. The FDA and EMEA has been 
awarded the mandate to require paediatric testing before marketing approval can be 
conferred. 
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 Finally in this era of globalisation, there is growing awareness of the clinical 
research discrepancy between clinical research which is concentrated in rich countries 
and the burden of disease which overwhelmingly lies in poor countries. The same 
situation applies to medicines in children. Cognizant of this, WHO is now 
spearheading efforts to address the need for safe and accessible child-specific 
PHGLFLQHVZLWKWKHZRUOGZLGHFDPSDLJQµPDNHPHGLFLQHVFKLOGVL]H¶ 
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9. OUTLINE OF THESIS 
Chapter 2: Methodology 
In this chapter, I outline the methodological steps that I took to perform a systematic 
review of paediatric randomised controlled drug trials that were published in 2007. I 
present the development of the search strategies for the three major electronic 
databases of publications, the inclusion and exclusion criteria for studies, data 
extraction, management and analysis. 
Chapter 3: Demographical and Epidemiological Characteristics 
Here I start to describe my findings in relation to the demographical and 
epidemiological characteristics of the trials.   
Chapter 4: Methodological and Reporting Characteristics 
In this chapter I present my findings in terms of the methodological and reporting 
quality of the trials. I report on the descriptions of safeguards put in place to protect 
trial participants including ethical measures.  
Chapter 5: Safety characteristics and Adverse Drug Reactions (ADRs) 
In this chapter I describe the adverse events reported by the trials as well as 
assessments on whether the participants experienced adverse drug reactions. 
Chapter 6: Relation to Global Disease Burden 
Here I discuss my re-analysis of a previously assembled database of paediatric 
randomised controlled drug trials published from 1996 to 2002 to investigate the 
relevance to global disease burden. I then present findings from my current systematic 
review in relation to the global disease burden in childhood disease. 
Chapter 7: Conclusion 
In this final chapter I discuss the findings of my systematic review in the context of 
the current situation of medicines in children. 
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CHAPTER 2: METHODS 
 
  
 
For this thesis I have undertaken a systematic review of randomised controlled 
trials (RCTs) involving the paediatric population from scientific reports published in 
2007. The methods are largely based on those developed and validated by the 
Cochrane Collaboration. However several unique alterations were made and novel 
techniques were used in this review to correspond with the original objectives of this 
research. In this chapter these methods are described in a detailed and stepwise 
manner.  
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2.1 INTRODUCTION 
For this research, randomised controlled drug trials (RCTs) are selected as the 
main focus of study for several reasons. RCTs are the most robust experimental 
GHVLJQDYDLODEOHLQFOLQLFDOUHVHDUFKDQGDUHUHJDUGHGDVWKHKLJKHVWOHYHORUWKHµJROG
VWDQGDUG¶ RI HYLGHQFH IRU KHDOWKFDUH LQWHUYHQWLRQV (Sackett et al., 1996).  The 
allocation of treatment purely by chance allows unbiased comparisons to be made on 
the efficacy (Campbell et al., 1998) and also safety of the treatment in question 
(Akobeng, 2005a, Ashby, 2008).  
Healthcare professionals, researchers and regulatory bodies pay considerable 
attention to findings from RCTs (Caldwell et al., 2004). Regulatory agencies such as 
the FDA and EMEA now require RCTs to be performed before marketing approval is 
conferred (EMEA, 2001, Choonara, 2007, Rodriguez et al., 2008, Hoppu, 2008).  
On the other hand, it is acknowledged that there are several limitations and  
disadvantages of RCTs (Jadad and Enkin, 2007). According to Rawlins (2008), these 
include: 
 Inappropriateness due to practical (especially rare diseases), bioethical 
or legal reasons 
 Irrelevance of the null hypothesis underpinning RCTs in many 
instances 
 The many difficulties with the theories of probability; particularly 
those presented by potentially misleading statistical phenomenons such 
as regression to the mean and multiplicity, as well as the infrequent use 
of potentially valuable Bayesian approaches 
 Concern with the generalisability of the results, both on efficacy and 
harms 
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 Substantial costs involved in conducting RCTs 
RCTs are primarily concerned with demonstrating efficacy while safety data 
are usually obtained from observational studies in the post marketing and licensing 
period (Papanikolaou et al., 2006). This is because individual RCTs are usually 
underpowered to detect adverse effects which are infrequent events (Vandenbroucke, 
2004). Nevertheless large-scale RCTs or systematic reviews of RCTs can convey 
useful safety data (Papanikolaou and Ioannidis, 2004). This relies on safety results 
from RCTs; which unfortunately are poorly reported (Ioannidis and Lau, 2001, 
Ioannidis et al., 2004, Ioannidis, 2009, Pitrou et al., 2009,).  
In paediatrics, Sammons et al. (2008) found that more than a quarter of 
clinical trials published between 1996 and 2002 did not report that they monitored 
safety (Sammons et al., 2008). There is further evidence that the reporting of safety 
and toxicity information in RCTs involving children is inadequate (Ioannidis and Lau, 
2001, Cohen et al., 2007, Anon., 2007, Klassen et al., 2008).  
In conclusion, this thesis is set in the context where RCTs are given high 
importance in evidence-based medicine but also where the limitations and 
disadvantages of RCTs are recognised (Rawlins, 2008). Thus, the aim is to explore 
the characteristics of RCTs published in 2007; focussing on important aspects such as 
demography, epidemiology, methodology, toxicity and others; to add to previous 
reviews (Campbell et al., 1998, Sammons et al., 2005). The ultimate goal is to 
highlight the essential role of RCTs in providing evidence to make medicines safe and 
effective for children (Vandenbroucke, 2004). 
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2.1.1. WHAT IS A SYSTEMATIC REVIEW? 
 A systematic review attempts to answer a specific research question by using 
explicit methods to systematically search and critically appraise the scientific 
literature available (Akobeng, 2005b). There is a detailed description on how the 
review was conducted so that it is reproducible by an interested reader and this 
primarily is how it is different from narrative reviews (Jadad, 2007).  
A systematic review includes clearly stated objectives, predefined eligibility 
criteria for studies, a replicable methodology mainly of a systematic search for 
relevant studies, critical analysis and synthesis of characteristics and findings of the 
included studies (Higgins and Green, 2009). 
 As stated in the previous chapter, the aim of this thesis is to elucidate drug 
toxicity in paediatric randomised controlled trials. Here is the first distinction from a 
Cochrane systematic review whereby a Cochrane review is usually concerned with 
answering a single research question; this systematic review attempts to answer 
several questions with a generally broader scope. The main research questions are 
listed in the following list. 
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2.1.2 MAIN RESEARCH QUESTIONS 
1. What are the characteristics of paediatric randomised controlled drug trials 
published in 2007? 
a. What are the characteristics of the paediatric participants taking part? 
b. What are the types of drugs and diseases studied? 
2. What are the methods used in the trials? 
a. What comparisons are used and are they appropriate? 
b. Have the trials been reported adequately? 
3. What toxicities are experienced within the trials? 
a. Are there adequate safeguards to protect trial participants from 
possible toxicity? 
b. Are safety characteristics adequately reported? 
4. Where are the trials performed and how do they relate to the global burden of 
disease? 
 
From this list, the difference from a Cochrane review becomes more apparent. 
Cochrane reviews often attempt to synthesize multiple outcomes from the different 
studies into a single estimate of the effects of a particular intervention. This is known 
as a meta-analysis (Moher et al., 1999, Jadad, 2007). The main interest of this 
systematic review is examining the characteristics of paediatric randomised drug trials 
covering the whole breadth of specialities and the multitude of different disease 
classes. This project can be better described as a descriptive or explorative systematic 
review, in contrast to an analytical systematic review concerned with examining the 
effects of a certain intervention.  
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Answering the main research questions require the analysis of many variables 
related to the RCTs. These will be further commented on later in the methods section 
as well as in the results. 
In summary this is a descriptive systematic review of RCTs involving children 
published in 2007. It aims to study toxicity occurring within the trials but also 
analyzes many of the following aspects of the RCTs; participants, drugs, diseases, 
methods and locations. 
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2.2 ELIGIBILITY CRITERIA 
 Eligibility criteria are another distinguishing feature of a systematic review 
compared to a narrative review (Higgins and Green, 2009, Akobeng, 2005b). To 
determine the type of studies that best address the main research questions listed 
earlier, the inclusion and exclusion criteria for this review are specified as follows.  
2.2.1 TYPE OF STUDY: RANDOMISED CONTROLLED TRIALS (RCTs) 
 For this review, a distinction is made between randomised controlled trials and 
controlled clinical trials. Only randomised controlled trials are included in this review. 
All types of RCTs are eligible including parallel trials, factorial design trials as well 
as cross-over trials (Jadad, 2007). The random allocation procedure is a key eligibility 
criterion (Akobeng, 2005a). Studies where randomisation is not mentioned or 
described are excluded.  
2.2.2 TYPE OF PEOPLE: THE PAEDIATRIC POPULATION 
 In this review, the people or population of interest is the paediatric population. 
'HILQLQJ WKLV DV DQ HOLJLELOLW\ FULWHULRQ SURYLGHV XQLTXH FKDOOHQJHV µ&KLOG¶ RU
µSDHGLDWULF¶FDQFDUU\YHU\GLIIHUHQWPHDQLQJVLQ many different perspectives. For this 
project I have elected to use guidelines produced by The International Conference on 
Harmonisation of Technical Requirements for Registration of Pharmaceuticals for 
Human Use (ICH) (Food and Drug Administration, 2000, EMEA, 2001). The ICH is 
a joint collaboration of both regulators and industry experts from the European Union, 
Japan and the USA concerned with the study of human medicines. ICH guidance is 
endorsed by both the FDA and the EMEA. 
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ICH guidelines have been adopted for the classification of age groups in the 
paediatric population. The categories are as follows: 
 preterm newborn infants 
 term newborn infants (0 to 27 days) 
 infants and toddlers (28 days to 23 months) 
 children (2 to 11 years) 
 adolescents (12 to 16-18 years (dependent on region)) 
 
This categorization system leads to another difficulty that is also 
acknowledged by the ICH guidelines (EMEA, 2001). The paediatric population does 
not fall neatly in these age groupings and may actually move across the categories 
over the course of a study. Furthermore many paediatric RCTs recruit patients across 
several different categories and many trials even recruit from both the adult and 
paediatric age groups (Sammons et al., 2005). This may present issues in the process 
of classifying the studies according to age groups, due to the overlapping categories. 
Another challenge is deciding the cut-off age of participants. For instance how should 
trials involving patients between 16 and 30 years old, or 17 and 45 years old be 
categorised? As seen in the suggested age categories the ICH guidelines are unclear 
on this matter, describing adolescents as being up to 16 or 18 years of age depending 
on region. 
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Therefore the ICH age categories are further refined to be used as eligibility criteria 
for RCT in this systematic review. They are described as follows: 
 All RCTs involving (but not limited to) patients from preterm neonates up to 
16 years old 
o This would mean that mixed studies involving both paediatric and 
adult populations would also be included, for example RCTs with a 
sample population of 15-45 year old patients 
 Each intervention arm of the RCT would need to have a patient of 16 years or 
below 
 All age categories for each RCT would be reflected in the database when 
classifying age groups 
o For example, a trial with patients between 12 months to 12 years of age 
would be classed as involving all three categories i.e. infants, children 
and adolescents 
One exclusion criterion is the opposite of the above criteria i.e. RCTs without 
any participants below the age of 17 would be excluded from the systematic review.    
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2.2.3 TYPE OF INTERVENTION: DRUG TRIALS 
 $VZLWKWKHZRUGµFKLOG¶WKHUHLVDPXOWLWXGHRIZD\VWRGHILQHWKHPHDQLQJRI
WKH ZRUG µGUXJ¶ 7KLV UHYLHZ LV SULPDULO\ FRQFHUQHG ZLWK SKDUPDFHXWLFDO SURGXFWV
used mostly in therapeutic situations but also including diagnostic, anaesthetic and 
SURSK\ODFWLFLQGLFDWLRQV7KHZRUGµGUXJ¶LVXVHGLQWKLVFRQWH[WDQGWULDOVZKHUHWKH
primary intervention studied can be classed to one of the above categories would be 
eligible for the review.  
Conversely several categories of interventional trials that would be excluded 
have been predefined. They are as follows: 
 Physiological treatments such as continuous positive airway pressure (CPAP) 
and physiotherapy 
 Dietary and food supplement or enrichment products including micronutrients, 
macronutrients, probiotics and prebiotics 
 Dental products 
 Herbal, homeopathic, traditional or any medicinal products where the active 
pharmaceutical ingredient is undefined 
 
To allow for the broadest range of drug RCTs to be included in the review I 
have not specified any limitations for route of administration, compared to the 
previous review by Sammons et al. (2007) where only trials of intravenous and oral 
drugs were included. 
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2.2.4 PUBLICATION YEAR: 2007 
This project was conceptualised in 2007 with data collection beginning in 
2008. The year 2007 was chosen as it coincided with the enactment of new European 
drug legislation as described in chapter 1 (Permanand et al., 2007). Articles are added 
to electronic databases on almost a daily basis but often with a lengthy lag time from 
actual publication (Higgins and Green, 2009).  Therefore by setting an endpoint to the 
search at the later end of 2008 would allow sufficient time for reports of RCTs 
published in 2007 to be indexed and thus available to the electronic search.  
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2.3 SEARCH STRATEGIES 
 As mentioned previously, a comprehensive and reproducible search to identify 
studies relevant to the research questions is a key distinguishing feature of a 
systematic review. As demonstrated by the eligibility criteria, the wide scope of this 
systematic review sets it apart from most Cochrane reviews. Therefore the primary 
goal is to develop an efficient method of identifying the majority of eligible RCTs and 
then to obtain the relevant information from them.  
In this section, the main sources of studies relevant to the review are detailed. 
Also described are the iterative process of designing and conducting the search 
strategies, the management of references, the process of data extraction and finally the 
development of the database for this review. 
2.3.1 SOURCES OF STUDIES 
 The most efficient way to identify reports of studies relevant to this review 
would be by searching electronic bibliographic databases (Higgins and Green, 2009). 
There are numerous online databases that compile and index scientific literature. In 
the medical sciences, the two most widely used databases are MEDLINE (Medical 
Literature Analysis and Retrieval System Online, US NLM, 2008) and EMBASE 
(Excerpta Medica Database, Elsevier, 2010).   
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1. MEDLINE and EMBASE 
 MEDLINE is maintained by the United States National Library for Science 
and currently holds some 16 million references to journal articles in the field. For this 
project, MEDLINE was accessed through the OVID gateway provided by the 
eLibrary portal of the University of Nottingham. 
 Although MEDLINE contains a vast amount of literature, research has shown 
that systematic reviews utilising MEDLINE as the only bibliographic database is no 
longer acceptable as there could be large numbers of relevant studies that would be 
potentially missed (Dickersin et al., 1994, Woods et al., 1998, Suarez-Almazor et al., 
2000, Sampson et al., 2003). Nieminen and Isohanni (1999) noted that MEDLINE has 
a more North American emphasis and may provide insufficient coverage of European 
clinical research. Sampson et al. (2003) suggested that there is a risk of introducing 
bias into the meta-analyses from reviews that search MEDLINE solely.  
EMBASE is another bibliographic database that is widely used for accessing 
medical literature. It is run by Elsevier and contains 20 million references to scientific 
articles. EMBASE appears to have more European exposure (Nieminen and Isohanni, 
1999). Although there is a significant degree of overlap between the two databases; 
there are more than a thousand of journals uniquely indexed in each database  
(Higgins and Green, 2009). It is now standard practice for systematic reviews 
conducted presently to search both MEDLINE and EMBASE.  
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Relevant to this review there is evidence that EMBASE provides a larger 
coverage of pharmacology-related articles (Robinson, 2005). Nonetheless, I expect to 
encompass a wide range of the relevant medical literature by including both of these 
major databases in this systematic review. EMBASE was accessed via the same 
OVID gateway as MEDLINE. 
2. COCHRANE CENTRAL REGISTER OF CONTROLLED TRIALS 
Along with EMBASE and MEDLINE, the Cochrane Central Register of 
Controlled Trials (CENTRAL) is included as the three most important sources of trial 
reports used for systematic reviews (Higgins and Green, 2009). CENTRAL is 
different in nature from MEDLINE or EMBASE. It began as an effort by the US 
National Library of Sciences working with the Cochrane Collaboration to identify all 
randomised or controlled healthcare studies in their MEDLINE database (Dickersin et 
al., 2002). The identified reports are then tagged electronically to allow systematic 
reviewers to efficiently search for the studies, thereby becoming a virtual register of 
clinical trials indexed in MEDLINE. 
CENTRAL underwent further development when two deficiencies became 
apparent; that is was infrequently updated and that it would be limited to trials 
indexed in MEDLINE only meaning that many trials would be potentially missed by 
reviewers (Dickersin et al., 2002, Higgins and Green, 2009). As a result the Cochrane 
Collaboration greatly expanded the resources searched to contribute to trials listings 
in CENTRAL. Currently all relevant randomised or controlled trials identified in 
searches by all Cochrane Review Groups or centres in the course of their systematic 
reviews would be listed in CENTRAL.  
 
49 
 
These trials are identified by two primary methods; electronic searches of 
bibliographic databases and handsearching of reports in conference proceedings, 
journals or other material. 
Following work on searching EMBASE (Lefebvre, 1996) and the inclusion of 
many regional databases and specialised registers in searches by Cochrane reviewers, 
the databases searched are no longer limited to MEDLINE. The handsearches access a 
vast amount of material, including isolated abstracts and conference proceedings, grey 
and even unpublished work. As of January 2008 CENTRAL lists in excess of 500,000 
reports, the majority of which were sourced from MEDLINE (310,000 reports) and 
EMBASE (50,000 reports) (Higgins and Green, 2009). For this review CENTRAL 
was accessed via the Wiley Interscience library portal accessible online at the 
following website:  
http://www.mrw.interscience.wiley.com/cochrane/cochrane_clcentral_articles_fs.html 
3. OTHER SOURCES and FINALISING  
Cochrane reviewers attempt to minimize bias by including the greatest breadth 
of evidence possible. This involves searching many sources of relevant studies (as 
seen in the process of contributing to CENTRAL). It was decided to exclude the 
following sources due to low yields or resource limitations.  
 Handsearching of journals, conference proceedings, books, unpublished and 
grey literature was dropped at the outset of the search due to limited resources.  
 Regional databases were excluded after trial runs revealed difficulties in 
developing efficient search strategies, low yields and resource limitations as 
non-English results required translation facilities which were not available to 
me. 
 Specialised registers were excluded for the same reasons. 
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4. WHY NOT JUST SEARCH CENTRAL? 
All three of the major databases, MEDLINE, EMBASE and CENTRAL, were 
searched for this systematic review in line with the recommended procedure for all 
Cochrane reviews (Higgins, 2009). However the question might arise that since 
efficiency is crucial in this project, why not just search CENTRAL as it actually 
contains of the result of searches on MEDLINE, EMBASE and various other sources 
as seen in the following illustration? 
 
 
Illustration from Cochrane Handbook for Systematic Reviews of Interventions 
Version 5.0.2 [updated September 2009] (Higgins and Green, 2009) 
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Firstly the effort of identifying and tagging relevant reports indexed in 
MEDLINE by the US-based workers actually ceased in 2004 (personal 
communication via email from Bobbi Scherer, Associate Director of US Cochrane 
Centre). Therefore the listings in CENTRAL for studies published in 2005 up to the 
present are limited to contributions by the individual Cochrane Review Groups.  
Secondly the contributing Cochrane Review Groups are organised around 
disparate specialities or medical fields. It is reasonable to expect that coverage does 
not extend to all fields where paediatric trials are conducted.  
Thirdly, there is a significant delay from the time any report appears in 
MEDLINE or EMBASE before it is potentially indexed in CENTRAL. For 
MEDLINE records this may be several months and between 1-2 years for EMBASE 
records; as CENTRAL is only updated quarterly (Higgins and Green, 2009). 
For example a search of CENTRAL limited to the year 2007, conducted in 
July 2008, would potentially miss: 
 studies in MEDLINE in areas where there are no active Cochrane Group 
reviews as there is no retagging effort for 2007 
 reports of studies indexed in MEDLINE in late 2007 onwards 
 reports of studies added to EMBASE beginning from late 2006 onwards  
Finally the low proportion of paediatric systematic reviews have been noted 
previously (Martinez-Castaldi et al., 2008) . Thus many published paediatric clinical 
trials would probably be absent from CENTRAL as there have been limited effort in 
searching for and appraising them.  
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2.3.2 SEARCH STRATEGIES 
Considering the specific type of trial reports examined by this review (drug 
RCTs involving the paediatric population published in 2007), MEDLINE and 
EMBASE were searched using highly developed search strategies. CENTRAL was 
searched using a tested paediatric filter.  
1. MEDLINE 
 In 1994, Carol Lefebvre designed a highly sensitive search strategy to identify 
RCTs in MEDLINE (Dickersin et al., 1994). This strategy became known as the 
Cochrane Highly Sensitive Search Strategy (HSSS) and was used widely by 
systematic reviewers including my supervisors (Sammons et al, 2005).  
A decade later there was a major effort (involving Carol Lefebvre, Julie 
Glanville and other colleagues) to develop a search strategy using objective and 
research-based approaches, similar to that used in designing and evaluating a 
diagnostic test (Glanville et al., 2006). The workers selected a gold standard of known 
reports of RCTs as well as a comparison group on non-RCT reports indexed in 
MEDLINE. This selection was then used to identify keywords that can be used as 
search terms. The ability of the keywords to discriminate between RCTs and non-
RCTs were ascertained using logistic regression and were tested on other MEDLINE 
records. The result was six different search strategies that can be used depending on 
whether the emphasis of the search was sensitivity or specificity. These strategies 
were later tested on another gold standard set namely the McMaster Clinical Hedges 
Database with similar results (Wilczynski et al., 2007). 
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The most sensitive strategy developed by Glanville et al. (2006) uses 7 
keywords to retrieve 99.5% of RCTs from their own gold standard group of studies 
and 98.5% of RCTs from the McMaster gold standard. This strategy was named the 
CRD/Cochrane HSSS (2005 revision). This strategy has been used to search for RCTs 
in MEDLINE. Only human studies were included. 
To narrow the search down to drug trials, two medical subject heading 
(MeSH) phrases previously utilised by Sammons et al. (2005) were used ± µGWIV¶DQG
µH[S 'UXJ 7KHUDS\¶ 7KH WHUP µGWIV¶ PHDQV µGUXJ WKHUDS\ LQ IORDWLQJ VXEKHDGLQJ¶
and will retrieve all drug therapy related articles indexed under that subheading, 
ZKHUHDVWKHWHUPµH[S'UXJ7KHUDS\¶H[SORGHVWKHVXEMHFWKHDGLQJRIGUXJWKHUDS\WR
retrieve relevant articles. These two MeSH phrases were combined with the Boolean 
RSHUDWRUµ25¶WKXVDOORZLQJIRUDEURDGDQGVHQVLWLYHVHDUFKRIGUXJUHODWHGVWXGLHVLQ
the search strategy yet at the same time narrowing down the scope of the search. 
In the same year of the work by Glanville et al. (2006), the Hedges team at 
McMaster University performed a similar study of age-specific search terms to 
retrieve clincial trial reports relevant to the different age groups (Kastner et al., 2006). 
In this study the gold standard were results of a manual handsearch of 161 core 
medical journals. Again the results were several combinations of keywords that can 
be selected depending on whether a sensitive or specific search was needed in the 
review. For this systematic review, the most sensitive combination of keywords for 
paediatric medicine and neonatal medicine were adopted from their study (combined 
ZLWKWKH%RROHDQRSHUDWRUµ25¶ 
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Finally the search was limited to studies published in 2007. The full search 
strategy is as follows. 
 Searches Comments 
1 clinical trial.pt. 
 
CRD/Cochrane HSSS (2005 revision) 
(Glanville et al., 2006) 
 
Note the original strategy included  
WHUPVLQFOXGLQJµGWIV¶WKLVWHUPLVLQVHUWHGEHORZ 
2 randomized.ab. 
 
3 placebo.ab. 
 
4 randomly.ab. 
 
5 trial.ab. 
 
6 groups.ab 
 
7 1 or 2 or 3 or 4 or 5 or 6 
 
Combining all 6 terms 
8 Animals/ 
 
 
9 Humans/ 
 
10 8 and 9 Studies where both humans and animals were 
studied 
11 8 not 10 
 
Isolating studies where only animals were studied 
12 7 not 11 
 
Excluding trials where no humans were studied 
13 dt.fs. 
 
Focussing on drug studies  
(Sammons et al., 2005) 
14 exp Drug Therapy/ 
 
15 13 or 14 
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 Searches Comments 
 
16 
 
12 and 15 
 
 
Combining human RCTs with drug studies 
17 child:.mp. 
 
Validated age specific search strategy by Hedges 
Team 
(Kastner et al., 2006) 18 adolescent.mp. 
 
19 infan:.mp. 
 
20 gestation:.tw. 
 
21 17 or 18 or 19 or 20 
 
Combining all 4 terms 
22 16 and 21 
 
Combining human drug RCTs with paediatric age 
groups 
23 limit 22 to yr="2007" 
 
Reports published in 2007 only 
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2. EMBASE 
 Initially less effort has gone into developing search strategies for EMBASE. 
Carol Lefebvre did some early work (Lefebvre, 1996), however MEDLINE was 
searched more often than EMBASE in systematic reviews. This was reflected in 
records held by CENTRAL where EMBASE contributed less than 10% of the studies 
held while MEDLINE-sourced reports constituted almost 60% of all the studies 
(Higgins and Green, 2009). As previously mentioned, evidence then accumulated on 
the importance of searching both MEDLINE and EMBASE as well as other sources 
when conducting systematic reviews. This led to more work on search strategies for 
EMBASE notably by the Hedges team at McMaster University.  
Sharon Wong and colleagues identified relevant search terms and tested them 
on results from handsearches of 55 medical journals indexed in EMBASE (Wong et 
al., 2006). They then developed several search strategies for RCTs indexed in 
EMBASE from the combination of search terms identified. A three keyword 
combination that was found to be the best optimisation of sensitivity (94.5% of 
handsearched trials) and specificity (92.6% of non-relevant studies from 
handsearches) was selected for this review.  
There does not seem to be any age-specific search strategies developed for 
EMBASE in the literature. Therefore the age group classifiers provided by the Ovid 
Gateway were used for this study. I did not use any terms to narrow the search to drug 
trials only. Trials of non-drug interventions were identified and excluded when the 
individual abstracts were reviewed (see section 2.5). Again Boolean operators were 
used to combine search terms as appropriate and the search results were limited to 
studies published in 2007. The full search strategy can be seen as follows. 
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 Searches Comments 
1 Random:.tw. 
 
Optimised strategy by Wong et al (2006). 
2 placebo:.mp. 
 
3 double-blind:.tw. 
 
4 1 or 3 or 2 
 
Combining all three terms 
5 limit 4 to yr="2007" 
 
Studies published in 2007 only 
6 limit 5 to  
(infant <to one year> or  
child <unspecified age> or  
preschool child <1 to 6 years> or 
school child <7 to 12 years> or 
adolescent <13 to 17 years>)  
 
Age group categories provided by Ovid 
Gateway for EMBASE 
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3. CENTRAL 
 The BestBETs (Best Evidence Topics) team is a Manchester-based group that 
has embraced evidence based medicine by providing brief, well-structured reviews of 
the best available evidence of a specific clinical topic. In 2002 (updated in 2003) they 
developed and tested a sensitive paediatric filter to identify any paediatric related 
studies in MEDLINE (Mackway-Jones K, 2002). This maximally sensitive filter has 
49 search terms. These search terms were adapted to be used for CENTRAL, resulting 
in a list of 18 search terms. Where appropriate, the wildcard character denoted by an 
astHULVNµ¶ZHUHXVHGWRDOORZIRUSOXUDOYHUVLRQVDQGGLIIHUHQFHVLQVSHOOLQJDVZHOO
as terminology. 
 
Screen capture of the search webpage for Cochrane CENTRAL via Wiley 
Interscience portal. 
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The list of paediatric-related search terms that have been used is as follows. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Keywords 
1 preterm* 
2 prematur* 
3 perinat* 
4 neonat* 
5 newborn* 
6 bab* 
7 infan* 
8 toddler* 
9 child* 
10 pediatr* 
11 paediatr* 
12 boy* 
13 girl* 
14 kid* 
15 juvenil* 
16 teen* 
17 adoles* 
18 Pubescen* 
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4. SUMMARY 
In summary MEDLINE and EMBASE were searched for RCTs using 
validated search strategies. The results of the searches were then narrowed down 
according to the pre-VSHFLILHGHOLJLELOLW\FULWHULD%RROHDQRSHUDWRUVµ$1'¶µ25¶DQG
µ127¶ZHUHXVHG WR combine validated keywords representing the different aspects 
of the eligibility criteria. For CENTRAL a set of validated age-specific keywords 
were utilised to search for relevant studies. There was no language restriction applied 
for any of the three search strategies. These unique search strategies are designed for 
the highest sensitivity in identifying relevant studies for this systematic review. 
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2.4 MANAGING REFERENCES 
 Storing and processing the thousands of references resulting from the search 
strategies detailed previously required bibliographic software. The main 
characteristics required were user-friendliness, availability of technical support and 
the ability to detect duplicate references, particularly with the subtle differences in 
indexing used by the different databases. With these in mind, the Endnote software 
was used (Version X, Philadelphia, USA, copyright owned by Thomson Reuters).  
 After executing the search strategies for MEDLINE and EMBASE, each and 
every resulting reference on the Ovid gateway was exported into individual libraries 
on Endnote. The search page provided by Wiley InterScience for CENTRAL has only 
five input slots for search terms. Therefore the 18 age-specific keywords developed 
earlier were entered in four separate stages. The four files of search results were then 
exported into an Endnote library. All available fields for all the references were 
exported into Endnote. 
 The three libraries were then combined into a single Endnote library and the 
µILQG GXSOLFDWHV¶ FRPPDQG LQ (QGQRWH ZDV H[HFXWHG DV GHSLFWHG LQ WKH VFUHHQ
capture). All duplicates were highlighted below the originating reference. Each 
duplicate pair was carefully inspected to ensure there were no unique references that 
might be erroneously deleted. After inspection was completed, all detected duplicates 
were deleted. 
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6FUHHQFDSWXUHRI(QGQRWHVRIWZDUHVKRZLQJµ)LQG'XSOLFDWHV¶WRRO 
Note: Database shown not used for this systematic review 
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2.5 SELECTING AND OBTAINING STUDIES  
 The title and abstract for each remaining reference was read and any of the 
inclusion or exclusion criteria identified, to determine whether the report should be 
included in the review. Whenever there was insufficient information in the title or 
abstract, all the other fields on Endnote were searched for any additional information. 
I consulted my supervisors for any reports whenever I was unsure of the suitability 
and obtained the full paper if needed. A low threshold of hesitancy was implemented 
in the assessment; any paper where eligibility was unclear was further assessed.  
Although the Cochrane Handbook recommends that two independent 
reviewers assess the eligibility of the study, this was not possible for this PhD. 
Nonetheless the precautions taken should minimise the introduction of bias or human 
error. Furthermore this systematic review has a wide scope with a prominent 
descriptive focus rather than a solely analytical purpose; therefore minimisation of 
bias during assessment of eligibility is felt not to be crucial to the study. 
The unit of interest for this review are the individual RCTs. However this may 
not be the same as the reports of the studies as there may be multiple reports of a 
single study being published (Higgins and Green, 2009). Therefore all reports 
assessed as being eligible for this review were double-checked by examining adjacent 
references, especially the author, title and abstract fields in Endnote. The most 
complete or recently updated report of a study where multiple reports are present was 
selected. Where different result sections have been reported in separate papers, data 
was collected from all the papers. 
No authors of the selected papers were contacted for clarification. This was 
not possible considering the very large numbers of references obtained, in addition to 
time and resource constraints. 
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 The full article was obtained for all studies deemed eligible for this review. 
The bulk of these were obtained from fulltext online publications. If not published 
online, print copies were obtained directly from the University of Nottingham library 
or from the Interlibrary Loan service. Each article was then labelled with the 
corresponding record number of the reference within the Endnote library.  
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2.6 DATA EXTRACTION AND MANAGEMENT 
 In the context of this review, data is defined as information about or derived 
from a study (Higgins and Green, 2009). I have determined what data to be included 
based on the main research questions (section 2.1.1), corresponding to the major 
themes studied in this systematic review. A 1-page data extraction form was designed 
to allow comprehensive yet efficient extraction of data from the articles. Piloting of 
the form with a small sample of RCT reports was successful in terms of practicality 
when dealing with the large amounts of reports and data. The data extraction form and 
brief explanation of the data types can be seen on the next page. The types of data 
collected will be elaborated further in the specific chapters. 
 The Cochrane handbook strongly recommends that data from each article is 
extracted by more than one independent reviewer to minimise errors and the 
introduction of potential biases. As mentioned previously, this was not a realistic 
proposition in the context of this review as a PhD studentship. Nevertheless a further 
measure was put in place where both supervisors will review and extract crucial 
safety data from a significant proportion of the articles. This is described further in 
chapter 5. 
 A statistical database was created using the Statistical Package for the Social 
Sciences software (SPSS version 16.0, SPSS Inc., Chicago, IL, USA) to store and 
analyse data from the data extraction forms. The variables on the database were coded 
to correspond closely to the data collection forms. The full SPSS database and all 
Endnote libraries created and used in this review are included in the CD 
accompanying this thesis. 
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Data collection form designed for this review 
Each data type is further described in the results chapters 
No  
Journal  
Country  
HDI 1 2 3 
Income 1 2 3 4 
Index ENDNOTE 
PaedID YES NO 
Random (J1) YES NO 
GenName  
ATC KEY 3 
ICD10 KEY 4 
Consent YES NO 
Assent YES NO 
TypeofTrial Safe Eff. PK 
TypeofComparison KEY 5 
RouteofAdmin KEY 6 
DoseMent YES NO 
DoseUnit KEY 7 
RxType KEY 8 
Formulation YES NO 
PrimeOutcome YES NO 
SampleSize YES NO 
STOP YES NO 
Blinding (J2) 0 1 2 
Arms 1 2 3 4 5 
Crossover YES NO 
Diagram YES NO 
Ethics YES NO 
CentresNo 1 2 Multi 
Interntnal YES NO 
CentreType Hosp-IN Hosp-OUT Comm. 
Mixed YES NO 
ChildNo  
Withdr/drop(J3)  YES NO 
Child No Category KEY 10 
ChildAge Preterm Term-27d 28d-23mo 2-11yrs 12-16 
SafeMethod YES NO 
SMC/DMSB YES NO 
AEs YES NO 
AEgrade KEY 12 
ADR YES NO 
ADRgrade Sev Mod Mild 
Death YES NO 
DeathClass YES NO 
Funding YES NO 
FundSource KEY 13 
OverseasFund YES NO 
Registered KEY 14 
Random Adq (J4) YES NO 
Blinding Adq (J5) YES NO 
67 
 
2.7 CONCLUSION 
 In conclusion a detailed description of the methods used to perform this 
systematic review has been provided. Although drawing heavily from the 
recommendations by the Cochrane Handbook, unique search strategies have been 
designed to search for paediatric RCTs based on validated techniques developed by 
several distinguished research groups. However resource limitations meant that 
certain recommendations from the Cochrane Handbook were not implemented, 
particularly the requirement of multiple independent reviewers. Nonetheless essential 
measures were put into place to minimise the introduction of errors or biases. Endnote 
was used to manage the large number of reports resulting from the search. A SPSS 
statistical database was created to store and analyse the great amount of data extracted 
from the eligible studies.  
 Further details on specific methods will be provided in the subsequent 
chapters including on the categorisation and coding of variables recorded from the 
studies and types of statistical analyses. 
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CHAPTER 3:  
DEMOGRAPHICAL & 
EPIDEMIOLOGICAL 
CHARACTERISTICS 
 
 
 In this chapter, the results from the search strategies in chapter 2 are described. 
The paediatric randomised controlled trials (RCTs) identified in this systematic 
review are studied to determine their demographical and epidemiological 
characteristics; the characteristics of the participating paediatric population, the 
diseases involved and the drugs being trialled. This is set in the context where 
relatively little is known on the overall situation of RCTs involving children. Thus the 
current work hopes to elucidate the current situation of paediatric drug RCTs, add to 
previous studies, and more importantly to identify areas requiring further attention 
from paediatric researchers, health professionals and drug regulators. 
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1. INTRODUCTION 
 The past two decades has seen a considerable interest in medicines used in 
children. Previously, paediatric drugs were inadequately evaluated in their population 
leading to the situation where prescription of unlicensed and off label drugs was 
widespread. Growing concern with the risks associated with such use, coinciding with 
rising awareness that medical practice should be evidence based resulted in major 
changes in drug regulation in North America followed by European enactments later 
on. Subsequently the World Health Organisation (WHO) initiated global programmes 
to promote safety of medicines used in children titled Promoting Safety of Medicines 
for Children (Watts, 2007) and to improve access and availability of child-specific 
medicines for children all over the world - Make Medicines Child Size (Choonara and 
Bauchner, 2008).  
The main goal of these efforts is to ensure drugs prescribed to children are 
supported with high quality evidence obtained from paediatric RCTs (except when 
RCTs are unfeasible). Although RCTs have been well studied, there has been 
relatively little work done to elucidate the overall situation of RCTs involving 
children.  
 Campbell et al., (1998) published one of the earlier efforts to study paediatric 
RCTs. They handsearched 15 years of the Archives of Disease in Childhood journal 
(excluding the Fetal and Neonatal edition) between 1982 and 1996 and identified 249 
RCTs published within that period. Most of the RCTs (69%) were conducted in the 
UK. They found that most of the RCTs were small; roughly half recruiting fewer than 
40 children in total thereby fewer than 20 patients were studied in each treatment 
group. More than 80% of the RCTs were single centre trials. 
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 In 2003, the FDA reported on 53 studies involving children of 33 drugs that 
were granted patent extensions under the new provisions of the Modernization Act of 
1997 (Roberts et al., 2003). More than 50,000 patients participated in these studies 
although the vast majority totalling 41,356 children aged between 6 months and 2 
years took part in 2 large studies of ibuprofen over-the-counter products. The 
information gained from these studies led to labelling changes for the drugs including 
important dosing and safety revisions. The 53 studies included all types of studies, not 
just RCTs. 
Chan and Altman (2005) undertook a broad review of all randomised trials 
published in PubMed (which encompasses MEDLINE) in the month of December 
2000. They identified 519 RCTs, of which only 37 (7%) were categorised as 
paediatric. They did not describe any characteristics specific on the paediatric RCTs 
but lamented on the small sample sizes in the RCTs overall. The median number of 
participants overall was 80, with 32 patients studied per treatment group. They 
calculated that with 32 patients per treatment group, a trial has only a 39% power to 
detect a difference of between 10% and 30% in events at the p=0.05 significance 
level. Note that the sample sizes in this review were markedly larger than in the 
paediatric RCTs studied by Campbell et al. (1998).  
The first broad review of paediatric clinical trials was performed here in our 
department by Sammons and Choonara (2005). They examined paediatric clinical 
trials of oral and intravenous drugs published from 1996 to 2002 that were indexed in 
MEDLINE. The review included pharmacokinetic trials as well as RCTs but excluded 
human immunodeficiency virus (HIV) and oncology trials because these areas have 
been well covered by previous reviews (Hargrave et al., 2001, Nolan et al., 2002). 
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736 trials were identified; 619 (84%) involved paediatric patients solely while 
the remainder (117, 16%) included both adult and paediatric patients. There were 
more multicentre studies (173, 24%) compared to the review by Campbell et al. 
(1998). The sample sizes also appeared larger, with single centre studies recruiting a 
median of 50 patients while multicentre studies recruiting a median of 227 patients. 
The great majority of the trials originated from North America and Europe, consisting 
73% of the total number of trials. The most common specialty areas studied were 
general paediatrics, infectious diseases and neurology. 
In the background of the regulatory changes aimed at stimulating paediatric 
clinical trials recently, several research groups analysed the widely held opinion that 
paediatric research lagged behind adult research.  
Cohen et al. (2007) examined both adult and paediatric RCTs published 
between 1985 and 2004 in five high-impact medical journals (New England Journal 
of Medicine [NEJM], Journal of the American Medical Association [JAMA], Lancet, 
British Medical Journal [BMJ] and Canadian Medical Association Journal [CMAJ]). 
From 5420 RCTs, they found that there were almost five times as many adult RCTs 
compared to solely paediatric RCTs. They also found that the number of adult RCTs 
published increased significantly on an annual basis while the number of paediatric 
RCTs remained stagnant. From their subset of RCTs published in 2000, they 
discovered that paediatric RCTs had a smaller sample size compared to adult RCTs 
(median 272 vs 318 patients), although the difference was not statistically significant.  
 
 
 
 
72 
 
Martinez-Castaldi et al. (2008) reviewed all articles published in NEJM, 
JAMA, Annals of Internal Medicine, Pediatrics, Archives of Internal Medicine and 
Archives of Adolescent and Pediatric Medicine over a three month period in 2005. 
They found that there were significantly more adult RCTs compared with paediatric 
RCTs (24% vs 9%). However no specific characteristics of the paediatric RCTs were 
described.  
Pandolfini et al. (2008) conducted a review of European published and 
ongoing paediatric drug therapy trials between 2004 and 2007. The major disease 
categories studied by the 379 published trials were Infectious Diseases, Neoplasms 
and Nervous System Diseases according to the ICD-9 classification system that they 
used. Again, certain specific characteristics of the published trials such as sample 
sizes or age groups were not reported. 
Thus although a few trends are becoming apparent such as the small sample 
sizes, the dearth of paediatric RCTs compared to adult studies and that most 
frequently studied areas were in general paediatrics, infectious and nervous system 
diseases; epidemiological information on paediatric RCTs overall remains unclear. 
What is known on the children participating, the diseases studied or the drugs trialled 
were sourced from sporadic studies. These reviews were either limited to a single 
paediatric journal (Campbell et al., 1998), a subset of high impact publications 
(Cohen et al., 2007, Martinez-Castaldi et al., 2008) or a single geographical region 
(Pandolfini et al., 2008). Furthermore these studies varied widely in their design and 
analyses, ranging from studying paediatric RCTs specifically (Campbell et al., 1998) 
to reviewing all RCTs (Chan and Altman, 2005) and examining all articles (Martinez-
Castaldi et al., 2008). 
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In this context I plan to broadly describe paediatric drug RCTs published in 
2007, building on the work of Sammons and Choonara (2005); detailing the specific 
characteristics of the trials, paediatric participants, disease areas and drug types in the 
RCTs.   
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2. METHODS 
 Each paediatric RCT identified using the search detailed in chapter 2 was 
carefully read to obtain data on the following subjects: 
2.1 Location and setting of the RCTs 
The country where the RCT was conducted was recorded. In some reports this 
was obvious or explicitly stated. When unclear, supplementary information, index 
citations and author affiliations were examined to determine country where the RCT 
was performed. When the RCT recruited participants from more than one country (ie. 
cross border or international studies) all participating countries were recorded.   
This information was then used to classify the RCT location according to 
Human Development Index (HDI) of 2007 (UN Development Programme, 2007) and 
the World Bank Income Level (World Bank, 2007). The HDI is a composite measure 
including life expectancy, literacy rate, education enrolment and per-capita GDP. It is 
used to rank countries into developed (high HDI), developing (medium HDI) and 
underdeveloped (low HDI) categories. The World Bank ranks countries into high, 
middle and low income categories according to their gross domestic product (GDP) at 
purchasing power parity (PPP) per capita. Multinational RCTs that recruited across 
HDI or Income Level categories were noted.  
Taking into account the wide variation of the healthcare systems between 
countries, a simple classification system was used for the setting of the RCT. RCTs 
were determined to have been performed either in general practice/outpatients, in 
hospital wards or in the community setting (schools, villages, towns). The number of 
centres involved was simply classified as either a single centre study or a multicentre 
study. 
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2.2 Characteristics of the participants 
 Firstly it was determined whether the RCT recruited from both the paediatric 
and adult populations (adult defined as any participants aged 17 and above ± see 
chapter 2).  The total number of paediatric patients participating in the RCT was then 
recorded. Mixed trials where the number of children was not described were 
identified. The sample sizes were then divided into ranges. 
 The age range of the participants in each RCT was obtained from the results 
section. However many of the mixed age group RCTs only described mean ages for 
the treatment arms. In these cases, the age range was determined from the methods 
section. It was then determined whether each of the ICH age group categories were 
present in the RCTs.   
2.3 Characteristics of the drugs and diseases 
 The main drug therapy being trialled in each RCT was determined and 
recorded. Where the main intervention was a combination of several drugs or a certain 
drug regimen, this was recorded as well. The treatment under question was then 
classified according to the WHO Anatomical Therapeutic Chemical (ATC) 
classification system (WHO, 2008). The complete ATC classification was obtained 
for the drug treatment for each RCT and the drugs were coded according to the 
highest level of the ATC system. The route of administration for the drug under trial 
was recorded, as well as whether the dose was mentioned and the unit of the dose ie. 
whether the dose was tailored to body weight, surface area or any other variable. 
 The disease relating to each RCT report was coded according to the 2007 
revision of the WHO International Statistical Classification of Diseases and Related 
Health Problems (ICD-10, WHO, 2007).  
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2.4 Funding  
 The full reports of the RCT were examined to discover any declarations or 
acknowledgements of funding. The major source of funding for the trial operations 
were recorded and classified. Complimentary or free-of-charge supply of drug 
products, instrumentation and software were not considered as study funding.  
 Any difficulties arising when categorising a trial was presented to my 
supervisors at supervisory meetings and a consensus decision obtained. The statistical 
methods used in this descriptive analysis included calculating medians, interquartile 
ranges (IQRs), means and ranges. 
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3. RESULTS 
 The search was finalised and databases were locked in November 2008. The 
search strategies yielded 15,577 abstracts; 2747 from MEDLINE, 3149 from 
EMBASE and 9681 from Central respectively. Duplicate citations were then removed 
using Endnote and 8945 abstracts remained. Each of the abstracts were read to 
identify eligible paediatric RCTs. Subsequently 582 eligible RCTs were identified, 
with an additional 22 RCTs that were reported in non-English articles identified from 
their abstracts provided in English. 
 
 
Diagram 1: Citation flow from search strategies  
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3.1 LOCATIONS AND SETTINGS 
1. Trial Locations 
There were 96 (16%) RCTs that recruited patients in more than one country. 
The remaining 508 (84%) recruited within one country. The majority of the cross 
border studies involved member countries of the European Union including the 
United Kingdom, as well as the USA and Canada.  
For the single country RCTs, almost a quarter (115/508, 23%) were performed 
in the USA. India had the second highest number of RCTs with 32 (6%) followed by 
Turkey and Iran (27, 5% and 25, 5% respectively). Please see the appendix for the 
country locations of the RCTs. 
When categorised according to HDI status, 392 (65%) RCTs were conducted 
in high HDI countries, 153 (25%) RCTs were performed in medium HDI countries 
while 28 (5%) were from low HDI countries. The remainder of 31 (5%) RCTs were 
multinational studies that recruited from countries across more than one HDI group. 
 
Human Development Index (HDI) category No of trials (n) Percent (%) 
High 392 65 
Medium 153 25 
Low 28 5 
Multinational studies recruiting across HDI 
categories 31 5 
Total 604 100 
Table 1: Setting  of paediatric RCTs published in 2007 categorised according to HDI 
(U.N. Development Programme, 2007) 
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Similarly, when classified according to World Bank Income groups the 
majority of the RCTs were conducted in high and upper middle income countries, 
consisting almost 70% of the database. There were 95 (16%) studies from lower 
middle income countries and 51 (8%) studies from low income countries. Forty-two 
(7%) RCTs were multinational trials that recruited across World Bank income groups, 
similar to those mentioned previously for the HDI categories. 
 
World Bank Income group No of trials (n) Percent (%) 
High Income 352 58 
Upper Middle Income 64 11 
Lower Middle Income 95 16 
Low Income 51 8 
Multinational studies recruiting across income 
categories 42 7 
Total 604 100 
Table 2: Setting of paediatric RCTs published in 2007 categorised to World Bank  
              Income Group (World Bank, 2007) 
2. Setting of trials 
 There were 268 (44%) studies that were performed in more than one centre. 
The remaining 336 (56%) were single centre RCTs. Approximately one-third (219, 
36%) of the trials involved hospital in-patients (including patients admitted for day 
cases). The rest were conducted in the community; 307 RCTs (51%) were done in 
community health facilities such as general practices and outpatient departments 
while 69 RCTs (11%) were based in non-healthcare facilities including schools, 
villages and towns. In nine of the reports, the type of study setting was unable to be 
determined. 
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3.2 PATIENTS 
1. Sample Sizes 
 In all, 428 (71%) of the RCTs recruited from the paediatric population only. 
The remaining 176 (29%) studies recruited both adult and paediatric patients. A large 
proportion from the mixed population group RCTs (143/604, 24% of total studies) did 
not report the number of participants by age group. Therefore the number of children 
participating in these trials could not be ascertained.  
 A total of 101,048 neonates, infants, children and adolescents took part in drug 
RCTs from the reports that indicated their sample population sizes. The median 
sample size of the RCTs was 89 (IQR= 41-120 patients).  
 
Trial sizes (no of participants) No of trials (n) Percent (%) 
2-9 16 3 
10-49 130 22 
50-99 105 17 
100-499 164 27 
500-999 31 5 
1000 and above 15 2 
Indeterminate 143 24 
Total 604 100 
Table 3: Sample sizes of paediatric randomised controlled drug trials published in    
2007 
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The number of paediatric patients in each study ranged from 2 to 8352 
patients. There were two studies in which only 2 paediatric patients were recruited; 
both were mixed age group RCTs. The first was a trial comparing high dose 
intravenous steroid regimens for acute optic neuritis that recruited a 7 and a 10 year 
old in each group (Menon et al., 2007). The second compared Buspirone versus 
placebo to treat spinocerebellar ataxia where a 14 and a 15 year old were included 
(Assadi et al., 2007). 
 There were 15 RCTs that recruited more than 1000 children each. The largest 
trial in the database recruited a total of 8352 children. This trial compared two 
influenza vaccine types in infants and children between 6 and 59 months of age 
(Belshe et al., 2007). 
 
2. ICH age groups of trial participants  
 As with participant numbers, in many reports of mixed population RCTs the 
ages of paediatric participants were not provided in adequate detail. Most of the trials 
UHFUXLWHG SDWLHQWV LQ WKH ,&+ µFKLOGUHQ¶ DJH FDWHJRU\ RI -11 years old (397/604 
5&7V  DQG WKH µDGROHVFHQW¶ FDWHJRU\ RI -16/18 years old (366/604 RCTs, 
61%). Over a quarter of the trials in the database recruited infants of 28 days to 23 
months of age (157/604, 26%) while there were far fewer studies involving neonates; 
both preterms (26/604, 4%) and full term babies (23/604, 4%).  
Taken together, only 41 trials in the database were neonatal studies of both 
preterm and full term babies. The neonatal trials involved between 8 and 2017 
neonates with a median of 60 participants (IQR=29-181, mean=241). Please see 
appendix for a full list of the 41 neonatal RCTs. 
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ICH age group category No. of trials (n)* Percent (%)+ 
Preterm neonates 25 4 
Full term neonates 22 4 
Infants and toddlers 157 26 
Children 397 66 
Adolescent 366 61 
Table 4: ICH paediatric age groups of participants in paediatric drug RCTs published 
in 2007 
* Note that there is overlap between age group categories (as described in chapter 2), 
for instance studies involving patients between 12 months and 12 years old will span 
all 3 categories of infants, children and adolescents. 
+ out of 604 RCTs in the database 
 
Figure 1: Percentage of trials recruiting each ICH age group category 
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3.3 DRUGS and DISEASES 
1. Drugs 
 The most common drugs studied in the RCTs belonged to the nervous system 
(group N) category of the WHO ATC classification system; totalling 155 (26%) of all 
the RCTs. This was followed by group J or the anti-infectives for systemic use group 
(101, 17%) and group R - respiratory system drugs (74, 12%). These three areas 
comprised over half of the RCTs in the database.  
 
ATC CLASS Group No. of trials % 
Nervous system N 155 25.7 
Anti-infectives for systemic use J 101 16.7 
Respiratory system R 74 12.3 
Antiparasitic products,insecticides and repellents P 45 7.5 
Systemic hormonal preparations,excl. sex hormones 
and insulins H 42 7.0 
Alimentary tract and metabolism A 41 6.8 
Antineoplastic and immunomodulating agents L 41 6.8 
Dermatologicals D 40 6.6 
Musculo-skeletal system M 20 3.3 
Blood and blood forming organs B 15 2.5 
Cardiovascular system C 13 2.2 
Sensory organs S 10 1.7 
Genito urinary system and sex hormones G 4 0.7 
Various* V 3 0.5 
Total  604 100.0 
Table 5: WHO ATC drug classes studied by paediatric RCTs published in 2007 
* These were the following RCTs: amifostine in paediatric osteosarcoma (Gallegos-
Castorena et al., 2007), xylitol in acute otitis media (Hautalahti et al., 2007) and 
dexrazoxane in acute myeloid leukaemia/myelodysplastic syndrome (Tebbi et al., 
2007).  
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Looking at ATC subgroups, the most frequently studied nervous system drugs 
were anaesthetic agents followed by analgesics and stimulant drugs used in attention 
deficit hyperactivity disorder (ADHD). 
NERVOUS SYSTEM (Group N)  No. of trials (n) 
Percent 
(%) 
Anaesthetics 56 36 
Analgesics 33 21 
Psychoanaleptics (stimulants for ADHD) 29 19 
Anti-epileptics 19 12 
Psycholeptics 15 10 
Other 3 2 
Total 155 100 
Table 6: Nervous system drug RCTs 
The great majority of group J consisted of vaccine and antibacterial drug RCTs. 
ANTI-INFECTIVES FOR SYSTEMIC USE (Group J) No. of trials (n) 
Percent 
(%) 
Vaccines 51 50 
Antibacterials 32 32 
Antimycotics 8 8 
Antivirals 4 4 
Antimycobacterials 3 3 
Immune sera/immunoglobulins 3 3 
Total 101 100 
Table 7: Anti-infectives for systemic use RCTs 
Anti-asthmatic drugs were most frequently studied in the respiratory drug category. 
RESPIRATORY DRUGS (Group R) No. of trials (n) 
Percent 
(%) 
Drugs for obstructive airway diseases 54 73 
Antihistamines 10 13 
Nasal 8 11 
Cough and cold 2 3 
Total 74 100 
Table 8: Respiratory drug RCTs 
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 The major routes of administration for the main drug being trialled were oral 
(231/604 studies, 39%), intravenous (121/604, 20%), intramuscular (50/604, 8%), 
local pulmonary and topical dermal (7% each). 
Route of administration  No. of trials (n) Percent (%) 
Oral 231 38.2 
Intravenous 121 20.0 
Intramuscular 50 8.3 
Local Pulmonary 45 7.5 
Topical Dermal 42 7.0 
Subcutaneous 25 4.1 
Intranasal/Sublingual/Buccal/Otic 21 3.5 
Local tissue infiltration/injection 17 2.8 
Caudal/epidural 15 2.5 
Ophthalmic 10 1.7 
Systemic Pulmonary 9 1.5 
Rectal 8 1.3 
Intramuscular (injection for local effect only) 6 1.0 
undescribed 4 0.7 
Total 604 100.0 
Table 9: Routes of administering the main study drugs in paediatric RCTs published 
in 2007 
 
2. Diseases 
 The predominant disease area studied by the RCTs was infectious and 
parasitic diseases (135 trials, 22%). This was followed by the symptoms, signs and 
abnormal findings category (114 trials, 19%) reflecting the many trials in anaesthesia 
and of analgesic drugs. Respiratory diseases were the third most common disease area 
in the database (78 trials, 13%). 
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 WHO ICD-10 Categories of disease No. of trials (n) 
Percent 
(%) 
Certain infectious and parasitic diseases 135 22.4 
Symptoms, signs and abnormal clinical and laboratory 
findings, not elsewhere classified 114 18.9 
Diseases of the respiratory system 78 12.9 
Diseases of the skin and subcutaneous tissue 40 6.6 
Endocrine, nutritional and metabolic diseases 38 6.3 
Diseases of the nervous system 32 5.3 
Mental and behavioural disorders 31 5.1 
Neoplasms 26 4.3 
Injury, poisoning and certain other consequences of external 
causes 
19 3.2 
Certain conditions originating in the perinatal period 18 3.0 
Diseases of the digestive system 14 2.3 
Diseases of the blood and blood-forming organs and certain 
disorders 11 1.8 
Diseases of the genitourinary system 9 1.5 
Diseases of the eye and adnexa 8 1.3 
Diseases of the ear and mastoid process 7 1.2 
Congenital malformations, deformations and chromosomal 
abnormalities 7 1.2 
Diseases of the circulatory system 6 1.0 
Diseases of the musculoskeletal system and connective tissue 5 0.8 
Factors influencing health status and contact with health 
services 5 0.8 
Pregnancy, childbirth and the puerperium* 1 0.2 
Total 604 100.0 
Table 10: ICD-10 disease categories of paediatric RCTs published in 2007 
 
*RCT of depo contraception recruiting 14 to 26 year olds (Rickert et al., 2007) 
 
 
87 
 
3.4 FUNDING SOURCES 
 A large proportion of the RCTs did not describe their source of funding, these 
226/582 trials constituted 39% of the database (funding data was unable to be 
extracted from the 22 non-English text RCTs).  Of the remaining 356 RCTs (61%), 
the pharmaceutical industry was declared as the major trial sponsor in 177 trials. 
There were 79 self-funded RCTs. 
 
Main trial sponsor No. of RCTs (n) Percent (%) 
Industry 177 50 
Academic or self-funded 79 22 
Governmental/health authority funding 62 17 
Foundation or charitable funding 38 11 
Total 356 100 
Funding not mentioned 226 - 
Unable to ascertain funding source* 22 - 
Table 11: Main trial sponsors of paediatric RCTs published in 2007 
*RCTs reported in non-English text but with English abstracts provided 
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4. DISCUSSION 
 It is reassuring that large numbers of randomised controlled drug trials 
involving the paediatric population are taking place globally. This review identified 
604 paediatric RCTs published in 2007 alone, a relatively large number compared to 
prior reviews. For instance Chan and Altman (2005) identified 37 paediatric RCTs 
from Pubmed published in December 2000, Cohen et al. (2007) identified a mean of 
35 paediatric RCTs and 43 mixed age RCTs per year over a 20 year period (albeit 
only from 5 general medical journals), Sammons and Choonara (2005) identified 
between 93 and 127 clinical trials per year while Pandolfini and Bonati (2008) found 
1149 reports over a 4 year period. This increased availability and exposure of 
paediatric RCTs should increase the evidence base for safe and effective use of 
paediatric medicines around the world. 
 Conducting paediatric RCTs require access to substantial resources 
(Steinbrook, 2002, Caldwell et al., 2004) and suitable expertise (Wilson, 1999, 
Gazarian, 2009). It is unsurprising that the majority of paediatric RCTs published in 
2007 were conducted in rich or highly-developed countries. This is in agreement with 
the general trend in randomised and controlled trials over the past 60 years (Gluud 
and Nikolova, 2007) where trial publications predominantly originated from the USA, 
UK, Germany, Italy, Holland, Canada and France. Nonetheless, the relative obscurity 
of clinical research from poor and developing countries in medical journals has been 
lamented before (Horton, 2003) and Tutarel (2005) suggested that the editorial board 
composition of paediatric journals is contributory to this discrepancy. 
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Drug-related research is largely driven by commercial interest (Li et al., 2007) 
in which rich nations are the most relevant. However with the growing awareness that 
there is a much greater number of ill and dying children in poor and developing 
countries (Black et al., 2003, Bryce et al., 2005) opinion is growing that 
pharmaceutical research and development should address the greater need of people 
in poor nations (Cohen-Kohler, 2007). In recent developments, the WHO is playing a 
leading role with large campaigns to improve the situation with medicines in children 
on a global level (Watts, 2007, Choonara, 2008). 
This review has established that there are increasing numbers of paediatric 
RCTs taking place in countries such as India, Turkey, Iran and Brazil. This adds to the 
mounting evidence of the globalisation of clinical trials (Thiers et al., 2008) although 
this may be again due to commercial reasons (Glickman et al., 2009) rather than 
public health concerns. Chapter 6 of this thesis will discuss in further depth on the 
global situation of paediatric RCTs in relation to the disease burden in children. 
Encouragingly I have found a substantial number of multicentre and even 
multinational paediatric RCTs. That 44% and 16% of all the RCTs were multicentre 
and international respectively, represents a noteworthy advancement over the 1996-
2002 period where 24% were multicentre trials and only 1% of trials were 
international (Sammons and Choonara, 2005). There appears a growing recognition of 
the importance and benefit of collaborative studies with national research networks 
coming to the forefront ((Nunn, 2009, Seibert-Grafe et al., 2009, Weber et al., 2009). 
There is now a major effort towards developing a global network of paediatric 
researchers (Koren et al., 2009). 
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 Such cooperation is greatly welcomed and it is hoped that greater 
involvement of developing countries in addition to the established research centres in 
North America and Europe will enhance paediatric pharmacological research.  
Campbell et al. (1998) first commented on the small sample sizes of paediatric 
RCTs. RCTs with small sample sizes is not limited to paediatric studies and is 
observed in RCTs generally (Chan and Altman, 2005). The concern with small 
sample sizes is that the trials would then be inadequately powered to detect 
differences between interventions, leading to unreliable evidence from meta-analyses 
of studies (Rerkasem and Rothwell, 2010). The median number of participants in this 
review was 89, which although an improvement over numbers reported by Campbell 
et al., (1998), was only slightly higher than reported by Chan and Altman (2005) and 
markedly lower than reported by Cohen et al. (2007).  
This finding reinforces the importance of collaboration between paediatric 
researchers to obtain higher recruitment numbers and therefore greater statistical 
power, as well as better generalisation of RCTs results to the general paediatric 
population. This does not mean that small RCTs are unimportant; in fact valuable 
information can be obtained as long as a priori power calculations have been 
performed during the design period preceding the study. This is discussed further in 
the following chapter. 
A major finding of this review is that many RCTs that involve both children 
and adults inadequately describe the characteristics of the paediatric participants. The 
heterogeneous paediatric population with differing pharmacokinetic and 
pharmacodynamic profiles compared to adults lends substantial credibility to the 
FDWFKSKUDVHµFKLOGUHQDUHQRWVPDOODGXOWV¶(Gidding, 2007, Klassen et al., 2008). 
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The omission of essential details such as the numbers and specific age groups 
of paediatric participants in such trials impacts negatively on the validity and 
generalisability of the evidence on the paediatric population. This finding strongly 
supports the conclusions of a large systematic review examining Cochrane reviews of 
drug intervention studies by Cramer et al., (2005); in which inadequate reporting of 
trials contributes to a paucity of child-relevant, child-specific evidence.  
Funding declarations is another area where inadequate reporting has been 
discovered by this review. From the RCTs that declared their funding, roughly half 
were sponsored by pharmaceutical companies. This emphasises the crucial role of 
industry in paediatric drug research and development. Building upon the cooperation 
of paediatric researchers, global dialogue between academia, the pharmaceutical 
industry and regulatory authorities will be essential to improve healthcare for children 
(Rose, 2009). 
There were relatively few RCTs involving neonates in the database. In 
contrast, drugs used in neonates are more likely to be unlicensed or off-label among 
the paediatric age groups.  Conroy et al. (1999) were first to describe that 90% of 
neonates were given either off-label or unlicensed drugs. These high rates were later 
supported by many other studies (Pandolfini and Bonati, 2005). Moreover, neonates 
appear to suffer high rates of adverse drug reactions (Kaushal et al., 2001, Moore et 
al., 2002, Sammons et al., 2008, see also chapter 5). Hence, more research is needed 
to evaluate the appropriate amount and clinical areas regarding clinical trials 
involving neonates. 
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Previous concerns have been raised that studies conducted in children have 
been in drugs that confer high financial returns rather than in drugs that benefit 
children the most (Jong et al., 2001). It was noted that from the paediatric studies 
submitted to the FDA between 1998 and 2004, the highest numbers were in 
psychotropic drugs (31), anti-hypertensives (22) and studies of conjunctivis/rhinitis 
drugs (18).  Only 11 studies of HIV drugs, 9 of drugs for respiratory infection and 6 
studies on anti-malarials were submitted (Benjamin et al., 2006). 
The many trials of anti-infective, antiparasitic and respiratory drugs were 
encouraging as they broadly correspond with the major target areas highlighted by the 
:+2µPDNHPHGLFLQHVFKLOGVL]H¶FDPSDLJQ7KHUHZDVDSUHSRQGHUDQFHRIYDFFLQH
and asthma trials, which was again heartening considering the importance of these 
treatments for children worldwide (Shann and Steinhoff, 1999, Pearce, 2007). 
There were large numbers of nervous system drugs in this review comprising 
mostly anaesthetics, analgesics and ADHD drugs. Anti-epileptics only account for 
slightly over 10% of the nervous system drugs studied despite reported figures that 
state 60-90% of people with epilepsy worldwide are untreated or inadequately treated, 
including vast numbers of children (Scott RA, 2001, Meinardi et al., 2001). This is 
also discussed in further detail in chapter 6. 
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5. CONCLUSION 
 This review has elucidated several important characteristics of paediatric drug 
RCTs published in 2007. There appear to be more RCTs involving children 
performed and reported than ever before. Most are conducted in rich and developed 
countries, but RCTs are increasingly globalised. The RCTs appear to study the 
appropriate clinical areas to improve treatments for important childhood diseases such 
as infectious illness and asthma. Several aspects of the RCTs need more attention. 
Concerns include reporting standards especially concerning mixed age group studies, 
small sample sizes relating to questionable statistical power of the studies and the 
dearth of studies involving neonates despite the high rates of adverse drug reactions 
and off label and unlicensed prescriptions in neonates. Greater cooperation between 
paediatric researchers worldwide, as well as constructive dialogue involving industry 
and regulators, promises to ensure continued advancement in paediatric RCTs to 
improve medicines in children. 
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CHAPTER 4:  
METHODOLOGICAL & 
REPORTING  
QUALITY 
 
 
 The collective effort to generate evidence for drugs used by the paediatric 
population is steadily gaining momentum, as seen in the previous chapter. However to 
assist clinical decisions made by health professionals, the evidence generated needs to 
be of sufficient quality, meaning that the results of RCTs need to be internally and 
externally valid. This would depend on the design and conduct of RCTs, but 
moreover health workers and policy makers need to be able to access such 
information. This chapter describes the assessment of methodological and reporting 
aspects of paediatric RCTs published in 2007. The main aim is to advance the process 
of translating evidence generated from paediatric RCTs into informed health care 
decisions. 
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1. INTRODUCTION 
1.1 Methodological and Reporting Quality 
 Evidence based medicine is about the judicious use of current best evidence, 
in combination with clinical expertise, to make decisions on individual patients or on 
policies in public health (Sackett et al., 1996). This idea has long been embraced by 
the medical fraternity and there is a great effort ongoing to compile, analyse and 
synthesise evidence from the multiple types of clinical research, most prominently by 
the Cochrane Collaboration. As the highest level of evidence (see section 2.2.1), 
RCTs are the cornerstone of this work of systematically reviewing and meta-
analysing numerous research to provide the best current evidence (Higgins and Green, 
2009). 
 5&7V FDQ EH FRQVLGHUHG WKH µIRXQGDWLRQ¶ RI FOLQLFDO HYLGHQFH WKHLU TXDOLW\
impacts greatly on the reliability of the reviewed evidence, and by extension directly 
on the health of patients. Thus the findings of a RCT need to be valid. There are two 
components involved; internal and external validity. Internal validity means that in a 
study where different groups of patients are given different drugs, the difference seen 
in the outcome can be fully attributed  to the drug being studied (only apart from the 
unlikely occurrence of random error). External validity or generalisability relates to 
whether the results are applicable to the population where the drug is going to be used 
(Juni et al., 2001). Therefore the internal validity of a RCT depends on avoiding the 
introduction of biases (selection bias, performance bias, detection bias and attrition 
bias) while external validity closely relates to how well the RCT has been reported. 
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Studies have confirmed that methodological characteristics, for example the 
concealment of treatment allocation, affect results of clinical trials as well as the 
overall assessment of treatment effects. Schulz et al. (1995) and Moher et al. (1998) 
found that inadequate concealment of treatment allocation leads to a significant 
overestimation of treatment effect. Consequently the assessment of trial quality has 
been accepted as an important part of systematic reviews by the Cochrane 
Collaboration (Higgins and Green, 2009).  
There have been many studies examining the quality of RCTs in various 
fields. In child health, Anttila et al. (2006) assessed the quality of reporting of 15 
RCTs involving children with cerebral palsy and found that the reporting quality was 
largely inadequate. Thakur et al., (2001) reviewed all 642 papers published in two 
paediatric surgery journals in 1998 to examine methodological standards associated 
with quality reporting although the sample included only three RCTs. Moher et al., 
(2002) used three separate tools to assess a sample of 251 reports of complementary 
and alternative medicine RCTs involving children, and again found reporting quality 
to be insufficient.  
 The work mentioned above highlights two important points. Firstly that in 
most cases, the assessment of the methodological quality of a RCT is closely 
intertwined with the quality of reporting. Secondly that there seems to be a paucity of 
studies investigating the quality of RCTs of medicines involving the paediatric 
population. Therefore, this chapter aims to scrutinise the quality of RCTs of a broad 
range of drug treatments involving the paediatric population. 
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1.2 Protection of the Rights of Participants  
The protection of the rights of participants is fundamental in modern clinical 
research as prescribed by the Declaration of Helsinki and is especially relevant when 
the research involves the vulnerable paediatric population (Goodyear et al., 2008).      
There is considerable interest in the ethical aspects of paediatric clinical research 
(Sammons, 2009, see also section 1.3.1) going back many years (Steinbrook, 2002).
 Despite the presence of solid guidelines on the ethical conduct of paediatric 
clinical research (AAP, 1995, RCPCH, 2000), there have been concerns with the 
relatively low proportions of reports of child health research that document ethical 
approval and informed consent, as raised by Weil et al. (2002). Nevertheless, 
Bauchner and Sharfstein (2001) found that RCTs specifically had almost universally 
documented (97%) that ethical approval was obtained. On the other hand, the 
documentation of assent has been mostly ignored (Sifers et al, 2002) although there is 
growing opinion that it is an important ethical and regulatory requirement of RCTs 
(Ungar et al., 2006). 
 In addition to the quality aspects of the trials mentioned earlier, I also 
investigate the documentation of these important characteristics relating to the 
protection of trial participants, within RCTs in the database. 
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1.3 Formulation Information 
Another unsatisfactory situation in paediatric pharmacology is the lack of 
suitable oral dosage forms particularly liquid forms and especially for younger 
children and infants (Nahata, 1999). Schirm et al. (2003) found that although 
approximately half of all paediatric prescriptions in the community were for oral 
medicines, paediatric formulations were often inadequate.  
This problem closely relates to the large proportions of unlicensed and off 
label medicines used in paediatrics (see section 1.4). Frequently pharmacists are 
forced to resort to prepare extemporaneous formulations of drugs for children, with 
accompanying issues of excipients, dosing accuracy i.e. bioequivalence and 
bioavailability as well as efficacy, amongst others (Standing and Tuleu, 2005, Krause 
and Breitkreutz, 2008). Significant effort is under way to improve the availability of 
appropriate formulations for paediatric medicines (Knoppert, 2009). 
 Unfortunately, formulation information is often neglected in published reports 
of paediatric clinical trials. Standing et al. (2005) found that only 37% of reports of 
paediatric oral drug trials in 10 high impact medical journals gave adequate 
formulation information for the study to be replicated, and more than a quarter (26%) 
did not even state the formulation used. This is surprising considering that this 
information is needed for the findings to be valid. Dosage forms may vary for each 
drug being studied and different formulations can have different bioavailability.   
 Therefore, reports of the paediatric RCTs of oral medicines in this systematic 
review are analysed to determine whether appropriate formulation information has 
been documented. 
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2. METHODS 
 The overall comparison method of each RCT in the database was determined. 
The number of cross-over studies was also noted. The number of treatment arms in 
each study was identified. 
2.1 Methodological and Reporting Quality 
There have been numerous studies looking at the assessment of trial quality, 
specifically the tools used to measure quality. Moher et al. (1995) reported that there 
were 9 checklists and 25 scales available in the literature for assessing trial quality. 
With ongoing work this number has at least doubled (Jadad and Enkin, 2007). On the 
other hand, few of these tools have actually undergone validation to be used by 
reviewers. The most frequently used validated tool appears to be the Jadad scale 
(Jadad et al., 1996). 
For this review, the Jadad scale has been selected for several reasons. Firstly 
the large numbers of reports require a scale that can be used effectively. Secondly the 
Jadad scale is numerical, allowing statistical analyses to be performed on findings 
from the review. Thirdly all the items in the Jadad scale can be incorporated into the 
CONSORT Statement (see later) so that RCT reports can be analysed efficiently for 
both methodological and reporting quality.  
On the other hand, the Cochrane Collaboration explicitly discourages the use 
of the Jadad scale solely, seemingly due to apparent omission of the assessment of 
DOORFDWLRQFRQFHDOPHQW7KH\UHFRPPHQGWKHXVHRIDµGRPDLQ-EDVHG¶DVVHVVPHQWRI
six specific domains of a certain RCT report developed between 2005 and 2007 
(Higgins and Green, 2009). However this tool is much more complex and subjective 
compared to the Jadad scale despite admittedly providing a more rigorous assessment 
of the risk of bias.  
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Early in the course of WKHUHYLHZWULDOUXQVXVLQJWKH&RFKUDQH&ROODERUDWLRQ¶V
tool revealed that they were time-consuming and perhaps more appropriate for 
smaller systematic reviews of a specific clinical research question. Consequently the 
decision was made to use the Jadad scale with a slight modification to enable a quick 
assessment of allocation concealment to be made.  
This alteration entails that the fourth point of the Jadad scale, involving 
whether the randomisation sequence generation was adequate, to be conferred only if 
allocation was felt to be adequately concealed (for example using central allocation, 
sequentially numbered sealed envelopes or sequentially numbered sealed drug 
containers). Jadad scale items were identified using the data extraction form (see 
Chapter 2). Each RCT report was scored out of five. The following table details the 
Jadad scale items. 
 
No Item Scoring 
1 Was the study described as randomised? SRLQWIRUµ\HV¶ 
SRLQWIRUµQR¶ 
2 Was the study described as double-blind? SRLQWIRUµ\HV¶ 
0 SRLQWIRUµQR¶ 
3 Was there a description of withdrawals? SRLQWIRUµ\HV¶ 
SRLQWIRUµQR¶ 
4 The sequence for generating the randomisation was 
appropriate 
*and allocation of intervention was adequately concealed* 
SRLQWIRUµ\HV¶ 
SRLQWIRUµQR¶ 
5 The method of double blinding was appropriate 
 
SRLQWIRUµ\HV¶ 
SRLQWIRUµQR¶ 
 Total 
 
Scored out of 5 
 
Table 1: Validated Jadad 5-point scale, adapted from Assessing the Quality of Reports 
of Randomised Clinical Trials: Is Blinding Necessary? (Jadad et al., 1996). 
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The Consolidated Standards of Reporting Trials (CONSORT) statement was 
the culmination of a major effort by a group of trial investigators, methodology 
researchers and journal editors to improve reporting of RCTs (Altman et al., 2001). It 
is a checklist of 22 important items that must be included in a report of a RCT. In 
addition to the Jadad scale items, all of which are incorporated in the statement, 
several items of the statement have been adapted to assess reporting quality of the 
RCTs in this review specifically relating to methodology (some statement items are 
covered in the previous as well as the next chapter as they relate to the specific topics 
covered). The items were assessed using the overall data collection form for this 
systematic review. They are described in the following table. 
 
Paper section  
and topic 
Descriptor 
Title and 
Abstract 
Whether there was any description that the study involved the 
paediatric population 
Methods:  
Interventions 
 
Whether the dosages of the drug were mentioned 
Whether the dosages were described solely as mass for example in 
milligrams (mg) or other parameters were included for example 
scaled to bodyweight (mg/kg) or surface area (mg/m3) 
Methods: 
Outcomes 
Whether a primary outcome measure was clearly defined 
Methods: 
Sample size 
or power 
calculations 
Whether sample size or power calculations were performed a priori 
Results: 
Participant 
flow 
 
Flow of participants through each stage 
The CONSORT flowchart must be included 
Table 2: Reporting quality items adapted from the CONSORT statement (Altman et 
al., 2001) 
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2.2 Documentation of the Protection of Trial Participants 
 Each RCT report was carefully read to check that approval from ethical 
committees or institutional review boards was obtained and documented. It was also 
determined whether the trial reported that informed consent was obtained from the 
participants or care givers. RCTs that mentioned that assent of the eligible paediatric 
participant was noted, except in trials where this was not possible for instance in trials 
involving infants, emergency situations or where the participants were unconscious. 
2.3 Formulation Information 
 For each report of a RCT of an oral drug, it was determined whether the 
dosage forms and the manufacturer of the drug used in the RCT was mentioned. 
When both were present, the formulation information was considered adequate and 
appropriate for paediatric use. For all oral drug RCTs where participants included 
children below 12 years of age, liquid formulations were judged to be appropriate. 
When solid formulations were used such as tablets or capsules, formulation 
information was considered adequate when an accompanying account of whether 
children were able to swallow the dose whole or how the dose was administered was 
given (Standing et al., 2005). 
2.4 Statistical Analysis 
 As mentioned, all data were retrieved using the standardised collection form as 
detailed in Chapter 2. Statistical descriptors used included proportions, means and 
SHUFHQWDJHV 7KH 6WXGHQW¶V W-test was used in hypothesis testing for the differences 
between means arising from the analyses.    
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3. RESULTS 
 From the 604 RCTs identified, 242 (40%) were active-comparator trials where 
the main drug treatment studied was compared to another drug or other drugs. Thirty-
five percent (213 trials) were placebo-controlled trials. A further 79 (13%) were trials 
comparing different dosing regimens or formulations of the same drug. The remainder 
consisted of RCTs with untreated controls, comparing different routes of 
administration or comparing to non-pharmacological interventions. The comparisons 
made by the RCTs are described in the following table. 
Type of Comparison Number (n) Percent (%) 
Drug vs drug 242 40 
Drug vs placebo  213 35 
Different dose/regimen/formulation 79 13 
Untreated controls or vs withdrawal of treatment 46 8 
Different route of administration  12 2 
Compared to non-drug interventions 12 2 
Total 604 100 
Table 3: Types of comparison used by the RCTs 
   
The majority, 441 (73%) trials, compared two parallel groups while the 
remaining 27% compared more than two intervention groups. There were 54 (9%) 
studies that used a cross-over design. 
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3.1 Methodological and Reporting Quality 
 Out of the 604 RCTs in the database, assessments for quality were made for 
the 582 RCTs with their full text in English. The remaining 22 RCTs were reported in 
several other languages and the limited access to translation resources precluded the 
analysis of these papers. 
The mean Jadad score for the RCTs was 3.22 (Standard Deviation, SD=1.31). 
Sixty-six percent (383) studies scored 3 or more out of 5, 10% (58 RCTs) and 24% 
(141 RCTs) scored just 1 and 2 points respectively. The final Jadad scores for the 
RCTs can be seen in the following table. 
 
Jadad Score  
(out of 5) 
Number of trials 
(n) 
Percent  
(%) 
1 58 10 
2 141 24 
3 134 23 
4 112 19 
5 137 24 
Total 582 100 
Table 4: Jadad scores of the RCTs  
*non-English language reports were not scored due to limited resources for translation 
 
There was no significant difference in the mean Jadad scores of RCTs 
involving neonates compared to RCTs of older children (two tailed p-value=0.8410). 
  Group   Neonatal RCTs     Non-neonatal RCTs   
Mean Jadad Score 
 
3.268 3.218 
Number of trials (N) 41 
 
541 
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Only RCTs were included in this systematic review, therefore all the reports 
scored the first point on the Jadad scale. Looking at the other four items on the Jadad 
scale, scoring rates ranged between 49% and 67%. Scoring rates of individual items 
can be seen in the next table. 
 
Jadad Score Item 
Studies 
scoring 
point 
(n) 
Item 
absent 
(n) 
Percent 
of 
studies 
scoring 
point 
(%) 
 
Was the study described as randomised? 
 
582 0 
 
100 
 
 
Was the study described as double blind? 
 
309 273 53 
 
Was there a description of withdrawals and 
dropouts? 
 
391 191 67 
 
Was the method to generate the sequence of 
randomisation described and appropriate?* 
 
316 266 54 
 
Was the method of double blinding described 
and appropriate? 
 
282 300 49 
Table 4: Individual items of the Jadad scoring system 
*and allocation of intervention was adequately concealed 
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In almost one-fifth (111, 19%) of the RCT reports, there was no indication in 
either the title or abstract that the study involved the paediatric population. All were 
mixed age group studies that recruited both adults and patients 16 years old and 
below. Except for 10 (2%) reports, all of the trials (572, 98%) documented the 
dosages used. Almost half (285, 49%) of the studies scaled the dose according to body 
weight, while a further 25 trials (4%) reported that doses were scaled according to 
body surface area. The remaining 262 trials described doses in singular mass, volume 
or concentration units. 
Description of dose Number (n) Percent (%) 
Bodyweight included e.g. mg/kg 285 49 
Mass/volume/concentration only 262 45 
Surface area included 25 4 
Not described 10 2 
Total 582 100 
Table 5: Description of doses in the RCTs 
 
 It was felt that the primary outcome measure or measures were clearly defined 
in 354 (61%) of the RCT reports. An almost identical number of trials (358, 62%) 
documented that a priori sample size or power calculations were performed. A 
diagram or chart describing the flow of participants through each and every stage of 
the RCT (as recommended by the CONSORT statement) was available in 223 (38%) 
of the reports.  
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3.2 Ethical Approval and Informed Consent 
 From the 582 reports examined, 528 (91%) described that the study obtained 
approval from an ethics committee or an institutional review board. Ninety-seven 
percent (537 reports) declared that informed consent was received. In 128 (22%) of 
the reports, it was mentioned that assent from the child was obtained or that consent 
was obtained directly from the participants aged 16 and below. Looking specifically 
at studies recruiting adolescents aged 12 to 16 years, 109/366 (30%) RCTs 
documented that assent was sought.   
 
3.3 Formulation information 
 Out of 226 RCTs of oral drugs, 145 (64%) included information regarding the 
formulation used, while only 86 (38%) described the manufacturer of the drug used. 
Thus information on drug formulation was judged to be adequate in 86 out of 226 
(38%) of the oral drug RCTs.   
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4. DISCUSSION 
 High quality RCTs form the foundation of scientific evidence for the use of 
paediatric medicines. This review has found that overall, drug RCTs involving the 
paediatric population published in 2007 are of good quality, scoring a mean of 3.22 
points on the Jadad scale.  
RCTs scoring 3 points and above are regarded as being of good quality as it 
has been shown previously that studies that score 2 points and below produce 
exaggerated treatment effects of up to 35% beyond those of good quality studies 
(Moher et al., 1998). Unfortunately over one-third of the RCTs in this systematic 
review scored less than 3 points on the Jadad scale, representing a significant 
proportion of trials that may provide sub-optimal evidence for paediatric medicines. 
Furthermore when the key components of methodological quality are examined 
individually, several areas were identified where improvements are needed. 
Just slightly over half of the RCTs were described as being double blind. 
Double blinding involves ensuring RCT participants, investigators as well as the 
treatment providers and outcome assessors are unaware of the assigned intervention 
(Boutron et al., 2006). This is needed to prevent major biases from being introduced; 
such as performance bias when there may be unequal care provided apart from the 
drug being evaluated (Juni et al., 2001), and ascertainment bias where the results of 
the trial are influenced by the knowledge of which intervention each participant is 
receiving (Jadad and Enkin, 2007).  
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Although not all RCTs are appropriate to be double-blinded, this result echoes 
that of Schulz et al. (1996), where only half of trials in obstetrics and gynaecology 
that could have been double-blinded were actually double-blinded. Schulz et al. 
(1996) also found that the studies that were double blind reported their blinding 
methods poorly and did not evaluate the success. Further evidence to this effect came 
from Boutron et al. (2005).  
Thus it is felt that there should be greater awareness of the need for double 
blinding by investigators and sponsors of RCTs involving paediatric participants, 
considering there exists empirical evidence that double blinding affect estimates of 
treatment effect (Schulz et al., 1995).  
In fact double blinding may be needed to prevent wrong conclusions being 
made following a RCT (Noseworthy et al., 1994). In addition, blinding techniques for 
RCTs have been well documented for both drug trials (Boutron et al., 2006) and non-
drug trials (Boutron et al., 2007). Nevertheless, it was found that in the large majority 
of the RCTs that were double blind, the method of double blinding was described 
appropriately, with 282/309 or 91% of the double blind trials scoring the final point 
on the Jadad scale. 
Two-thirds of RCTs in the database described patient withdrawals and 
dropouts. By knowing how many participants withdrew and the reasons for 
withdrawal, readers can assess whether the randomisation procedure has been 
conducted properly as imbalances in these occurrences between treatment groups can 
point to bias (Altman et al., 2001). This information is also important for the 
µLQWHQWLRQ-to-WUHDW¶ DQDO\VLV WR EH PDGH 7KLV analysis basically entails including all 
randomised patients irrespective of whether they completed the treatment protocol 
(Hollis and Campbell, 1999).  
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7KXVµLQWHQWLRQ-to-WUHDW¶LPSDFWVRQH[WHUQDOYDOLGLW\E\DOORZLQJWKHHIIHFWVRI
a drug treatment to be estimated in the general population instead of the idealised 
situation of a clinical trial. On the other hand, only just over one-third of the RCTs 
included a full chart of patient flow through the trial as recommended by the 
CONSORT statement. Such a fORZFKDUWJXDUDQWHHVWUDQVSDUHQF\WRDOORZµLQWHQWLRQ-
to-WUHDW¶ DQDO\VHV ZKHUH GHVFULSWLRQV LQ WKH WH[W KDYH EHHQ RIWHQ EH IRXQG WR EH
inadequate (Egger et al., 2001). 
A major criticism of the Jadad score that has been used here is that it neglects 
to assess the concealment of treatment allocation during the randomisation process 
(Higgins and Green, 2009). The landmark study by Schulz et al. (1995a) discovered 
that studies with inadequate allocation concealment yielded significantly larger 
treatment estimates of up to 41% compared to studies where allocation concealment 
was concealed adequately. This finding supported the hypothesis that significant bias 
can be introduced into trials that do not conceal treatment allocation. For example, 
selection bias can be a distinct possibility, either as a result of deliberate subversion 
(despite being well intentioned) or unintentionally (Schulz, 1995a). This results from 
trial investigators who are aware of treatment allocations. They may channel 
participants with a better prognosis to the experimental group and poorer prognosis to 
WKH FRQWURO JURXS E\ GHOD\LQJ D SDWLHQW¶V HQWU\ XQWLO WKH GHVLUHG DOORFDWLRQ RU E\
excluding or refusing entry to eligible participants (Schulz et al., 1995b). 
Therefore the decision was made to assess the concealment of treatment 
allocation of RCTs in this systematic review and incorporate the assessment into the 
fourth item on the Jadad scale. Allocation concealment is also an important item on 
the CONSORT checklist, being item 9 out of the 22 point checklist.  
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As with double blinding, only just over half of the RCTs were deemed to have 
an appropriate randomisation sequence that was adequately concealed. Again, this 
requires attention so that the estimated effects of drug treatments being studied are not 
exaggerated, thus yielding inaccurate evidence.  
Another criticism with the Jadad scale is that it is more a reflection of 
reporting quality rather than methodological quality. This has been a long-standing 
argument and it was felt that many of the tools described by Moher et al. (1995) that 
are used to assess trial quality, were liable to confuse reporting and methodological 
quality (Higgins and Green, 2009). A study by Huwiler-Muntener et al. (2002) 
assessed 60 RCTs and found that studies with similar reporting quality can have 
important differences in methodological quality. On the other hand, other authorities 
are of the opinion that methodological quality of a trial is intertwined with the quality 
of reporting (Juni et al., 2001). 
Rather than dwelling on the arguments, I have taken a pragmatic view for this 
study. For health professionals, the reports of RCTs (and resulting systematic review 
or meta-analyses) are usually the only way of learning the results of the trials 
conducted, for the evidence to be used in clinical practice. It is felt that both 
methodological quality and reporting quality are essential. Furthermore with the 
ongoing efforts of medical journal editors to improve reporting quality for example 
the CONSORT statement (Altman et al., 2001) as well as the increasing oversight of 
RCTs through trial registers (Sammons et al., 2005, Pandolfini and Bonati, 2009), 
reporting quality should move closer to reflect methodological quality. Thus no 
separate analysis of the two was attempted for this systematic review. 
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This systematic review has found that paediatric-specific reporting is another 
area that requires improvement, particularly for RCTs that recruited both from the 
adult and paediatric populations. In chapter 3, it was seen that these mixed age group 
RCTs did not describe paediatric participant numbers nor their age group categories 
appropriately. In this chapter it was found that in almost one-fifth or 111 of the RCTs 
in the database, there was no indication in either the title or abstract that the trial 
recruited from the paediatric population. This represents a significant body of 
evidence that may be missed by busy health care professionals.  
It was found that 61% of RCTs from the database designated a clear primary 
outcome measure. The primary outcome measure is the pre-specified outcome 
measure considered to be the most important to patients, clinicians, policymakers and 
trial sponsors (Moher et al., 2010). For many diseases, there may be a multitude of 
ways to measure the effects of a treatment. When a primary outcome measure is 
described in a RCT report, it allows the reader to determine the appropriateness or 
accuracy of the outcome measure being used. More importantly, findings from the 
RCT can then be compared to other trials within the disease area or using related 
treatments (Altman et al., 2001).  
The documentation of a priori power or sample size calculations is closely 
related to having a designated primary outcome measure, as power calculations are 
based on the primary outcome. It was found that a similar number, less than two-
thirds of the RCTs in the database, documented the calculations. Thus it seems an 
important characteristic of RCTs regarding statistical significance is inadequately 
reported in paediatric RCTs.  
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This problem is lamented across numerous medical specialities (Halpern, 
2005, Charles et al., 2009). With sample size calculations being neglected, 
compounded with the generally low number of participants in paediatric RCTs (see 
chapter 3), there is a significant possibility of underpowered trials. In underpowered 
trials, patients endure the burden as well as the risk of clinical experimentation, but 
without being able to provide valid and generalisable evidence for better healthcare. 
Needless to say this situation is regarded as being unethical (Halpern et al., 2002).  
As would be expected, the reporting of dosages used was nearly universal. 
Nearly half of the trials reported doses scaled to body weight and several more scaled 
according to body surface area. This use of allometric technique probably indicates 
the situation in which many drug doses used in paediatric populations are based on 
incomplete or no pharmacokinetic data (Abernethy and Burckart, 2010). No single 
allometric technique has proven to be the most appropriate (Mahmood, 2006, 
Johnson, 2010). Nonetheless despite the many complexities of conducting 
pharmacokinetic studies in the paediatric population (Anderson et al., 2007), it is 
hoped that ongoing pharmacokinetic work will continue to contribute to the growing 
initiatives aiming to improve drug treatment for children (MacLeod, 2009). 
The findings on formulation information from this study almost mirror those 
of Standing et al. (2005). Formulation information appropriate for the paediatric 
population is largely neglected in clinical trials, highlighting a much wider problem 
with the inadequacy of paediatric oral dosage forms in general (Mulla et al., 2007).  
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Examples can be severe; such as when toxic excipients led to the deaths of 
many children in Nigeria during the Mypikin tragedy  (Bonati, 2009) to the 4 children 
under 36 months who died from choking on albendazole tablets during a deworming 
FDPSDLJQ LQ(WKLRSLD :+27KH µ0DNHPHGLFLQHVFKLOG VL]H¶ FDPSDLJQE\
the WHO (Knoppert, 2009) promises to make significant strides in the effort to 
change this reality. 
It was encouraging that except for a tiny minority, RCTs in the database 
documented that informed consent was obtained and that 91% received ethical or 
institutional review board approval. This agrees with the findings by Bauchner and 
Sharfstein (2001). There should be a greater effort by medical journal editors to 
require all paediatric RCTs to document that informed consent and ethical approval 
was attained. This is in cRQFHUW ZLWK %DXFKQHU¶V  RSLQLRQ WKDW VWUXFWXUHG
reporting of ethical committee or institutional review board approval would further 
the protection of paediatric participants in clinical trials. However less than one-third 
of studies involving adolescents appear to document that assent was received. There is 
now a greater recognition of the autonomy of the paediatric participant in trials (John 
et al., 2007, Ungar et al., 2006, see also Chapter 1) and future work will need to 
explore whether there is increased awareness amongst investigators and sponsors 
regarding assent especially among older children. 
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5. CONCLUSION 
 The work done for this chapter has made several discoveries that deserve 
highlighting. Most paediatric drug RCTs published in 2007 seemed to be of good 
methodological quality. However several important design characteristics of the trials 
need further attention so that the resulting evidence is valid as well as generalisable to 
improve the use of medicines in the paediatric population. These include double 
blinding, adequate concealment of treatment allocation, as well as appropriate power 
or sample size calculations. Furthermore, it is felt that more effort is required to 
ensure that these RCTs report paediatric specific information for example the 
inclusion of paediatric age groups, formulation information appropriate for children 
and the documentation of assent in trials where older children are involved. The 
evidence based use of medicines in children requires high quality, ethical and well 
reported RCTs involving the paediatric population. 
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CHAPTER 5: SAFETY  
 
  
The preceding chapters have highlighted that appropriate, high quality 
paediatric randomised controlled trials (RCTs) are needed to provide the evidence 
base for medicines used by children so that they benefit from, and are not harmed, by 
the medicines. In this chapter, paediatric RCTs published in 2007 are analysed to 
document adverse events experienced by the participants and assess whether adverse 
drug reactions occurred. In addition I attempt to ascertain whether adequate measures 
were taken to safeguard RCT participants from harm. Therefore this chapter explores 
the following aspects of RCTs involving the paediatric population; toxicity occurring 
within the RCTs, the protective measures put in place, and implications of the safety 
information obtained from the RCTs to the paediatric population in general. The 
objective is not only to identify areas of improvements so that paediatric participants 
are less at risk of toxicity in RCTs, but also to determine whether adequate safety 
information is contributed by the RCTs for the safe use of medicines in children.  
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1. INTRODUCTION 
 As mentioned in preceding chapters, changes in US and European drug 
regulation have created a stimulatory environment for paediatric drug trials to be 
performed (Smyth, 2007, Hoppu, 2008, Saint-Raymond and Seigneuret, 2009). As a 
result larger numbers of paediatric RCTs have been conducted (Sammons et al., 
2008); providing valuable information for the judicious use of medicines in children 
(Roberts et al., 2003, Rodriguez et al., 2008). However when participating in clinical 
drug trials, paediatric patients are exposed to a risk of experiencing adverse drug 
reactions (ADRs) (Sammons et al., 2008, Turner et al., 1999). This risk is a concern 
for parents, clinicians, investigators, trial sponsors and regulatory agencies. This is 
especially important considering the vulnerable nature of the paediatric participants 
and that their participation in a clinical trial is by proxy consent of their caregivers 
(Caldwell et al., 2004, Smyth and Weindling, 1999, Sammons et al., 2007, Kodish, 
2003). 
 There have been a good number of studies looking at ADRs occurring in the 
paediatric population. For instance, Bourgeios et al. (2009) reported on paediatric 
ADRs in the outpatient setting throughout the US. Clavenna and Bonati (2009) 
reviewed prospective studies of paediatric ADRs following on from Impicciatore et 
DO¶V HDUOLHUPHWD-analysis of paediatric ADRs. Choonara and Conroy (2002) 
and Neubert et al. (2004) reviewed paediatric ADRs in relation to unlicensed and off 
label drugs. There have been many pharmacovigilance studies (Choonara, 2006) by 
other research groups (Horen et al., 2002, Cohen et al., 2008, Le et al., 2006, Kaushal 
et al., 2001, Moore et al., 2002, Jha et al., 2007, Fattahi et al., 2005 ± see section 5 of 
chapter 1). 
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 However to my knowledge, the only major effort to characterise toxicity 
experienced by paediatric patients in clinical trials was performed by Sammons et al. 
(2008). This landmark study reviewed more than 700 clinical trials of oral or 
intravenous drugs over a 7 year period between 1996 and 2002. Adverse events (AEs) 
were common and were found in 71% of the trials while 1 in 5 (20%) trials reported 
serious adverse events. Adverse drug reactions (ADRs) were determined to have 
occurred in more than 1/3 (36.5%) of the trials, with severe ADRs judged to have 
occurred in 5%.  
 Six of the trials were halted by independent oversight bodies after severe 
ADRs were experienced. These bodies are usually termed as safety monitoring 
committees, SMCs (EMEA, 2005) or data safety monitoring boards, DSMBs (DeMets 
et al., 1999) and their important role was clearly demonstrated. Yet a major finding of 
Sammons et al. (2008) was that only 2% of all the trials had a SMC/DSMB in place. 
This was in contrast to the significant proportions of trials with AEs or ADRs.  
Another major finding was the high rates of ADRs and mortalities seen in neonatal 
trials.   
 Therefore I aim to provide an update on drug toxicity and reappraise the 
presence of SMCs/DSMBs in paediatric RCTs. By analysing a wider set of RCTs 
including HIV/Oncology RCTs as well as including RCTs of drugs administered 
other than through the oral or IV routes, this review hopes to build upon Sammons et 
DO¶V  ZRUN LQ FKDUDFWHULVLQJ $'5V RFFXUULQJ ZLWKLQ WKH 5&7V )XUWKHUPRUH
this chapter also looks at the reporting of AEs and ADRs by paediatric RCTs, in the 
context of the growing concern with the apparently inadequate reporting of 
information on safety or harms in RCTs overall (Ioannidis, 2009). 
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2. METHODS 
 The definitions used for this study largely follow on from those used by 
Sammons et al. (2008). However several additions were made to the analysis.  
2.1 SAFETY CHARACTERISTICS 
Each paediatric RCT report from my database was analysed to evaluate the 
following safety aspects: 
1. Safety Monitoring 
It was assessed whether safety monitoring was mentioned in the methods 
section RI HDFK $Q\ PHQWLRQ RI WKH ZRUGV µVDIHW\¶ µDGYHUVH
HIIHFWHYHQWH[SHULHQFHUHDFWLRQ¶ µVLGHXQZDQWHGHIIHFW¶ µWR[LFLW\¶RU DQ\ LQGLFDWLRQ
that adverse events were monitored for was noted. 
2. SMC/DSMB and Terminated or Amended Trials 
Each paper was then checked to determine whether a safety monitoring 
committee (SMC), data safety monitoring board (DSMB) or an independent safety 
evaluator was present to oversee the trial. In addition, it was determined whether any 
interim analysis (Fossa and Skovlund, 2000) was performed or whether stopping rules 
(Hedenmalm et al., 2008) for the trials were designated. These were assumed to be 
present whenever a SMC/DSMB is mentioned. 
Any trial that was discontinued was also noted and the reason for 
discontinuation was determined. Any RCT that reported an alteration to the study 
protocol arising from an interim analysis or from new information/alerts arising from 
newly published reports or from the SMC/DSMB of the RCT itself was recorded. 
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3. Adverse Events (AEs) and Mortalities 
Whether any adverse events were detected were determined from carefully 
reading the results section. The definition and classification of adverse events (AEs) 
used in this study was based on guidelines produced by the European Agency for the 
Evaluation of Medicinal Products (EMEA, 2001) in compliance with the International 
Conference for Harmonisation (ICH). 
 An AE is defined as any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product and which does not 
necessarily have to have a causal relationship with this treatment (EMEA, ICH topic 
E2A, 1995). AEs are classified as serious, significant or mild according to the following 
groupings: 
i) Serious AE - any untoward medical occurrences at any dose that results in 
death, is life-threatening, requires inpatient hospitalisation or prolongation 
of existing hospitalisation, results in persistent or significant 
disability/incapacity, or is a congenital anomaly/birth defect. 
ii) Significant AE - defined as haematological and other laboratory 
abnormalities and any AE that led to an intervention, including withdrawal 
of drug treatment, dose reduction or significant additional concomitant 
therapy. 
iii) Mild AE - defined as any AE occurring that did not need any intervention. 
 
The most serious AE in each report was determined and used to stratify the 
trials. The number of papers reporting any mortality was recorded. In particular, any 
RCTs which indicated a positive trend in mortality in the intervention group or non-
placebo comparator groups were noted. 
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4. Adverse Drug Reactions (ADRs) 
An ADR is defined as an adverse event that is thought to be linked in either 
time or dose to a drug given to that patient (Turner et al., 1999, Sammons et al., 
2008). Each randomised trial included in this study was assessed as to whether a 
possible ADR had occurred and were classified according to the highest severity of 
ADR in the report.  
The classification used for ADRs are as follows: 
1. Severe: fatal or potentially life threatening or causing permanent 
disability 
 
2. Moderate: requiring treatment or prolonging stay in hospital 
 
3. Mild: no treatment required and no effect on length of stay in hospital. 
 
All trials reporting a serious AE (SAE) were further reviewed by two 
paediatric clinical pharmacologists, Professor Imti Choonara and Associate Professor 
Helen Sammons, independently to judge whether any of the serious AEs were 
possible ADRs. The decision by each reviewer was noted and all differing ratings 
were discussed at a meeting to obtain a consensus expert opinion.   
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2.2 ANALYSIS 
1. ATC Drug Categories 
 The proportion of RCTs that reported an SAE, mortality or where a severe or 
moderate ADR was judged to have occurred, was calculated for each ATC drug 
category. This was done to assess whether certain types of drugs (or disease 
categories) were associated with a higher incidence of toxicity within RCTs involving 
children. 
 The proportions of RCTs reporting SAEs were cross tabulated to the median 
sample size of paediatric participants from RCTs in each ATC category. This was 
done to determine whether an artefactual relationship existed due to chance, in the 
assumption where a higher number of SAEs would occur naturally with greater 
participant numbers. For example if a certain ATC category consisted of mostly large 
trials, the hypothesis would be that this category would contain a higher number of 
SAEs due to the larger population sizes thus confounding the effect of the drug type.    
2. Age Group Categories 
 The above comparison was also performed for each ICH age group category to 
assess whether a certain age group (especially neonates) experienced a higher 
incidence of toxicity or mortality within the RCTs. 
3. SMCs/DSMBs 
 Trials reporting serious AEs, mortalities or that were determined to have 
encountered severe or moderate ADRs, were compared to the rest of the RCTs in the 
database in terms of whether SMCs/DSMBs were documented.  
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4. Statistical Analysis 
 Data from each report were retrieved using a standardised data extraction form 
(provided in chapter 2) then stored and analysed using SPSS version 16.0 (SPSS Inc., 
Chicago, IL, USA). Categorical variables were described with frequencies, 
percentages and 95% confidence intervals. The degree of agreement between 
reviewers was described b\WKH.DSSDFRHIILFLHQWț)LVKHU¶VH[DFWWHVWZDVXVHGWR
calculate p-YDOXHV IRU GLIIHUHQFHV LQ SURSRUWLRQV 7KH 6SHDUPDQ¶V UDQN FRUUHODWLRQ
coefficient rho (rs) was used to check whether there were any associations between the 
safety characteristics and sample size populations of the RCTs. 
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3. RESULTS 
582 paediatric randomised drug trials were analysed. The 22 RCT reports in the 
database that had an English abstract but where the main text was not in English were 
excluded. 
3.1 SAFETY CHARACTERISTICS 
1. Safety Monitoring 
More than a third (207, 36%) lacked any description of how safety was 
observed during the study while the other 375 (64%) trials mentioned safety 
monitoring in the methods section. 
In the results section 463 (80%) of the trials reported on adverse events 
including studies reporting that no adverse events had occurred, while 119 (20%) of 
the trials had no description of adverse events.  
2. SMCs/DSMBs and Terminated or Amended Trials 
Only 69 out of the 582 (12%) reports documented that a SMC, DSMB or 
independent safety evaluator was designated to oversee the trial. An additional eight 
trials mentioned either termination rules or that interim analysis was done but without 
specifically mentioning the presence of a SMC/DSMB.  
SMCs terminated three RCTs due to toxicity and changed the protocol of one 
trial after an episode of toxicity. Another trial was halted for administrative reasons. 
Details of these terminated trials or where SMCs/DSMBs took action can be seen in 
table 1. 
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Author Drug studied 
 
 
Comparator Disease Age group N Action Taken by SMC/DSMB 
Lands  
et al. 
Ibuprofen  
high-dose  
 
Placebo Cystic 
Fibrosis 
6-18 yrs 142 Protocol changed by SMC/DSMB 
H2-antagonists recommended after 1 patient 
had gastrointestinal (GI) bleed 
Van 
Meurs 
et al. 
Inhaled  
nitric oxide 
 
Placebo Preterms with  
severe 
respiratory 
failure >1500g 
<34 weeks  
Gest 
29 Terminated due to risk of grade 3 or 4 
intraventricular haemorrhage (IVH), 
in conjunction with other evidence in the literature 
In trial 2 patients in placebo arm had IVH 
Lorch  
et al. 
Seq high-dose  
chemotherapy 
 
Single.  
high-dose 
chemo 
Relapsed/ 
refractory  
germ cell tumour 
16-59 yrs 211 Terminated due to excess toxicity in comparator arm 
Treatment-related deaths was 4% in study arm vs 16% in 
comparator arm, p=0.01 
Sullivan 
et al. 
Recombinant 
human 
epidermal  
growth factor 1-
48 
 
Placebo Severe  
Necrotizing 
Enterocolitis 
neonates 
<12 weeks 
8  7HUPLQDWHGGXHWR³DGPLQLVWUDWLYHUHDVRQVXQUHODWHGWR
WKHFRQGXFWRIWKHWULDO´ 
Bonsante 
et al. 
Low-dose  
hydrocortisone 
 
Placebo Prevention of  
chronic lung 
disease  
in preterms 
Preterms 
24-30 
weeks 
50 Terminated due to emerged external evidence of risk of 
GI perforation  
In trial 2 neonates in treatment arm & 1 in placebo arm 
developed GI perforation  
 
Table 1: Teminated trials and where SMCs/DSMBs altered the protocol 
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3. Adverse Events and Mortalities 
 From the 463 RCTs that reported on AEs, 41 (7%) reported that no AEs 
occurred within the trial. These were overwhelmingly small and short duration RCTs. 
The remaining 422 RCTs that did document AEs, were then categorised according to 
the most serious AE described within the RCT.  
Thus 210 (36%) RCTs reported serious AEs occurring within the trial (table 
2). 87 (15%) RCTs reported mortality occurring within the trial (table 2).   
 
Category of most serious Adverse Event (AE) Number (n) Percent (%) 
SERIOUS 210 36.1 
Significant 70 12.0 
Mild 142 24.4 
No AEs experienced 41 7.0 
AEs NOT DOCUMENTED BY REPORT 119 20.4 
TOTAL 582 100.0 
Table 2: Grade of AEs documented in the trials 
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4. Adverse Drug Reactions (ADRs) 
Of the total of 582 trials, ADRs were considered to have occurred in 305 
(52%) of the studies. A further 141 (24%) were determined to have experienced no 
ADRs. In the remaining 136 (23%) RCTs, it was impossible to judge whether ADRs 
were suffered by the participants, these were mostly where the report did not describe 
AEs.'Most of the trials were judged to contain mild ADRs (160, 28%). However either 
moderate or severe ADRs were determined to have occurred in 79 (14%) and 66 
(11%) of trials respectively (table 3).  
Category of Adverse Drug Reactions 
(ADRs) judged to have occurred   Number (n) Percent (%) 
SEVERE 66 11.3 
MODERATE 79 13.6 
Mild 160 27.5 
None 141 24.2 
UNABLE TO ASSESS 136 23.4 
Total 582 100.0 
Table 3: ADRs judged to have been suffered by participants in the RCTs 
 
Independent examination of 210 reports containing serious AEs (SAEs) 
GHPRQVWUDWHG µPRGHUDWH¶ DJUHHPHQW EHWZHHQ WKH WZR SDHGLDWULF FOLQLFDO
pharmacologists as tR ZKHWKHU $'5V KDG RFFXUUHG ț     &, -0.59). 
Several meetings resulted in a concensus opinion for each RCT that was initially rated 
differently.  The remaining 372 were rated by myself. Back-testing of my own ratings 
revealed an agreement level of 83.8% (differing in 34/210 or 16.2% of the ratings) in 
the judgement of whether an ADR had been experienced, compared with the joint 
expert opinion. 
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The severe ADRs detected in the RCTs included most of the major organ 
systems. Chemotherapy-related toxicities were the most prominent (table 4). Other 
severe ADRs detected were cardiotoxicity, nephrotoxicity, psychiatric symptoms 
including suicidal ideation, haematotoxicity including neutropaenia, 
thrombocytopaenia and leucopaenia, steroid related ADRs, gastrointestinal bleeding 
and infections (tables 5 ± 7).  
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Table 4: Paediatric RCTs where severe ADRs were detected (ATC Group L: antineoplastic and immunomodulating agents) 
No Drug Control/Comparator Disease Age Severe ADRs  
946 Doxo,Bleo,Vinb,Dacarbaz
ine + RT 
No Rx 
RT only 
+RGJNLQ¶V/\PSKRPD 16-75yrs 
recruited 
Leucopaenia, cardiotoxicity, inadequate details on 
events 
1001 Invasive chemo with high-
dose cytarabine & 
methotrexate (ONCO) 
Std post-remission rx ALL  12 months & 
below 
Sepsis, nephrotoxicity, hepatotoxicity, neurotoxicity 
1169 Seq high-dose chemo  
(ONCO) 
Single. high-dose chemo 
 
Relapse/ refractory germ cell 
tumours 
16-59 yrs Multiple chemotherapy related toxicities, trial 
terminated due to excess mortality in arm B 
1238 Intensified maintenance 
chemo. (ONCO) 
No treatment Post-remission Acute 
Promyelocytic Leukaemia 
15-70yrs Excess death rate in treatment arm, 15%v3% 
1286 ChemoRT with 
carboplatin 
(ONCO) 
ChemoRT with cisplatin Locoregionally advanced Ca 
nasopharyngeal 
16-70 yrs Sepsis 
1493 Different chemo regimes 
(ONCO) 
As noted B-cell non-Hodgkin 
lymphoma 
2.5-20.5 yrs Multiple chemotherapy related toxicities and deaths 
1494 8-course CHOP regimen 
(ONCO) 
6-course intensified CHOP 
regimen  
Agressive non-Hodgkin 
lymphoma 
16-65 yrs Multiple chemotherapy related toxicities and deaths 
1496 Reduced intensity chemo 
(ONCO) 
Standard intensity FAB chemo High-risk CNS non-Hodgkin 
B lymphoma and B acute 
lymphoblastic leukaemia 
 
6 mo ± 21 
yrs 
Sepsis and haemorrhages 
1897 ABX-CBL hybridoma-
gen. murine IgM 
monoclocal antibody 
(ONCO) 
Antithymocyte globulin Steroid-resistant acute graft-
vs-host disease 
2-65 yrs Neutropaenia, pneumonia 
1956 Etoposide-Ifosfamide 
+ HD MTX (ONCO) 
Doxorubicin + 
HD MTX 
Osteosarcoma 3.1-19.5 yrs Multiple chemotherapy related toxicities 
1988 GM-CSF (ONCO) No Rx Priming for Induction 
regime for ALL 
15-50 yrs Multiple chemotherapy related toxicities and deaths 
2180 High Dose Methotrexate 
Intrathecal (ONCO) 
Low dose Methotrexate 
intrathecal 
Chemotherapy for acute 
lymphoblastic leukaemia 
1.5-15 yrs Neurotoxicity 
2233 Chemo regimen 
(ONCO) 
 
Chemo regimen Osteosarcoma 4-41 yrs Chemotherapy related toxicities and deaths 
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2245 Vincristine pulses + 
dexamethasone (ONCO) 
Untreated controls ALL continuation rx Younger 
than 18 
Chemotherapy related toxicities and deaths 
99912 Chemo regimens 
(ONCO) 
Other chemo regimens  Early-stage Hodgkins 15-70 yrs Cardiotoxicity and second malignancies 
8882108 Cyclophosphamide + 
antithymocyte globulin 
Cyclo alone Conditioning regimen for 
bone marrow transplant 
<10-60 years Chemotherapy related toxicities and deaths 
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Table 5: Paediatric RCTs where severe ADRs were detected (ATC Groups J&P: antiinfectives for systemic use and antiparasitic drugs) 
No Drug Control/Comparator Disease Age Severe ADRs  
317 Liposomal AmB 
+ Caspofungin 
Lipo AmB 
(hi-dose) 
Invasive Aspergillosis ± 
haem. Malignancies 
16-75 years Nephrotoxicity ± inadequate details of event  
575 Nifurtimox-eflornithine 
 
 
Eflornithine Sleeping sickness 
Trypanosoma brucei 
gambiense 
15-70 years Neutropaenia 1v6 
957 Amphotericin B 1mg/kg vs  0.75mg/kg alt day vs 1mg/kg vs 
0.75mg/kg daily  
Indian visceral leishmaniasis 2-65 yrs Nephrotoxicity, hepatotoxicity, thrombocytopaenia 
1228 Paromomycin 
 
Amphotericin B Visceral leishmaniasis 5-55 yrs Hepatotoxicity, ototoxicity, nephrotoxicity 
1262 Anidulafungin 
 
Fluconazole Invasive candidiasis 16-91 yrs Convulsions 
1409 Amodiaquine+SP OR 
Amo+artesunate 
Artemether-lumefantrine Uncomplicated falciparum 
malaria 
1-10 yrs Convulsions 
1908 Artemether-lumefantrine 
 
Dihydroartemisin-piperaquine Drug resistant falciparum 
and vivax malaria 
1-60 years Sudden death, ?cause 
2178 Posaconazole 
 
Fluconazole/Itraconazole OR 
Fluconazole OR Itraconazole 
Prophylaxis of fungal 
infection in neutropaenic 
patients 
13-82 yrs Cardiac arrhythmias 
888147 Gatifloxacin 
 
Cefixime Uncomplicated Enteric fever 2-65 yrs Thrombocytopaenia 
888507 Human rotavirus vaccine 
 
Placebo Rotavirus gastroenteritis 6-14 weeks Possible intussusceptions 
888839 Hep A vax + hexavalent 
combi vax 
Hep A vax + separate vax Prophylaxis Infants Serum sickness 
888950 Inhaled Zanamivir 
 
Placebo Prophylaxis of influenza 12 yrs & 
above 
Bronchitis 
8881448 4 groups : Choroquine (CQ) 50mg vs Amodiaquine (AQ) 
15mg vs AQ 30 mg v CQ 25 mg 
 
Uncomplicated malaria 2-177 
months 
Convulsions 
8881482 Live Att. rotavirus vaccine 
 
3 different virus 
concentrations VS placebo 
Prophylaxis 6-12 weeks Intussusception 
8881788 HPV vaccine 
 
Hep A vax Prophylaxis 15-25 years Infectious events and abnormal pregnancy 
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Table 6: Paediatic RCTS where severe ADRs were judged to have occurred (ATC Group N: nervous system drugs) 
No Drug Control/Comparator Disease Age Severe ADRs  
161 Levetiracetam Placebo Idiopathic generalised 
epilepsy 
4 to 65 years Suicidal ideation 
298 Venlafaxine ER 
 
Placebo Paed Social  Anxiety 
Disorder 
8-18 years Suicidal ideation  
521 IV Valproate 
 
IV Diazepam Status epilepticus 5-144 
months 
Respiratory depression 
593 Bupropion 
X 2 doses 
Placebo Smoking cessation 14-17 yrs Depression, suicidal ideation 
710 IV Valproate IV Phenytoin Status epilepticus 2-17 yrs Hypotension and respiratory depression 
 
754 Fluoxetine 
 
Placebo Adolescent depression 12-17 yrs Suicidal ideation and events 
 
766 Olanzapine 
 
Placebo Bipolar Mania 13-17 yrs Neutropaenia, possible suicidal ideation and 
exacerbation of bipolar disorder  
771 Idebenone 
X 3 doses 
Placebo )ULHGUHLFK¶V$WD[LD 9-17 yrs Neutropaenia 
1793 Lamotrigine OR 
Topiramate (SANAD trial) 
Valproate Gen and unclassifiable 
epilepsy 
5 years & 
above 
Severe psychiatric symptoms 
1794 Carbamazepine OR 
Gabapentin OR 
Lamotrigine  (SANAD 
trial) 
Oxcarbazepine OR 
Topiramate 
Partial epilepsy 5 yrs & 
above 
Severe psychiatric symptoms 
2130 Venlafaxine 
 
Placebo Generalised Anxiety 
Disorder 
 
6-17 yrs Suicidal ideation 
888587 
 
Multidrug Intravenous 
Anaesthesia (Midazolam, 
Ketamine, Propofol) 
General Endotracheal 
Anaesthesia(Propofol,Vecuron
ium,Isoflurane) 
MRI scanning 1-7 years Respiratory depression 
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Table 7: Paediatric RCTs where severe ADRs were detected (remaining ATC drug groups) 
No Drug Control/Comparator Disease Age Severe ADRs  
78 Deferiprone PO 
Desferrioxamine IV 
Deferiprone PO Thalassemia major 5-24.5 
Years 
Cardiotoxicity & neutropaenia 
244 Continuous Subcut Insulin 
Infusion 
Multiple Daily Injections Type 1 DM 3.1 to 5.3 
years 
Hypoglycaemia 
723 Dexa. IV vs 
Dexa+Glycerol PO vs 
Glycerol PO 
Vs Placebo IV + PO 
4 arms 
Double dummy for all 
Bacterial meningitis 2-184 
months 
Gastrointestinal bleeding 
799 Continuous SC Insulin Inj. 
(Aspart/Lispro Insulin ± 
quick acting) 
Multiple Daily Inj.  
(Glargine OD + human 
Insulin) 
Type 1 DM 9-18 years Hypoglycaemia 
873 Ibuprofen high-dose  
 
Placebo Cystic Fibrosis 6-18 yrs Gastrointestinal bleeding 
894 Amifostine 
 
No treatment Chemo for Osteosarcoma 
(toxicity protection) 
7-15 years Nephrotoxicity 
965 Levocetirizine 
 
Placebo Atopic children 12-24 
months 
Possible convulsions 
1253 IV Terbutaline 
 
Placebo (NSaline) Status asthmaticus 2-17 yrs Cardiac arrhythmia 
1772 Glimepiride 
 
Metformin Type 2 DM 8-17 yrs Hypoglycaemia, ketoacidosis 
2001 Idursulfase Placebo Mucopolysaccharidosis II 
(Hunter Syndrome) 
6-20 yrs Respiratory depression 
2076 Mometasone inh 400mic vs 800 mic vs Placebo 
 
Severe persistent asthma 13-83 yrs Steroid related ADRs 
2078 Dexrazoxane 
 
No Dexrazoxane Prevention of cardio-
pulmonary toxicity during 
chemo of paed Hodgkins 
21 yrs and 
younger 
Higher risk of second malignancy 
2328 Magnesium sulphate 
 
Placebo Neuroprotection after 
traumatic brain injury  
14 above Excess mortality in treatment group 
888217 Steroid for 3 days + 
Tacrolimus, 
mycophenolate, 
basiliximab induction 
Steroid maintenance  Immuno 
Suppression for live-donor 
renal transplant  
5-60 years Steroid related ADRs 
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888476 Budesonide/formoterol 
 
Salmeterol/fluticasone Uncontrolled asthma 12 above Sepsis steroid-related 
888928 Dexa OR glycerol OR 
dexa+glycerol 
Placebo Bacterial meningitis 2mo ± 12 yrs Gastrointestinal bleeding 
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Severe ADRs were considered to have occurred in seven of the RCTs that 
involved neonates. As seen in table 1, two of these RCTs were terminated by their 
respective SMCs (Van Meurs et al., 2007, Bonsante et al., 2007). The other severe 
ADRs seen in the neonatal studies were necrotising enterocolitis (NEC), growth 
retardation, pulmonary and CNS haemorrhages and hypertension (table 8). 
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Table 8: Paediatric RCTs involving neonates where severe ADRs were considered to have occurred 
Record  
No 
Drug studied Comparator Disease Age group Severe ADRs 
675 Ibuprofen PO 
 
Indomethacin PO Patent Ductus 
Arteriosus 
 
Preterms NEC 
1330 Prednisolone PO daily 
 
IV methypred monthly Infantile 
haemangioma 
 
<4 months Growth retardation and hypertension 
1396 Ibuprofen PO 
 
Indomethacin IV Patent Ductus  
Arteriosus 
 
<35 weeks gest Pulmonary haemorrhage 
1401 Inhaled nitric oxide 
 
Placebo Preterms with 
severe resp 
failure 
<34 weeks gest Grade 3 or 4 IVH/PVL ± trial terminated  
1865 Drotrecogin alfa 
 
 
Placebo Severe sepsis 38 weeks to 17 
years 
Fatal CNS bleeding 
8881295 
 
IV immune globulin 
IHN-A21 
 
Placebo Prevention of 
Late Onset 
Sepsis in LBW 
neonates 
Prem. Neonates Multiple SAEs considered possible ADRs 
8881837 Low-dose 
hydrocortisone 
 
Placebo Prevention of 
chronic lung 
disease in 
preterms 
Preterms 
24-30 weeks 
Gastrointestinal perforation ± trial terminated due to risk 
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3.2 ANALYSIS RESULTS 
1. ATC Drug Categories 
 The RCTs were evaluated in relation to SAEs and the type of drugs studied. 
Cardiovascular drug RCTs had the highest proportion of trials reporting SAEs with 
69% (9/13) of the trials documenting SAEs occurring (table 9). This was followed by 
the antineoplastic and immunomodulating drug category, 68% (28/41) reporting SAEs 
occurring within their RCTs. Systemic anti-infective drugs had the third highest 
proportion of RCTs reporting SAEs occurring with over half (58/101, 57%) of the 
RCTs mentioning SAEs. 
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WHO ATC Drug Class 
Proportion 
reporting SAE 
(n/total) 
Percent 
(%) 
Cardiovascular system 9/13 69 
Antineoplastic and immunomodulating agents 28/41 68 
Anti-infectives for systemic use 58/101 57 
Blood and blood forming organs 7/15 47 
Systemic hormonal preparations,excl. sex hormones and 
insulins 18/42 43 
Respiratory system 25/74 34 
Antiparasitic products,insecticides and repellents 15/45 33 
Alimentary tract and metabolism 12/41 29 
Musculo-skeletal system 5/20 25 
Genito urinary system and sex hormones 1/4 25 
Nervous system 24/155 16 
Dermatologicals 5/40 13 
Sensory organs 1/10 10 
Various# 2/3 67 
Total 210/582 36 
Table 9: Proportion of RCTs in each ATC class reporting SAE(s) 
 
#2 out of 3 were oncology RCTs ± amifostine in osteosarcoma and dexrazoxane in 
AML/MDS (amifostine and dexrazoxane are not classified as antineoplastic or 
immunomodulating agents) 
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 When looking at RCTs reporting deaths occurring within RCTs, the same 
three drug classes predominate (table 10). RCTs of antineoplastic drugs and 
immunomodulators carried the highest proportion of mortality occurring with 23 out 
of 41 (56%) reporting deaths during the trial. Almost half of cardiovascular drug 
RCTs (6/13, 46%) and a quarter of systemic anti-infective RCTs (25/101, 25%) 
reported deaths during the trial period.  
One of the four RCTs (25%) in the genitourinary and sex hormones category 
reported SAEs and deaths occurring. This was a RCT of oestradiol and progesterone 
replacement on extremely preterm neonates where the median birth weight of the 
neonates was just 670g and the median gestational age was 25 weeks (Trotter et al., 
2007). 
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WHO ATC Drug Class 
Proportion 
reporting 
mortality 
(n/total) 
Percent 
(%) 
Antineoplastic and immunomodulating agents 23/41 56 
Cardiovascular system 6/13 46 
Anti-infectives for systemic use 25/101 25 
Genito urinary system and sex hormones* 1/4 25 
Blood and blood forming organs 3/15 20 
Antiparasitic products,insecticides and repellents 8/45 18 
Systemic hormonal preparations,  
excl. sex hormones and insulins 6/42 14 
Sensory organs 1/10 10 
Alimentary tract and metabolism 3/41 7 
Respiratory system 4/74 5 
Nervous system 5/155 3 
Dermatologicals - - 
Musculo-skeletal system - - 
Various# 2/3 67 
Total 87/582 15 
Table 10: Proportion of RCTs in each ATC class recording death(s) in the trials 
 
*Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in 
extremely preterm infants (Trotter et al., 2007) 
#2 out of 3 were oncology RCTs ± amifostine in osteosarcoma and dexrazoxane in 
AML/MDS (see chapter 3) 
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SAEs and mortality may not be drug related. The ATC drug class in relation to 
severe and moderate ADRs is shown in table 11. Drugs used in the treatment of 
malignancies were considered the most toxic in the paediatric RCTs. Of the 41 RCTs 
of antineoplastic and immunomodulating drugs, 17 (42%) were judged to have severe 
ADRs and a further 6 (15%) were judged to have moderate ADRs experienced by 
participants. In RCTs of other drug categories rates of severe ADRs were markedly 
lower, with 15% (2/13) of cardiovascular drug RCTs judged to have severe ADRs 
followed by antiparasitic agents and blood products, both with 13% (6/45 and 2/15) 
considered to have severe ADRs.  
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WHO ATC Drug Class 
Severe  
ADR 
(n/total) 
Percent 
(%) 
Moderate 
ADR 
(n/total) 
Percent 
(%) 
Antineoplastic and immunomodulating agents 17/41 42 6/41 15 
Cardiovascular system 2/13 15 1/13 8 
Antiparasitic products,insecticides and 
repellents 6/45 13 1/45 2 
Blood and blood forming organs 2/15 13 2/15 13 
Alimentary tract and metabolism 5/41 12 5/41 12 
Systemic hormonal preparations,excl. sex 
hormones and insulins 5/42 12 5/42 12 
Anti-infectives for systemic use 9/101 9 20/101 20 
Nervous system 12/155 8 15/155 10 
Musculo-skeletal system 1/20 5 2/20 10 
Respiratory system 5/74 7 10/74 14 
Dermatologicals - - 9/40 23 
Genito urinary system and sex hormones* - - 2/4 50 
Sensory organs - - 1/10 10 
Various# 2/3 67 - - 
Total 66/582 11 79/582 14 
Table 11: Proportion of RCTs where severe & moderate ADRs were detected 
 
*Effect of oestradiol and progesterone replacement on bronchopulmonary dysplasia in 
extremely preterm infants (Trotter et al., 2007) 
 
#2 out of 3 were oncology RCTs ± amifostine in osteosarcoma and dexrazoxane in 
AML/MDS (see chapter 3) 
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2. Crosstabulating to Sample Size 
The percentage of trials reporting SAEs in each ATC class was crosstabulated 
with the median number of patients in each ATC class (table 12). This was done to 
detect whether the size of the study populations in the ATC categories is associated 
with the number of SAEs reported by the trials. The median was chosen over the 
mean of the sample population sizes as large ranges in the study sizes can skew the 
mean, for instance the mean of 5 trials with the following sample sizes: 5, 17, 21, 43, 
3005 would be 618 which does not reflect the actual distribution.  
WHO ATC Drug Category Median Sample 
Size 
Proportion 
reporting SAE 
(%) 
Anti-infectives for systemic use 240 57 
Antiparasitic products,insecticides and repellents 202 33 
Sensory organs 200 10 
Dermatologicals 174 13 
Genito urinary system and sex hormones 117 25 
Antineoplastic and immunomodulating agents 103 68 
Systemic hormonal preparations,excl. sex hormones and 
insulins 68 43 
Nervous system 67 16 
Respiratory system 64 34 
Cardiovascular system 51 69 
Musculo-skeletal system 54 25 
Alimentary tract and metabolism 46 29 
Blood and blood forming organs 46 47 
Various* 478 67 
Table 12: Mean and Median Sample Sizes of RCTs in each ATC category 
WUHDWHGDVRXWOLHUEXWLQFOXGHGLQFDOFXODWLRQVIRU6SHDUPDQ¶VUKR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Chart 1: Scattergraph plotting median sample size and percentage reporting SAE of 
each ATC drug category 
 
)ROORZLQJFURVVWDEXODWLRQWKH6SHDUPDQ¶VUDQNFRUUHODWion coefficient rho (rs) 
was found to be -0.0529 with a two-tailed p-value of 0.860156 (N=14, df=12). This 
value is far from rs=1 or -1 which would indicate perfect correlation between the two 
variables. Therefore there appears to be no correlation between the sample sizes of 
RCTs in each ATC category and the proportion of SAEs reported in the trials. Where 
more RCTs of certain ATC classes such as antineoplastic, cardiovascular and anti-
infective drug classes were seen to report SAEs, the results show that this could not to 
be due to the confounding effect that these RCTs were larger, and therefore more 
likely due to probability alone to encounter SAEs. 
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3. Age Group Categories 
 
Overall, 41 trials included neonates (both preterm and term) while 541 trials 
did not involve neonates. Analysis of data from table 13 show that significantly more 
RCTs involving neonates reported that SAEs (51% vs 35%, p=0.043) occurred, 
compared to trials that did not involve neonates.  
ICH age group* Trials reporting SAEs 
(n) 
Total no. of trials 
involving age group 
(n) 
Percent  
(%) 
Preterm 18 25 72 
Term 7 22 32 
Infant 59 151 39 
Child 121 389 31 
Adolescent 132 357 37 
Table 13: Proportion of RCTs involving each age group reporting SAEs 
 
*Age groups of participants in many trials overlap the ICH categories  
 
 
This was also seen for trials that reported deaths (table 14). A significantly 
higher percentage of trials that involved neonates reported mortality occurring within 
the trial (39% vs 13%, p<0.01).  
ICH age group* Trials reporting 
mortality 
Total no. of trials 
involving age group 
% 
Preterm 16 25 64 
Term 3 22 14 
Infant 23 151 15 
Child 47 389 12 
Adolescent 56 357 16 
Table 14: Proportion of trials in each ICH age group where deaths were recorded 
 
*Age groups of participants in many trials overlap the ICH categories  
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Severe ADRs were detected in a higher proportion of RCTs involving 
neonates compared to trials that did not involve neonates, although this difference was 
not statistically significant (15% vs 12%, p=0.4475). Studies involving neonates had a 
lower median number of patients participating in the RCTs compared to the trials that 
did not involve neonates (60 vs 90). 
ICH age group* Trials with severe & 
moderate ADRs 
detected (n) 
Total no. of trials 
involving age group 
(n) 
Percent 
(%) 
Preterm 7 25 28 
Term 2 22 9 
Infant 16 151 11 
Child 38 389 10 
Adolescent 51 357 14 
Table 15: Proportion of trials in each ICH age group where severe and moderate 
ADRs were detected       
 
*Age groups of participants in many trials overlap the ICH categories  
 
 
 
 
RCTs involving both paediatric and adult patients reported significantly more 
SAEs and deaths occurring (table 16). Significantly more severe and moderate ADRs 
were also detected in these mixed-age population trials. 
 
Trial type RCTs with deaths RCTs with SAEs Severe & Moderate ADRs detected 
Mixed 21% 41% 33% 
Not mixed 12% 32% 20% 
Significance p<0.01 p=0.05 p<0.01 
Table 16: AEs, mortality and severe and moderate ADRs in mixed-age population 
RCTs 
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4. SMCs/DSMBs 
 It was then evaluated whether SMC/DSMBs were more likely to be put in 
place if serious adverse events or significant toxicity were expected during the trial. It 
was found that significantly more trials that mentioned a SAE occurring, documented 
that a SMC/DSMB was present in comparison to trials that had no or non-serious AEs 
(55/210, 26% vs 14/372, 4%) (table 17). 
 
 SMC/ DSMB 
present 
No SMC/ 
DSMB 
Total 
RCTs with SAEs 55 155 210 
RCTs without SAEs 14 358 372 
Total 69 513 582 
)LVKHU¶VH[DFWWHVW, p<0.05 
Table 17: 2x2 table comparing RCTs with SMCs/DSMBs that reported SAEs  
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Similarly, significantly more trials in which severe or moderate ADRs were 
detected, mentioned that a SMC/DSMB was formed (41/145, 28% vs 28/437, 7%) 
(table 18) . 
 SMC/ DSMB 
present 
No SMC/ 
DSMB 
Total 
RCTs with severe &  
moderate ADRs  
41 104 145 
RCTs without mild or no 
ADRs 
28 409 437 
Total 69 513 582 
)LVKHU¶VH[DFWWHVW, p<0.05 
Table 18: 2x2 table comparing RCTs with SMCs/DSMBs where severe and moderate 
ADRs were detected 
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4. DISCUSSION 
This work to characterise and analyse toxicity occurring in recent paediatric 
RCTs has revealed some interesting results. More than one-third of RCTs in the study 
report serious adverse events (SAEs) occurring and deaths occured in 15% of the 
trials. These SAEs and mortalities are not necessarily linked to the drug treatment 
being studied and may actually be a feature of the disease processes or background 
levels of risk unrelated to the therapy in the study. However when the adverse events 
were assessed to determine their relationship to the drugs being trialled, severe or 
moderate adverse drug reactions (ADRs) were considered to have occurred in a 
quarter of the RCTs. As pointed out by Sammons et al. (2008) previously, these 
findings do not indicate the risk of paediatric participants experiencing ADRs in 
RCTs, but merely the proportion of RCTs where ADRs were detected.  
Put together, severe and moderate ADRs were seen in a quarter (24.9%) of the 
RCTs in this review. Severe ADRs were considered to have occurred in 11% of the 
RCTs, more than double the percentage from the Sammons review. This difference is 
likely to be due to the inclusion of oncology RCTs in this review, which were 
excluded in the Sammons review. 
Severe ADRs were seen in many organ systems. Most have been documented 
in the literature such as the many chemotherapy related toxicities, steroid related 
ADRs and gastrointestinal bleeding related to high dose NSAIDs. Suicidal ideation 
relating to SSRIs in paediatrics have also been extensively discussed (Hammad et al., 
2006, Bridge et al., 2007). An independent SMC/DSMB plays an important role by 
constantly reviewing and being alert to emerging toxicity evidence. This was 
exemplified in two of the four terminated RCTs in this review (Van Meurs et al., 2007 
and Bonsante et al., 2007). 
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 However only 12% of the RCTs documented that a SMC/DSMB was 
GHVLJQDWHG WR RYHUVHH WKH WULDO 7KLV UHVXOW LQ FRQMXQFWLRQ ZLWK 6DPPRQV HW DO¶V
(2008) finding, further highlights the apparent absence of SMCs/DSMBs in RCTs 
involving children despite the evidence of toxicity described above. Occasionally in 
RCTs, initial data can suggest possible harmful effects i.e. toxicity rather than the 
beneficial effects being looked for. The interpretation and handling of these emerging 
harms is complicated and challenging, therefore a SMC/DSMB would be best suited 
to deal with this information (DeMets et al., 1999). 
It was found that significantly more studies with SAEs had independent 
SMCs/DSMBs, and this was also seen with studies where severe and moderate ADRs 
ZHUH GHWHFWHG +RZHYHU WKLV DSSHDUV WR EH D µWKH FKLFNHQ RU WKH HJJ¶ VFHQDULR LQ
which it was unclear whether RCTs with SMCs/DSMBs had more rigorous safety 
monitoring mechanisms, or that when toxicity was expected, investigators would be 
more likely to form SMCs/DSMBs to oversee the trial. Although more research is 
needed to explain this apparent association, there are many examples of previous 
clinical trials that attest to the important role of SMCs/DSMBs in protecting the safety 
of participants (Hillman and Louis, 2003, Pocock et al., 2004, Pocock et al., 2005, 
Hedenmalm et al., 2008). 
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The examples cited also describe the challenging situations faced by 
SMCs/DSMBs especially when trying to decide whether a trial should be stopped. On 
the other hand, there is presently extensive literature on the vital role of a 
SMC/DSMB and how it should function (Slutsky and Lavery, 2004, Pocock 2006). 
There is also a charter developed by the DAMOCLES Study Group (2005) as well as 
operational guidelines by the WHO (2005) to assist SMC/DSMBs in monitoring 
clinical trials. These guidelines as well as robust stopping rules are important as 
SMC/DSMBs would always need to be wary of false toxicity signals. As in the study 
by Sammons et al., (2008), this review has revealed several instances where 
SMCs/DSMBs acted to terminate potentially harmful RCTs or modified protocols in 
the interest of safety.  
The low proportion of paediatric RCTs that document the presence of 
SMCs/DSMBs appear in stark contrast.  There is a strong ethical argument that all 
clinical trials, except for the smallest and most straight-forward studies, should have 
SMCs/DSMBs in place (Cairns et al., 2001). This argument is even harder to dispute 
when paediatric populations are involved in clinical trials (Sammons, 2009). 
Furthermore, SMC/DSMBs are now becoming a regulatory requirement (EMEA, 
2005). Hence it is felt that all RCTs involving vulnerable populations need 
SMCs/DSMBs (Lang et al., 2008), in this case all RCTs involving the paediatric 
population.  
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As expected, RCTs of drugs used in treating cancer were found to be 
associated with the most toxicity; with a much higher proportion of RCTs where 
severe ADRs were detected compared to RCTs of other drug classes. This finding 
probably relates to the more complex and aggressive disease processes as well as the 
use of more toxic pharmacotherapy being studied in the trials. Nevertheless, the 
valuable information gained from these trials has been demonstrated before, leading 
to a massive difference in survival outcomes (Mitchell, 2007 ± see section 3.3 of 
Chapter 1). It was reassuring that severe ADRs were relatively infrequent overall in 
paediatric RCTs of other drug classes; ranging from zero to 15% of RCTs where 
severe ADRs were judged to have occurred.  
Significantly more SAEs and mortalities were seen in RCTs where neonates 
ZHUH VWXGLHG 7KLV ZDV DOVR VHHQ LQ 6DPPRQV HW DO¶V  UHYLHZ ,QWHUHVWLQJO\
when the adverse events were assessed, the difference in severe and moderate ADRs 
detected in trials involving neonates compared to older children were found to be non-
significant. Perhaps this indicates the more vulnerable nature of neonates, especially 
preterm neonates, rather than higher toxicity in the drugs being used. More research is 
needed to elucidate ADRs in neonates. Previous reviews of ADRs occurring in 
hospitalised children have not detected any differences between the rates of ADRs in 
neonatal units compared to other wards (Turner et al., 1999, Impicciatore et al., 2001, 
Le et al., 2006). However this could be explained by the different ADR detection 
methods used. In fact the various ADR detection methods used in different studies 
make an accurate estimation of ADR prevalence in the paediatric population a 
challenging task (Clavenna and Bonati, 2009). 
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Information on toxicity obtained in paediatric trials can be extremely valuable 
to improve the safety of medicines prescribed to the paediatric population. From a 
review of paediatric clinical trials submitted to the US FDA to obtain paediatric 
exclusivity, it was found that out of the 33 studies reviewed, 9 (27%) resulted in 
significant new safety information that led to labelling changes. Safety data were 
collected from all of the 33 studies (Roberts et al., 2003).  
However the effort to improve safety of paediatric medicines would benefit 
greatly from the adequate reporting of safety data from paediatric RCTs. In my 
review, more than one-third of the RCTs did not describe how safety was monitored 
in the trial and one-fifth did not even describe adverse events.  
It was also found that significantly more adverse events, moderate and severe 
adverse drug reactions were experienced in RCTs with mixed age populations where 
both adult and paediatric patients were included. However, as commented upon in 
chapter 3, most of these studies do not adequately report the characteristics of the 
paediatric-aged participants such as numbers for each ICH age category of the 
participants.  
In most of these reports, it was not possible to ascertain whether the adverse 
event was suffered by an adult patient or a paediatric patient. This is felt to be an 
important omission that needs to be highlighted, as adverse events or reactions 
suffered by a paediatric patient can bring different implications to those suffered by 
an adult. For instance during a drug RCT, a new occurrence of hypertension is viewed 
very differently if it is experienced by a 12 year old compared to a 60 year old. 
Additionally, metaanalysis of the findings at a later date may provide extra evidence 
on toxicity specifically for the paediatric population. If this information is not 
available, this opportunity would therefore be missed. 
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-RXUQDO SXEOLFDWLRQV DUH WKH µSXEOLF IDFH¶ RI 5&7V FRQGXFWHG DQG Zhen the 
two experts could only achieve a moderate agreement when rating the safety 
information, this might indicate more standardised and transparent reporting of safety 
data is needed (Ioannidis et al., 2004). However, the reasonably high rate of 
agreement of the consensus expert ratings with my own ratings for the 210 RCTs with 
SAEs provided a measure of confidence for the remaining 372 RCT without SAEs 
that I rated independently. 
In more than 23% of the RCTs, whether ADRs had occurred was not able to 
be determined. This represents a large gap where important safety data is unavailable 
to be evaluated. In fact, this apparent disinterest with safety information from 
randomised trials points to a much wider trend. Adult RCTs are far more numerous 
than paediatric ones (Martinez-Castaldi et al., 2008, Cohen et al., 2006) and this trend 
has been lamented in all RCTs recently by Ioannidis (2009). He reviewed 11 
empirical studies evaluating the reporting of harms in randomised trials and found that 
the reporting of harms occurring were mostly inadequate.  
Randomised controlled trials are an important source of toxicity information, 
and in conjunction with non-randomised or observational studies (Smith et al., 2008), 
provide essential insights for the assessment of safety of medicines used in the 
paediatric population (Ashby, 2008). Thus in addition to providing the evidence base 
on the efficacy of drug treatments, RCTs are also important in large-scale evidence of 
the harms of interventions (Papanikolaou and Ioannidis, 2004, Papanikolaou et al., 
2006). More research on the safety data or information on harms obtained from RCTs 
is needed to support recent efforts by regulators (Greener, 2008) as well as globally 
by the WHO (Choonara, 2008) to improve the safety of medicines used by children. 
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5. CONCLUSION 
 In conclusion, this chapter has revealed that although many paediatric RCTs 
report SAEs and mortalities occurring, drug toxicity is detected in a lesser portion of 
the trials. By far the greatest number of severe ADRs is seen in RCTs of drugs used to 
treat cancer, likely to be related to the toxic nature of chemotherapy. The findings 
from this work reiterate that more attention should be paid to the presence of 
SMCs/DSMBs; in fact it is felt that all paediatric clinical trials should be overseen by 
SMCs/DSMBs. Another area requiring more attention is the reporting of safety 
information from RCTs, especially in large RCTs where both adults and children are 
involved. Safer paediatric RCTs require better oversight and improved reporting of 
toxicity information from RCTs would allow better evaluation to make medicines 
safer for children.  
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CHAPTER 6: 
THE GLOBAL SITUATION  
 
 Throughout the writing of this thesis, it became increasingly evident that 
despite exciting changes occurring in the field of paediatric clinical pharmacology to 
enhance the safe and judicious use of medicines in the paediatric population, a crucial 
GLVFUHSDQF\FDPH VWHDGLO\ LQWR IRFXV 2YHUZKHOPLQJO\ WKHZRUOG¶V VLFNest children, 
who stand to benefit the most from medicines to treat their diseases, live in poor 
countries. They live in very different circumstances and also suffer from different 
diseases to paediatric populations living in resource-rich nations, where the majority 
of health research is conducted. Concurrently another trend became apparent where 
there is a noticeable shift of clinical trials to low and middle income countries 
(LMIC), postulated to be due to increasingly higher costs and regulatory requirements 
in high income countries (HIC). This chapter discusses the situation of published 
paediatric RCTs in relation to paediatric health on a global level. 
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1. INTRODUCTION    
 The greatest burden of disease in the paediatric population lies 
overwhelmingly in low and middle income countries (LMIC). In 2003, the Bellagio 
Child Survival Study Group estimated that almost all of the more than 10 million 
deaths in children younger than five occurred in LMIC (Black et al., 2003). The 
largest proportion of deaths occurred in the first 28 days of life, with 3.9 million 
neonates dying. Another 51% of the deaths were caused by 5 diseases; pneumonia 
(19%), diarrhoea (17%), malaria (8%), measles (4%) and HIV/AIDS (3%) (Bryce et 
al., 2005).  
 More than half or about 6 million of these children died of preventable or 
treatable diseases (Anon., 2003). The Bellagio group concluded that even with the 
most conservative assumptions, 63% of these deaths could have been prevented with 
child survival interventions already available (Claeson et al., 2003). There have 
already been substantial improvements to the situation. The latest figures by UNICEF 
(2009) show that the overall annual under-five mortality rate has already fallen to 8.8 
million in 2008. Nonetheless almost all these deaths still occur in LMIC, with Africa 
and Asia accounting for more than 90% of the deaths.  
 This situation reflects the absence or failure of healthcare infrastructure in 
WKHVH FRXQWULHV $ FORVHO\ UHODWHG GLVFXVVLRQ UHIHUV WR WKH µ JDS¶ ZKHUH WKH
Global Forum for Health Research reported that only 10% of worldwide expenditure 
on health research and development is devoted to the problems that primarily affect 
the poorest 90% of the world's population (Global Forum for Health Research, 1999).  
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7KH µ JDS¶ EHFDPH WKH JURXS¶V FDWFKSKUDVH WR GHPRQstrate the 
continuing mismatch between the needs and investments, where health research 
applied to the needs of LMIC remains grossly underresourced, in areas that account 
for the greatest burden of preventable disease.  
The Bellagio group estimated in 2003 that interventions needed to save the 6 
million children from dying of preventable causes would cost US$5.1 billion or about 
US$887 per child life saved (Bryce et al., 2005a). The focus of the group is on scaling 
up delivery of existing interventions known to be effective rather than on health 
research development. Nevertheless, improving delivery systems of life-saving 
interventions to children and mothers as well as the development of clinical research 
would bring about synergistic effects to the overall health of the paediatric population 
living in these resource-poor areas. 
Thus paediatric clinical pharmacology has the potential to make substantial 
contributions to the health and survival of children living in LMIC. The International 
Alliance for Better Medicines for Children (Macleod et al., 2007) has received 
support from numerous quarters including from the WHO with the passage of the 
World Health Resolution on Better Medicines for Children and the launch of the 
Make medicines child size campaign (MacLeod, 2009). A further indication of the 
relevance of the field is seen from recommendations made by the Copenhagen 
FRQVHQVXV7KLVZDVDQHIIRUWE\WKHZRUOG¶VOHDGLQJHFRQRPLVWV WRSULRULWLVH
WKH ZRUOG¶V SUREOHPV overall, not just related to health, in which MacLeod (2009) 
noted that from the 20 top measures considered most likely to be cost effective 
globally, nine directly relate to improving drug therapy for children. 
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There is now a rapidly evolving situation where clinical research is becoming 
increasingly globalised. Although commented on in some external literature, this 
trend has almost developed without being noticed in the medical literature with hardly 
any related publications documenting this growing trend in MEDLINE as described 
by Thiers et al., (2008). However their data shows that it is a real and growing 
phenomenon, largely caused by cost savings for the biopharmaceutical industry and 
also emerging research infrastructure in rapidly developing LMIC. 
Further evidence supporting this changing situation came from Glickman et al. 
(2009). They discovered that for industry-sponsored phase 3 clinical trials conducted 
by the 20 largest U.S.based drug companies, about one-third were performed solely 
outside the United States and more than half of study sites were outside the U.S. They 
also found that from 300 reports of clinical trials published in the New England 
Journal of Medicine (NEJM), the Lancet and the Journal of the American Medical 
Association (JAMA); the proportion of trials conducted in the U.S. and Western 
Europe decreased, while the number of countries where trial sites were located, 
particularly developing countries, more than doubled between 1995 and 2005.  
Profound questions are being asked about the ethical and scientific 
implications of this globalisation of clinical trials. Glickman et al. (2009) asks; who 
benefits from this trend? What is the potential for exploitation of research subjects? 
Are the resulting findings valid and generalisable to other settings?  
All these issues build the context of work for this chapter. The aim is to 
examine paediatric drug RCTs in relation to the global health situation for the 
paediatric population and also the increasing globalisation of clinical trials.   
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2. METHODS 
2.1 Setting the scene 
 For this chapter, the first step was to outline the global burden of disease in the 
paediatric population from the most recent data. Although under-five mortality 
features prominently in the literature, for example by the Bellagio study group and 
UNICEF, it was felt a wider view was needed to provide the background for the 
analysis of paediatric RCTs considering that this systematic review included older 
children as participants including adolescents. Furthermore, it was felt important to 
understand how non-fatal diseases contributed to the burden of disease and what 
differences can be seen between different country or regional groups. 
 The Global Burden of Disease project was initiated in 1990 and is a massive 
effort undertaken by several organisations including the WHO and the World Bank to 
provide estimates of morbidity and mortality data by age, sex and region, with the 
overall aim to guide health policy decisions (Murray and Lopez, 1996). The project 
collected comprehensive epidemiological data from each country on disease 
prevalences and causes of death; each country volunteered information from registries 
or health authorities and where information was scanty, modelling techniques were 
used to provide estimates on causes of death. 
 Mortality data regarding causes of death was categorised using the ICD-10 
system into three broad groups by the project researchers, they were described as 
group I - communicable, maternal, perinatal and nutritional conditions, Group II ± 
noncommunicable diseases and Group III ± injuries. 
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In addition to reporting data on mortality, the project introduced a single 
parameter called the Disability-Adjusted Life Years (DALY) as a single measure to 
quantify the burden of diseases, injuries and risk factors. The DALY reflects both the 
potential years of life lost due to premature death and also the years of life lost due to 
being in poor health or disability. Therefore one DALY reflects one year of healthy 
life lost due to premature death or disease.  
DALYs = The sum of years of potential life lost due to premature mortality and the 
years of productive life lost due to disability. 
Within the project, countries were classified according to gross national 
income per capita and analysed according to two major groups comparing high 
income countries (HIC) to low and middle income countries (LMIC). Four broad age 
categories were used; neonates and children younger than five (0-4 years of age), 
older children (5-14 year olds), adults (15-59 year olds) and the elderly (60 years and 
above). 
 To provide the background for comparisons of data from my systematic 
review, information regarding disease-related mortality and DALYs from the project 
was reviewed and summarised for the two paediatric age groups namely the 0-4 year 
olds and the 5-14 year olds. Mortality classified to be caused by Group III ± injuries 
were excluded for these two age categories. Thus paediatric disease-related mortality 
and DALYs were obtained for the country income categories.  
 
 
 
 
162 
 
2.2 Review of paediatric RCTs published between 1996 and 2002 
 A previously constructed database of RCTs involving oral and intravenous 
medicines in children was reanalysed (Sammons et al., 2008). The method of 
identifying relevant RCTs for the Sammons database has already been described. 
Briefly, they used the Cochrane Collaborations highly sensitive search strategy to 
search MEDLINE for paediatric RCTs published between 1996 and 2002.  
 For this current study, the full journal articles of the published RCTs contained 
in the Sammons database were re-examined to determine the country setting, disease 
studied, and main therapy being trialled, as well as the funding source and ethical 
approval where mentioned. The main disease and the main drug being studied were 
recategorised according to ICD-10 and WHO ATC systems respectively.  
Country locations of the RCTs were stratified according to the United 
1DWLRQ¶V +XPDQ 'HYHORSPHQW ,QGH[ +', FDWHJRULHV VRXUFHG IURP WKH +XPDQ
Development Report of 2002 (data from year 2000). The HDI is a composite of 
important indicators of human development comprising life expectancy, literacy rate, 
education enrolment and gross domestic product (see chapter 2). Countries are given a 
single score; 0.8 and above are classed as highly developed, 0.5-0.79 considered 
medium development and below 0.49 classed as low development. 
Medium and low HDI countries were grouped as developing countries. In 
addition to the aforementioned characteristics of the trials, data on the presence of 
SMC/DSMBs and ADRs, were also compared between the developed and developing 
countries.   
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2.3 Paediatric drug RCTs published in 2007 according to country settings 
 Country settings of paediatric RCTs compiled in the current systematic review 
were previously categorised according to HDI (2007) and World Bank per capita 
income levels of the year 2007 (see section 3.2).  
The following characteristics of the RCTs were compared between trials 
conducted in the different HDI and World Bank income categories: 
i. sample population sizes 
ii. types of disease areas of the trials according to the ICD-10 system 
iii.  types of drugs being studied according to the ATC system 
iv.  funding sources 
v. Jadad score of the RCTs 
vi.  documentation of sample size or power calculations 
vii.  inclusion of a patient/CONSORT flowchart 
viii.  documentation of ethical approval, informed consent and assent 
ix.  mention of safety monitoring 
x.  presence of SMC/DSMBs 
xi.  occurrence of serious adverse events (SAEs) and mortality in the trial 
xii.  adverse drug reactions (ADRs) judged to have been experienced  
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2.4 Comparisons to burden of disease data 
 Characteristics of paediatric RCTs from both datasets namely those published 
from 1996 to 2002 and in 2007 were related to data obtained by the Global Burden of 
Disease project regarding disease prevalences as well as disease-related burden and 
mortality. For the first database of trials published between 1996 and 2002, the burden 
of disease report published in 2006 (Lopez et al., 2006 - data obtained up to 2001) 
was used while for the second database of trials published in 2007, the latest WHO 
report on the global burden of disease published in 2008 was used (WHO - data 
obtained from 2004). 
 The major comparisons made were between high income countries (HIC) 
versus low and medium income countries (LMIC) of the World Bank income 
groupings (World Bank, 2007), as well as between developed (high HDI) and 
developing countries (medium and low HDI). 
  
2.5 Statistical Analysis 
 SPSS version 16.0 (SPSS Inc., Chicago, IL, USA) was used for storage and 
analysis of data. Means were compared using the unpaired t-test. The chi-squared test 
was used to examine the statistical significance of differences between multiple 
groups. Differences in proportions were compareGXVLQJ)LVKHU¶VH[DFWWH[WZLWKWZR-
tailed p values, which was also used when differences between multiple groups 
involved small numbers. 
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3. RESULTS 
3.1 The Global Burden of Disease in Children 
 The latest report from the Global Burden of Disease project was published in 
2008 utilising data collected from the year 2004 (WHO, 2008). When data from this 
report was analysed, it revealed that the vast majority of the paediatric population live 
in low and middle income countries (LMIC). More than 1.6 billion children live in 
LMIC while there are about 180 million children living in HIC (table 1). 
 Overall, almost 11 million children died of disease in LMIC in 2004. This 
compares dramatically to the 86,000 disease-related deaths in the paediatric 
population occurring in HIC.  
Children aged 0-14 years living in low income countries had a disease-related 
mortality rate of more than 20 times compared to those living in high income 
countries (100 vs 5 deaths, per 10,000 children). When considered as a group, 
children 0-14 years of age in LMIC had a disease-related mortality rate of more than 
13 times over children in HIC (70 vs 5 deaths, per 10,000 children).  
Deaths caused by injuries are a fraction of disease-related mortality overall, 
accounting for 7% of total mortality in the population aged 0-14 years old worldwide. 
The rate of injury-related deaths for 0-14 year olds was almost the same for middle 
income and low income countries, and were roughly twice above the rate in high 
income countries.  
The data showed that the great majority of deaths in the paediatric population 
occur in children under five. Of the 11.9 million deaths occurring in 0-14 year olds, 
under-five mortality accounted for 10.4 million or 87% of the deaths (figure 1). Thus 
the attention paid by most organisations to under-five mortality is clearly justified.  
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 Item HIC LMIC 
 
High Income 
Countries 
Middle 
Income 
Countries 
Low Income 
Countries 
Population of 0-14 year olds 179 million 773 million 894 million 
Disease-related deaths (x 1000) 86 1948 8990 
Injuries                         (x 1000) 17 393 449 
Total Deaths                (x 1000) 103 2341 9439 
Table 1: Deaths occurring in the paediatric population 0-14 years, classified by 
income category 
 
 
 
Source: The Global Burden of Disease Report: 2004 update. The WHO, 2008.   
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 Children in HIC died of very different diseases compared to LMIC countries 
(table 2). The two major groups of diseases that accounted for two-thirds of deaths 
(57,000 deaths) in HIC were perinatal conditions and congenital abnormalities. In 
LMIC, infectious and parasitic diseases together with respiratory infections caused 
more than 60% of deaths of children up to 14 years of age. However, deaths related to 
perinatal conditions were also prominent, with a total of 3,142,000 neonates dying in 
LMIC due to prematurity, birth asphyxia and trauma as well as neonatal infections. A 
further 371,000 children died of congenital abnormalities in LMIC. 
 
Major diseases causing death in 
children 0-14 years old  
(x 1000 children) 
HIC LMIC 
High Income 
Countries 
Middle 
Income 
Countries 
Low Income 
Countries 
Infectious and parasitic diseases 6 525 4055 
Respiratory infections 4 284 1770 
Perinatal conditions  37 745 2397 
Congenital abnormalities 20 134 237 
Table 2: Major disease-related causes of death in the global paediatric population 
Analysis of data from Table A3, Annex A, page 66-68, The Global Burden of 
Disease: 2004 update (WHO, 2008) 
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 To study the overall burden of disease in children including non-fatal illnesses 
and disability, the Disability-adjusted Life Years (DALYs) due to disease were 
examined for the paediatric population aged 0-14 years old (Table 3). Children in 
LMIC have approximately 6 fold more DALYs due to disease versus children in HIC 
(0.29 vs 0.05, per child). The paediatric population in LMIC also have 4 times more 
DALYs due to injuries compared to those in HIC (0.028 vs 0.007, per child). Overall, 
children in LMIC suffer from 6 times more DALYs compared to children in HIC 
(0.32 vs 0.05, per child). 
 
Item 
HIC LMIC 
High Income 
Countries 
Middle 
Income 
Countries 
Low Income 
Countries 
Population of 0-14 year olds 179 million 773 million 894 million 
DALYs* due to disease (x 1000) 8743 109,309 381,772 
DALYs due to injuries  (x 1000) 1199 19,088 28,045 
Total DALYs                (x 1000) 9942 128,397 409,816 
Table 3: Comparison of DALYs in children 0-14 between income levels 
Analysis of data from Table A4, Annex A, page 69-72, The Global Burden of 
Disease: 2004 update 
* DALYs = The sum of years of potential life lost due to premature mortality and the 
years of productive life lost due to disability 
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 Another major difference between HIC and LMIC emerged when causes of 
the DALYs were analysed. The majority of the burden of disease in the paediatric 
population of HIC arises from non-communicable diseases, contributing to more than 
60% of their total DALYs. The three major noncommunicable conditions were 
neuropsychiatric disorders, congenital abnormalities and respiratory diseases 
particularly asthma (table 4).  
Disease-related DALYs in 
children 0-14 years 
HIC LMIC 
High Income 
Countries 
Middle 
Income 
Countries 
Low Income 
Countries 
Total DALYs  
(x 1000 DALYs) 
9942 128,397 409,816 
Noncommunicable conditions 
(x 1000 DALYs)  
6055 38,124 49,313 
Neuropsychiatric disorders 2173 13,483 14,937 
Congenital abnormalities 1419 7971 4679 
Respiratory diseases 943 3911 4335 
Table 4: Major noncommunicable diseases causing DALYs 
Analysis of data from Table A4, Annex A, page 69-72, The Global Burden of 
Disease: 2004 update 
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In contrast, the biggest burden of disease suffered by children in LMIC is 
caused by communicable, maternal, perinatal and nutritional conditions, accounting 
for three-quarters or 75% of the total DALYs in LMIC (table 5). Infectious and 
parasitic diseases were the biggest causes of the DALYs in LMIC, followed by 
perinatal conditions, respiratory infections and nutritional deficiencies. 
Disease-related DALYs in 
children 0-14 years 
HIC LMIC 
High Income 
Countries 
Middle 
Income 
Countries 
Low Income 
Countries 
Total DALYs  
(x 1000 DALYs) 
9942 128,397 409,816 
Communicable, maternal, 
perinatal and nutritional 
conditions  
(x 1000 DALYs) 
2688 71,185 332,459 
Infectious and parasitic 
diseases 
477 21,558 154,384 
Respiratory infections 250 11,433 64,480 
Perinatal conditions 1768 31,290 93,331 
Nutritional deficiencies 191 6804 19,835 
Table 5: Major causes of disease burden in the paediatric population 
Analysis of data from Table A4, Annex A, page 69-72, The Global Burden of 
Disease: 2004 update 
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3.2 Reanalysis of Paediatric RCTs published between 1996 and 2002 
After omitting duplicate studies from the Sammons database, a total of 733 
papers were analysed. 575 or 78% of the RCTs took place in high HDI countries, 
while 122 (17%) and 36 (5%) took place in medium and low HDI countries 
respectively. 
 Following ICD-10 classification, the majority of RCTs that took place in 
medium and low HDI countries studied infectious and parasitic diseases (Table 6). 57 
out of 122 RCTs in medium HDI countries and 32 out of 36 RCTs in low HDI 
countries were in this category. Respiratory diseases were the second most common 
disease area studied (14 RCTs), followed by nervous system diseases (10 RCTs) and 
perinatal conditions (10 RCTs).  
When the medicines trialled in the RCTs were categorised according to the 
ATC system, a similar trend was observed. 99 out of 158 (63%) RCTs were those of 
anti-parasitic or systemic anti-infective drugs. Next were nervous system drugs, 
accounting for 20 of the RCTs (13%) (Table 7). 
On closer inspection of the antiparasitic and anti-infective groups, anti-
malarial therapies (24 RCTs) were most frequently studied, followed by therapies for 
geohelminthic infection (23), schistosomiasis (8), leishmaniasis (6), typhoid (5), 
upper respiratory tract infections (5), giardia (4) and tuberculous infections (3). 
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ICD-10 classification No (n) Percent (%) 
Certain infectious and parasitic diseases (A00-B99) 89 56 
Diseases of the respiratory system (J00-J99) 14   9 
Certain conditions originating in the perinatal period (P00-P96) 10   6 
Diseases of the nervous system (G00-G99) 10   6 
Diseases of the digestive system (K00-K93) 6   4 
Diseases of the genitourinary system (N00-N99) 3   2 
Diseases of the blood and blood-forming organs and certain 
disorders involving the immune mechanism (D50-D89) 3 2 
Congenital malformations, deformations and chromosomal 
abnormalities (Q00-Q99) 2 1 
Endocrine, nutritional and metabolic diseases (E00-E90) 2 1 
Mental and behavioural disorders (F00-F99) 2 1 
Injury, poisoning and certain other consequences of external 
causes (S00-T98) 2 1 
Diseases of the circulatory system (I00-I99) 1 1 
Diseases of the musculoskeletal system and connective tissue  
(M00-M99) 1 1 
Diseases of the eye and adnexa (H00-H59) 1 1 
Diseases of the ear and mastoid process (H60-H95) 1   1 
Symptoms, signs and abnormal clinical and laboratory findings, 
not elsewhere classified (R00-R99) 11 7 
Total 158 100 
Table 6: ICD-10 classes of paediatric RCTS in developing countries between 1996-
2002  
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ATC drug classification No (n) Percent (%) 
Antiparasitic products, insecticides and repellents (group P) 71 45 
Anti-infectives for systemic use (group J) 28 18 
Nervous system (group N) 20 13 
Alimentary tract and metabolism (group A) 8 5 
Antineoplastic and immunomodulating agents (group L) 7 4 
Respiratory system (group R) 5 3 
Systemic hormonal preparations, excl. sex hormones and 
insulins (group H) 5 3 
Musculo-skeletal system (group M) 4 3 
Dermatologicals (group D) 3 2 
Blood and blood forming organs (group B) 3 2 
Cardiovascular system (group C) 2 1 
Various (group V) 2 1 
Total 158 100 
Table 7: ATC classes of paediatric RCTs in developing countries between 1996 and 
2002 
 
Fewer RCTs from medium and low HDI countries mentioned safety 
monitoring in their respective reports; 442/575 (77%) in high HDI, 83/122 (68%) in 
medium HDI, 22/36 (61%) in low HDI RCTs (p=0.02). In particular, there was 
practically no mention of SMCs from RCTs conducted in developing countries. Only 
one out of the 158 paediatric RCTs from medium and low HDI countries mentioned a 
SMC (compared to 12 out of 575 RCTs from high HDI countries, p=0.32). This 
Brazilian trial of G-CSF in preterm infants with early onset sepsis was terminated by 
the SMC, there was a flaw in the trial design and calculation of number of participants 
(Miura et al., 2001). 
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Looking at toxicity reporting, fewer RCTs from developing countries specified 
whether trial participants experienced adverse events. 113/575 (20%) of RCTs from 
high HDI countries lacked mention of toxicity data, whereas 31/122 (25%) paediatric 
RCTs from medium and 12/36 (33%) from low HDI countries had no mention of 
toxicity data (p=0.07). In terms of mortality occurring in the RCT participants, there 
was no significant difference found among the HDI categories. 
Significantly fewer paediatric RCTs from developing countries mentioned that 
their study had obtained approval from an ethics committee or an institutional review 
board, compared to RCTs from developed or high HDI countries (61% vs 73%, 
p=0.0039).  
The major source of stated funding for paediatric RCTs in developing 
countries appeared to come from academic or governmental sources. 63 (40%) of the 
RCTs stated that they were funded by academic/governmental institutions. In contrast, 
significantly more RCTs in high HDI countries acknowledged funding from 
pharmaceutical companies (27% vs 15%, p=0.0028). 67 (42%) of the 158 RCTs from 
developing countries did not mention their funding source at all. A similarly large 
percentage (43%) of RCTs from high HDI countries did not mention their funding 
source. 
 
 
 
 
 
 
 
 
175 
 
3.3 Characteristics of paediatric drug RCTs published in 2007 according to setting 
1. Sample Sizes 
 Overall, RCTs performed in low income countries were larger compared to 
RCTs in medium and high income countries (table 8). As expected RCTs with study 
sites in multiple countries covering more than one income category (MSDI) were the 
largest on average. 
World Bank  
income category* 
Median number of 
participants in RCT 
Mean number 
of participants 
High income countries 75 185 
Medium income 
countries 
62 207 
Low income countries 214 307 
MSDI# 353 521 
Table 8: Sample sizes of paediatric drug RCTs published in 2007 
*sourced from World Bank, World Development Indicators 2007. Washington DC, 
USA. 
#Multinational RCTs with study sites in different income categories 
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2. ICD-10 disease classes 
In LMIC, a significantly higher proportion of RCTs studied infectious and 
parasitic diseases compared to HIC (39% vs 13%, p<0.01). In low income countries 
especially, 80% of the trials were in this class. Curiously, the most frequent ICD-10 
category in high income countries was the non-VSHFLILF µV\PSWRPV VLJQ DQG
DEQRUPDO FOLQLFDO DQG ODERUDWRU\ ILQGLQJV QRW HOVHZKHUH FODVVLILHG¶ WDEOH  7KLV
was also the most frequent category in middle income countries when separated from 
low income countries. For MSDI RCTs, the respiratory disease category was most 
common followed by infectious and parasitic diseases. 
World 
Bank  
income 
category 
Most frequent ICD-10 category of disease studied 
High 
income 
countries 
Symptoms, signs & 
abnormal clinical and 
laboratory findings, not 
elsewhere classified 
17% 
Respiratory diseases 
 
 
 
14% 
Certain infectious and 
parasitic diseases 
 
 
13% 
Medium 
income 
countries 
Symptoms, signs & 
abnormal clinical and 
laboratory findings, not 
elsewhere classified 
35% 
Certain infectious and 
parasitic diseases 
 
 
26% 
Respiratory diseases 
 
 
 
8% 
Low 
income 
countries 
Certain infectious and 
parasitic diseases 
 
 
80% 
Nervous system 
Diseases of skin and subcutaneous tissue 
Symptoms, signs, not elsewhere classified 
 
4% each 
MSDI# 
Respiratory diseases 
 
 
 
33% 
Certain infectious and 
parasitic diseases 
 
 
21% 
Endocrine diseases 
 
 
 
12% 
Table 9: Top three most common ICD-10 categories in paediatric RCTs published in 
2007 by income level 
#Multinational RCTs with study sites in different income categories 
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3. ATC drug classes  
 The ATC classes of the drugs studied in the RCTs revealed the explanation for 
large number of trials being classed in the non-VSHFLILFµV\PSWRPVDQG VLJQV¶,&'-10 
disease category. There were large numbers of paediatric RCTs of anaesthetic and 
analgesic agents published in 2007. According to the ICD-10 system, these trials were 
FODVVLILHG LQ WKH µV\PSWRPV DQG VLJQV¶ FDWHJRU\ UDWKHU WKDQ WKH QHUYRXV V\stem 
diseases category. These trials were mostly conducted in high income countries and 
can be seen in the nervous system class when the RCTs were categorised according to 
the ATC system (Table 10). 
 As seen earlier, antiparasitic products and anti-infectives for systemic use 
were the most common drugs studied in RCTs conducted in LMIC. 
 
World Bank 
income 
category 
Most frequent ATC category of drugs trialled 
High 
income 
countries 
Nervous system 
 
26% 
Anti-infectives for 
systemic use 
15% 
Respiratory drugs 
 
15% 
Medium 
income 
countries 
Nervous system 
 
36% 
Anti-infectives for 
systemic use 
18% 
Antiparasitic products 
 
8% 
Low 
income 
countries 
Antiparasitic products 
 
 
61% 
Anti-infectives for 
systemic use 
 
18% 
Nervous system& 
Dermatologicals 
 
Both 6% 
MSDI# 
Respiratory drugs 
 
36% 
Anti-infectives for 
systemic use 
 
26% 
Nervous system 
 
 
10% 
Table 10: Top three most common ATC drug classes in paediatric RCTs published in 
2007 by income level 
#
 Multinational RCTs with study sites in different income categories 
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4. Funding sources 
 A large number of RCTs from medium income countries did not report their 
main funding source for the trials (Figure 2). The largest proportion of RCTs 
performed in low income countries acknowledged charitable organisations as the 
main study sponsor. In contrast, most of the large multinational trials with study sites 
crossing income categories (MSDI) reported pharmaceutical companies as their main 
sponsors. Industry sponsors were also the most commonly acknowledged in RCTs 
performed in high income countries. 
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Figure 2: Main trial sponsors documented by paediatric RCTs published in 2007 by 
income level 
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5. Methodological quality 
 The mean Jadad score for studies conducted in LMIC were significantly lower 
than studies conducted in HIC (2.88 vs 3.33, p=0.05) (table 11).  
Category Mean Jadad Standard deviation (SD) 
HIC 3.33 1.265 
MIC 2.77 1.371 
LIC 3.24 1.242 
MSDI#  3.83 1.208 
Table 11: Mean Jadad score and standard deviation of the mean scores 
#
 Multinational RCTs with study sites in different income categories 
  
A significantly higher proportion of RCTs from HIC reported power or sample 
size calculations compared to LMIC trials (64% vs 52%, p<0.01). However there was 
no significant difference between HIC and LMIC in terms of RCTs that included a 
CONSORT participant flowchart (table 12). 
  
HIC 
 
LMIC p-value 
a priori sample 
size 
/power 
calculation 
performed 
64% 52% <0.01 
CONSORT 
participant 
flowchart 
37% 35% 0.78 
Table 12: Indicators of methodological/reporting quality in paediatric RCTs published 
in 2007 
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6. Documentation of ethical aspects 
 All 42 of the MSDI RCTs documented that ethical approval and informed 
consent was obtained (Figure 3). About one-third reported that assent was obtained 
from the paediatric participant.  
 A significantly higher percentage of RCTs conducted in HIC reported that 
ethical or institutional review board approval was obtained compared to RCTs in 
LMIC (93% vs 85%, p<0.01). However there was no significant difference relating to 
the documentation of informed consent (93% vs 90%, p=0.32). 
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Figure 3: Percentages of paediatric RCTs published in 2007 documenting ethical 
aspects by income level 
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7. Safety and toxicity characteristics  
A significantly higher proportion of trials conducted in HIC reported on their 
safety monitoring methods compared to RCTs performed in LMIC (65% vs 36%, 
p<0.01), while 93% of MSDI RCTs reported on safety monitoring (table 13).  
 
Income 
Group 
RCTs reporting safety 
monitoring  
(N/total) 
Percent 
(%) 
RCTs reporting 
SMC/ 
DSMB  
Percent 
(%) 
HIC 229/352 65 40/352 11 
LMIC 
MIC 46/159 29 7/159 4 
LIC 30/51 59 10/51 20 
MSDI 
 
39/42 
 
93 12/42 29 
Table 13: RCTs reporting safety monitoring and presence of SMC/DSMB, by income 
level of study setting 
 
Similar proportions of HIC and LMIC trials reported that a SMC/DSMB was 
formed (11% vs 8%, p=0.25). However a significantly higher percentage of MSDI 
RCTs reported on safety monitoring (93% vs 56%, p<0.01), and documented the 
designation of a SMC/DSMB to oversee the trials (29% vs 11%, p<0.01), compared 
to RCTs in HIC and LMIC. 
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 A substantial number of the RCT reports neglected to mention the occurrence 
of adverse events (including when no adverse events occurred). LMIC RCT reports 
were significantly worse compared to HIC in this aspect. Seventy nine percent (79%, 
275/352) of reports of RCTs performed in HIC included adverse events compared to 
70% of RCT reports from LMIC (147/210), p=0.03. MSDI RCTs almost universally 
reported on adverse events occurring within the trials (figure 4). 
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Figure 4: Reporting of adverse events in paediatric RCTs from each category of 
setting (%) 
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RCTs conducted in HIC reported a significantly higher rate of serious adverse 
events (SAEs). Thirty six percent (128/352) of the HIC trials reported a SAE 
compared to 24% of trials conducted in LMIC (p<0.01). Similar proportions of RCTs 
conducted in HIC and LMIC reported mortalities (13% in both) (table 14).  
Income 
Group 
Median 
sample size 
(N) 
Proportion 
with SAEs 
Percent  
(%) 
Proportion 
with 
mortality 
Percent  
(%) 
HIC 75 128/352 36 46/352 13 
LMI
C 
MIC 62 35/159 22 19/159 12 
LIC 214 16/51 31 9/51 18 
MSDI 353 31/42 74 13/42 31 
Table 14: Paediatric RCTs published in 2007 reporting SAEs and mortality, by 
income level of setting 
 
Severe and moderate ADRs were detected in a significantly higher proportion 
of RCTs conducted in HIC compared to LMIC (25% vs 16%, p=0.01). However, the 
largest percentages of trials reporting SAEs, severe and moderate ADRs as well as 
mortalities were seen in the big MSDI RCTs (table 15). 
 
Income Group 
Median 
sample size 
(N) 
Severe & Moderate  
ADRs detected Percent (%) 
HIC 75 88/352 25 
LMIC 
MIC 62 
 
26/159 16 
LIC 214 7/51 14 
MSDI 
 
353 
 
24/42 57 
Table 15: Paediatric RCTs published in 2007 where severe and moderate ADRs were 
detected, by income level of setting 
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The possible mechanisms for these differences between RCTs conducted in 
the different income level settings were explored by cross tabulating with the 
categories of trials that had the highest toxicities (table 16). There were no significant 
differences in the proportions of cardiovascular, chemotherapy, neonatal or mixed-age 
population trials from those conducted in HIC compared to LMIC.  
MSDI RCTs had much larger sample populations (see table 8 previously). The 
MSDI RCTs also were found to contain a significantly higher percentage of mixed-
age trials compared to the other income categories (50% vs 29%, p<0.01). 
Income 
level of 
study 
setting 
Cardio 
vascular 
RCTs 
(N) 
Chemotherapy 
RCTs 
 
(N) 
RCTs 
involving 
neonates 
(N) 
RCTs of both 
adult and 
paediatric 
patients (N) 
Total 
no of 
trials 
(N) 
HIC 7 28 21 92 352 
MIC 6 10 18 46 159 
LIC 0 0 0 17 51 
MSDI 0 3 2 21 42 
Total 13 41 41 176 604 
Table 16: Cardiovascular, chemotherapy, neonatal and mixed-age population 
paediatric RCTs published in 2007, by income level of study setting 
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4. DISCUSSION 
 The great majority of the paediatric population worldwide live in LMIC. They 
suffer and die from different diseases, and at much higher rates compared to those 
children living in HIC. Thus there is a very large difference in mortality rates between 
paediatric populations in HIC and LMIC. It was found that the relatively few child 
deaths in HIC occur perinatally and the paediatric population are mostly burdened by 
neuropsychiatric illnesses, congenital abnormalities and asthma. These diseases 
contribute significantly to the disease burden in HIC, as seen in the smaller 
discrepancy between DALYs of children in HIC and LMIC. Nevertheless the fact 
remains that far greater numbers of children are afflicted by disease and die in LMIC, 
particularly due to infections, in addition to the large number of deaths during the 
neonatal period.  
 Encouragingly both databases of paediatric RCTs show that infectious and 
parasitic diseases was the most commonly studied area in LMIC. Nevertheless it is 
apparent that the majority of RCTs were performed in developed countries, with 78% 
of trials in the Sammons database and 65% of RCTs in this review of 2007 
publications, conducted in high HDI countries. There also seems to be evidence 
suggesting an overall shift of paediatric RCTs from HIC to LMIC country settings. 
There appears to be significant differences between paediatric RCTs 
conducted in HIC and LMIC. Paediatric RCTs performed in LMIC were found to 
have lower methodological and reporting quality. Fewer of these RCTs were seen to 
document important aspects of RCTs in their published reports, including ethical 
approval, safety monitoring and the occurrence of adverse events. On the contrary, 
more RCTs from HIC were found to report SAEs and were judged to have severe and 
moderate ADRs.  
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Interestingly, closer analysis suggests that HIC and LIC RCTs were more 
similar compared to MIC RCTs. A possible explanation is indicated by the funding 
information volunteered by the RCT reports. More LIC RCTs were funded by drug 
companies compared to MIC RCTs. It is postulated that the methodological and 
reporting standards used by industry-sponsored investigators in LIC would be more 
similar to the HIC RCTs that are also mostly sponsored by the pharmaceutical 
industry.   
This review of paediatric RCTs published in 2007 also identified many RCTs 
with study settings located in countries that were in different HDI and World Bank 
income categories. These MSDI RCTs appear to have unique characteristics. They are 
much larger and are more likely to recruit both adult and paediatric populations to the 
study. The great majority identify drug companies as their main sponsors. These 
RCTs also appear to have exceptional methodological and reporting quality, scoring 
the highest on the Jadad scale. All of them documented that ethical approval and 
informed consent were obtained, moreover almost one-third recorded assent from 
paediatric participants.  
However, these cross category RCTS had the highest percentage of studies 
reporting serious adverse events, mortality and where severe and moderate adverse 
drug reactions were detected. This could be due to the large and heterogeneous 
sample populations, many of these trials recruited elderly patients as well as those 
with comorbidities. Another explanation is the possible application of better detection 
methods, as well as more transparent and organised reporting of adverse events in 
these MSDI RCTs. 
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When findings from this review were compared directly to data from the 
Burden of Disease project (WHO, 2008), a mere 35% (see chapter 3) of paediatric 
RCTs published in 2007 were performed in LMIC with a population of 1.6 billion 
below 15 years of age, from which there were 10.9 million deaths due to disease. The 
remainder, including most of the studies in the cross category class of RCTs, involved 
the paediatric population of HIC which numbered 180 million in total.  
 This corresponds with the mismatch referred to by the Global Forum for 
Health Research (1999). There are other literature that document this apparent 
discrepancy as well. Isaakidis et al. (2002) evaluated the amount of randomised 
clinical evidence in relation to the burden of disease in sub-saharan Africa. They 
identified only slightly over 1000 RCTs performed over a 50 year period. In relation 
to child health, UNICEF states that around half of global child deaths occur in sub-
saharan Africa.  
This is also in contrast to the hundreds of thousands of RCTs currently 
archived in the Cochrane register (see section 2.3.1.2). Gluud and Nikolova (2007) 
also show that most of the RCTs published since 1946 originated from North 
American and Western European countries, with Scandinavian countries the most 
productive in terms of RCTs per population. Rochon et al. (2004) also commented 
that RCTs published in high impact, international journals in 1999 had little relevance 
to international health especially the burden of disease in poor countries. 
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Swingler et al. (2003) estimated the correlation between systematic reviews in 
two major databases; namely the Cochrane database of systematic reviews (CDSR) 
and the database of abstracts of reviews of effects (DARE), and the global burden of 
disease. They found that the contents of both databases were both geared towards the 
priorities of established market economies or high income countries rather than global 
health concerns.  
On a broader scope, Pecoul et al. (1999) lamented on the lack of effective 
treatment for many diseases endemic in poor countries due to the lack of research and 
development for these diseases. Trouiller et al. (2002) analysed global drug 
development over the past 25 years and found that of the 1393 new drugs granted 
market authorisation, considerably fewer targeted infectious and parasitic diseases 
which accounted for the majority of the global disease burden but were minor in high 
income countries. 
$OO WKLV SRLQWV WR D µPRUDOO\ XQFRPIRUWDEOH JOREDO GUXJ JDS¶ DIIHFWLQJ SRRU
populations where Cohen-Kohler (2007) suggests that there is not only a lack of 
access to essential drugs but also an apparent absence of effort to address this 
problem. There is further relevance to paediatric populations in LMIC when 
additional issues are included in the consideration. It is recognised that there has been 
inadequate research on medicines for children (Klassen et al., 2008, Choonara, 2000). 
This is also reflected in the lack of high quality published evidence in the literature 
compared to those of adults (Cohen et al., 2007, Martinez-Castaldi et al., 2008).  
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Therefore the paediatric population in poor countries may suffer from a three-
fold inadequacy ± firstly the overall lack of scientific evaluation of medicines given to 
children, secondly the lack of research and development to provide safe and effective 
medicines appropriate for the illnesses that affect them and finally the lack of delivery 
infrastructure and mechanisms to allow them access to essential drugs. 
There are exciting efforts to tackle the situation. In 2007 WHO launched the 
µ0DNHPHGLFLQHVFKLOGVL]H¶FDPSDLJQFDOOLQJIRUPRUHUHVHDUFKDQGGHYHORSPHQWRI
safe, effective, child-specific medicines with a heavy emphasis on global child health 
needs. The major infectious diseases such as malaria, TB and HIV/AIDS afflicting 
children in poor countries are targeted as well as the tropical diseases that have long 
EHHQQHJOHFWHG2¶&RQQHOO 
The argument made here is not simply for more RCTs to involve paediatric 
populations in LMIC. As previously mentioned, the Bellagio study group estimates 
that millions of child deaths annually can be prevented by improved delivery of 
readily available interventions. However looking at the bigger picture, it is felt that 
improved delivery and access to healthcare should go hand-in-hand with high quality, 
ethical research to benefit child health. In themselves high quality, ethical clinical 
trials has the potential to bring numerous benefits to the population being studied. 
Yusuf (2002) suggests that RCTs in developing countries allow the evaluation 
of treatments specifically accounting for the environmental and genetic factors that 
may be very different to those affecting populations in developed countries, as well as 
that for diseases that are common in developing countries. He adds that by being 
involved in randomised trials, health professionals from poor countries may develop 
and spread the practice of evidence-based medicine thus improving healthcare 
provision. 
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On the other hand, there are multiple concerns and challenges that require 
addressing regarding performing randomised trials in the paediatric population of 
poor countries. The same bioethical principles apply when involving children in 
experimental situations (see section 3.1 chapter 1).  
Beyond the ethical challenges of paediatric studies, there are serious ethical 
issues specifically relating to the conduct of clinical trials in poor or developing 
regions. Emanual et al. (2004) discusses an ethical framework with specific 
benchmarks so that clinical trials in developing countries are ethical; the primary 
objective is to minimise exploitation of the populations involved in these randomised 
trials (Brody, 2002).  
This and many other discussions (Angell, 2000, Koski and Nightingale, 2001) 
arose from previous ethical quandaries relating to clinical trials in developing 
countries. For example, WKHTXHVWLRQRQZKDWWRXVHDVWKHµVWDQGDUGRIFDUH¶DVVHHQLQ
the zidovudine controversy. In several trials of zidovudine used to prevent perinatal 
HIV transmission in African and Asian countries, the use of a placebo group when an 
effective treatment was available, was widely regarded as unethical despite the 
µVWDQGDUGRIFDUH¶ LQ WKH ORFDOVLWXDWLRQbeing no treatment (Angell, 1997, Lurie and 
Wolfe, 1997, Lallemant et al., 1998). )XUWKHUPRUH WKH ORFDO µVWDQGDUG RI FDUH¶ was 
applied where in most cases, no medical care at all was made available to the trial 
participants. 
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Both of the databases here show that documentation of ethical approval were 
significantly lower in paediatric RCTs performed in developing or LMIC countries. 
This is concerning since it may indicate a lower level of ethical oversight in RCTs in 
SRRURUGHYHORSLQJDUHDV)XUWKHUHYLGHQFHLVVHHQIURP=KDQJHWDO¶VUHFHQW
review of randomised controlled trials conducted in China where only 18% of the 
studies documented informed consent and less than 10% reported that ethical 
approval was obtained.  
The trovafloxacin saga in Nigeria (Ahmad, 2001) highlights the vital 
importance of adhering to ethical principles; by obtaining and documenting both 
informed consent and ethical approval from the necessary parties. The drug was 
trialled in a group of severely ill children during a meningitis epidemic in Nigeria; 
without the authorisation of the local health authorities nor the informed consent of 
the parents. Thus it is felt appropriate to repeat the call made in chapter 4; that the 
protection of the rights of participants should be adequately maintained and 
documented. Ethical approval and informed consent (Annas, 2009) must be 
universally reported for paediatric RCTs. 
A related and equally important concern is with the safety oversight in 
paediatric trials in poor countries. Again, both reviews of RCTs found that 
significantly a lower proportion of studies performed in poor and developing 
countries descULEHGVDIHW\PRQLWRULQJ6DPPRQVHWDO¶VGDWDEDVHUHYHDOHGDQ
almost total absence of SMC/DSMBs in trials conducted in developing countries, 
while slightly fewer LMIC paediatric RCTs published in 2007 designated 
SMC/DSMBs. The situation is still evolving up to the present. A recent inquiry by the 
Indian government into a vaccine clinical trial after the death of an infant (Mudur, 
2009) suggests ineffective oversight could be at fault.  
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Conversely, a higher proportion of paediatric RCTs from high income 
countries seem to report SAEs. The analysis shows that a significantly higher 
proportion of HIC paediatric RCTs were judged to have had severe and moderate 
ADRs compared to RCTs conducted in LMIC. The reasons for this are unclear, as the 
most toxic types of trials such as chemotherapy RCTs and those that involve neonates 
appear to be equally spread out between HIC and LMIC trials in the database. 
Another significant discrepancy between HIC and LMIC may offer some clues 
to the difference mentioned in the preceding paragraph. From the 1996 to 2002 
period, more reports of paediatric RCTs conducted in developing countries did not 
include toxicity reporting i.e. adverse events occurring within the trial. This finding 
was repeated in paediatric RCTs published in 2007.  
Therefore, there is the suggestion that the apparently lower proportion of 
RCTs conducted in LMIC found to have toxicity relates to the gaps in safety reporting 
rather than a true difference in ADRs experienced by the patients. This is supported 
by the mean Jadad scores; RCTs conducted in HIC scored significantly higher 
compared to LMIC RCTs. The Jadad score include aspects of both methodological 
and reporting quality. Nevertheless, more research is needed to elucidate this apparent 
difference in adverse events and toxicity between paediatric RCTs in HIC and LMIC. 
Although Sterckx (2005), Cohen-Kohler (2007) and many others argue that 
access to effective medicines is accepted as an inalienable human right, the reality is 
that pharmaceuticals are a commercial product. Their development and supply is 
governed by commercial interests (Rose, 2009). This brings us to a significant new 
trend seen recently where the clinical research sponsored by the pharmaceutical 
industry is increasingly being conducted in developing countries (Glickman et al., 
2009). 
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According to Thiers et al. (2008), the reasons contributing to this shift include 
cheaper costs, greater recruitment capability, the growth of contract research 
organisations (CROs), expanding markets and the rapid development that is 
experienced by newly emerging countries with the corresponding strengthening of 
health research capabilities. 
This trend is also observed in the two databases in this review. Of the 
paediatric RCTs published between 1996 to 2002, 78% were performed in high HDI 
countries. This percentage was found to have substantially decreased to 65% in RCTs 
published in 2007. Furthermore, there was a dramatic increase in multinational 
paediatric RCTs from just 1% in publications between 1996 and 2002, to 16% in 
2007.  
Thus the globalisation of clinical trials also applies to paediatric RCTs. On the 
whole this trend promises to confer welcome benefits to ensure better medicines for 
children on a global level (MacLeod, 2009). Nevertheless paediatric clinical 
pharmacologists, parents, regulators and industry must continue to remain dedicated 
to the effort of providing children worldwide with safe and effective medicines 
supported by sound scientific evaluation. 
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5. CONCLUSION 
 The vast majority of the paediatric population of the world live in poor and 
developing countries. They suffer markedly higher morbidity and mortality compared 
to children in rich countries, caused by very different diseases. Improved access to 
health care interventions are needed to alleviate their heavy burden of disease, 
however it is felt that high quality and ethical clinical trials should go hand-in-hand 
with efforts to improve delivery of preventative and therapeutic measures. As 
expected, most RCTs involving the paediatric population are conducted in rich and 
developed nations but the situation is rapidly changing, corresponding with the rising 
trend of globalisation in clinical trials. Paediatric RCTs performed in resource-poor 
populations has the potential to confer many benefits. However it is essential to avoid 
the possibility of exploitation and harm to the participants. All involved parties need 
to pay attention to the ethical, methodological, safety and reporting aspects of these 
trials to obtain the best eviGHQFHLQWKHLQWHUHVWRIWKHZRUOG¶VFKLOGUHQ 
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CHAPTER 7: CONCLUSION 
 
 
 
 This final chapter provides an overview of the findings and discussions from 
the thesis. The background of this work is the changing situation concerning the 
evidence base for medicines used in children. Consequently it is important to describe 
the recent overall situation of paediatric randomised controlled trials (RCTs)  of 
medicines involving children, as RCTs are regarded as the highest level of evidence. 
Many aspects regarding these RCTs have been encouraging. However this review has 
also identified many areas that require attention to ensure paediatric RCTs are 
appropriately conducted and reported. The safeguarding of participants must be 
prioritised but when adverse drug reactions occur, accurate and transparent reporting 
is needed so that useful information is gained. The primary conclusion of this thesis is 
the idea that clinical research (including RCTs) should respond to the health needs of 
children worldwide, the vast majority of whom live (and die) in poor or developing 
areas. 
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1. CONTRIBUTION TO KNOWLEDGE AND FUTURE WORK 
 The situation with medicines used in children is evolving rapidly (Hoppu, 
2008, MacLeod, 2009) . Previously paediatric involvement in the testing of drugs was 
largely avoided (Steinbrook, 2002, Shirkey, 1999). This was attributed to the intention 
of protecting the under-aged from the risks of experimentation. In fact, the real reason 
may have been economic (Caldwell et al., 2004, Smyth, 2001). In the free market 
economy, the pharmaceutical industry is the main sponsor of research and 
development for drugs (Li et al., 2007, Rose, 2009). To my knowledge, this study is 
the first to look at declared funding of published paediatric RCTs. The results show 
that half of paediatric RCTs published in 2007 declared drug companies as the main 
source of funding; this is likely to be a substantial underestimation, when indirect 
funding and trials that did not declare their sponsors are considered.  
The rise of evidence-based medicine coupled with a much greater 
understanding that the paediatric population differed from adults in many ways other 
than just physical size (Klassen et al., 2008), have triggered major changes at the turn 
of the millennium. The widespread use of unlicensed and off label drugs in children 
accompanied by data suggesting greater risks of toxicity, not to mention being 
scientifically unjustifiable, has captured the attention of the medical community as 
well as the public (Conroy et al., 1999, McIntyre et al., 2000, Conroy et al., 2000a, 
Choonara and Conroy, 2002).  
As a result, new legislation first in the United States and then in the European 
Union was enacted to help ensure medicines used in children will be supported by 
rigorous scientific evaluation, which can only be obtained with the involvement of the 
paediatric population in clinical trials (Choonara, 2007, Greener, 2008, Roberts et al., 
2003).   
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 Randomised controlled trials (RCTs) are regarded as the highest level of 
clinical evidence since they are the least prone to bias. There has been a great effort in 
recent years by organisations chiefly the Cochrane Collaboration to compile and 
analyse RCTs. The refined information gained is then used to assist in clinical 
decision-making as well as to guide wider policy developments in the best interest of 
patients. In the background of aforementioned changes to the situation of paediatric 
medicines, the meticulously developed and validated tools used by bodies such as the 
Cochrane Collaboration are used here and the resulting work has elucidated many 
characteristics of RCTs involving the paediatric population. 
It is heartening that there have been far more RCTs involving the paediatric 
population conducted and then published in 2007 compared to the period between 
1996 and 2002 from Sammons et al.'s (2008) review. From the reports, more than 
100,000 children were involved in the RCTs with trials seen to be larger compared to 
those reviewed in previous studies.  
An issue highlighted by this review is the low number of RCTs involving 
neonates. Research shows that drugs used in neonatal units are frequently unlicensed 
and off label (Conroy et al., 1999). The neonatal population also experiences high 
rates of adverse drug reactions (Kaushal et al., 2001, Moore et al., 2002, Sammons et 
al., 2008). Moreover neonatal diseases form a large proportion of the burden of 
disease in developed countries (WHO, 2008). More work is therefore needed to shed 
light on this area; including what amount of clinical trials should involve neonates and 
how to install the mechanisms to do as such, if more randomised evidence relevant to 
neonates is required. 
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An important feature of this review was the use of both the ATC and ICD-10 
classification systems. This method provides an accurate and reproducible 
categorisation of RCTs. Therefore future work can quickly use the data obtained here 
for analysis and correlations, along with other health statistics available within the 
WHO domain. 
The study identified many trials of anti-infectives, respiratory as well as anti-
parasitic products. Again this was reassuring as these agents correspond to the bulk of 
the disease burden in children overall. There have been previous concerns raised that 
the pharmaceutical industry often conduct paediatric clinical trials in areas where 
there is potential profits to be gained in the adult market, rather than areas where 
paediatric evidence is most needed (Jong et al., 2001). Studies submitted for 
paediatric exclusivity indicate this as well (Rodriguez et al., 2008). A further 
indication of such a tendency is seen in this review. The highest number of RCTs is in 
the nervous systems drugs category but when the ICD-10 disease area is observed, the 
PDMRULW\ RI WKHVH VWXGLHV IHOO LQWR WKH µV\PSWRPV VLJQV DQG DEQRUPDO ILQGLQJV¶
category, reflecting on the large number of analgesic and anaesthetic agents being 
studied. Further research is needed to explore whether certain disease areas or drug 
types should be paid more or less attention. Also more work should be done to clarify 
the motivations behind paediatric RCTs as well as the funding sources for these 
studies as referred to earlier. 
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The assessment of quality of paediatric RCTs is another original contribution 
made by my work. Although an integral component of specific systematic reviews by 
the Cochrane Collaboration, the methodological or reporting quality of paediatric 
RCTs in general has not been documented previously. Overall, paediatric RCTs 
published in 2007 appear to be of good quality, with the mean Jadad score exceeding 
the threshold of 3 points usually regarded by reviewers to indicate good methodology 
or reporting (Jadad and Enkin, 2007). Nevertheless, deeper analysis revealed many 
areas where reporting of paediatric RCTs need improvement to allow readers to 
interpret the findings accurately in addition to forming appropriate conclusions. Good 
reporting is essential as it can affect the ability to assess and apply evidence in clinical 
situations. 
Mixed age group RCTs were found to generally overlook reporting important 
characteristics of the paediatric participants. Many did not volunteer the exact number 
of participants 16 year olds or under and also lacked mentioning the specific age or 
age ranges of the paediatric patients. Such information is needed for many reasons, 
for example considering the developmental processes undergone by the different age 
groups. Furthermore, these basic characteristics are required to assess the 
generalisability of the findings of the trial to the actual healthcare setting in 
paediatrics. 
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This study also contributes to the accumulating body of evidence that RCTs in 
general often disregard the adequate reporting of safety characteristics including 
adverse events and especially possible adverse drug reactions suffered by paediatric 
participants (Ioannidis, 2009). The assessment of potential toxicities is already 
complicated in view of their infrequent occurrence in small sample populations and 
further made to be extremely difficult when basic characteristics such as those 
mentioned above are missing. 
Thus it is hoped that this work should continue towards the development and 
implementation of a consolidated set of reporting standards of RCTs involving the 
paediatric population to supplement the CONSORT statement already in place 
(Moher et al., 2001). Important aspects of paediatric RCTs mentioned earlier as well 
as other items such as adequate formulation information for oral drugs (Standing et 
al., 2005) would then be crystallised into a checklist of items that must be included 
when reporting the studies. Such a checklist can also be associated with the ongoing 
effort to register all clinical trials involving children worldwide (Pandolfini et al, 
2009). 
The main original contribution of this thesis is felt to be the comprehensive 
assessment and description of paediatric RCTs in relation to the global health burden 
for the paediatric population. Clinical drug trials have traditionally been centred in 
highly developed or affluent nations due to a combination of factors; including 
existence of industry or academic initiative as well as availability of healthcare 
infrastructure and expertise. However as the world hurtles into the era of 
globalisation, commentators such as Annas (2009), Thiers et al., (2008) and Glickman 
et al., (2009) have noticed a steadily growing shift towards having trial settings in 
lower-cost locations in developing countries.  
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This review has found evidence that paediatric RCTs are undergoing the same 
changes. Paediatric RCTs located in developing countries as well as multinational 
trials appeared to be steadily increasing in number. However the results suggest that 
paediatric RCTs conducted in LMIC lag behind RCTs from high income countries 
(HIC); in areas such as reporting, methodology used and also the documentation of 
ethical characteristics of the studies.  
Fortunately there are ongoing high profile discussions on the oversight and 
ethical conduct of clinical trials in developing countries (Angell, 2000, McCarthy, 
2001, Pandolfini et al., 2003, Hyder et al., 2004). Most promisingly, there appears to 
be a greater desire for collaboration in the field of paediatric pharmacology as 
demonstrated by the Alliance for Better Medicines in Children (Koren et al., 2009), as 
well as a greater awareness of the importance of paediatric medicines shown by the 
WHO in launchLQJ FDPSDLJQV VXFK DV µ0DNH PHGLFLQHV FKLOG VL]H¶ (Choonara and 
Bauchner, 2008) and safer medicines for children (Watts, 2007). 
In summary, this was an in-depth study of published RCTs which are the 
highest level of clinical evidence for medicines used in the paediatric population. It is 
original in its breadth, currency and relevance to children overall. 
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2. LIMITATIONS AND JUSTIFICATIONS 
 This systematic review of paediatric RCTs published in 2007 has some 
limitations, mostly by virtue of its nature. Although highly sensitive search strategies 
were used (chapter 2), admittedly some relevant RCTs may be missed. However the 
sheer number of RCTs compiled and analysed has provided useful information 
consistent with the initial aims of this study. The large volume of reports yielded by 
the search strategies has also precluded the inclusion of further years in the interest of 
manageability of the database. Further work should follow looking at more recent 
publications of RCTs involving children, to illuminate on the changing situation 
mentioned earlier. 
 Research by Hartling et al., (2004) and Benjamin et al., (2006) has found that 
large numbers of paediatric clinical trials fail to reach publication and consequently 
DUHµORVW¶IURPWKHSXEOLFILHOG6XUSULVLQJO\WKHPDLQUHDVRQZDVIRXQGWREHWKDWWKH
results were never submitted for publication by the investigators themselves.  
This problem is discouraging, as investigators have an ethical commitment to 
their patients to publish their findings. Hence even the large number of studies 
compiled by this review may be an underrepresentation of the overall situation with 
paediatric drug RCTs. The effort to register paediatric clinical trials internationally 
within the WHO registry holds great promise for greater accessibility of RCTs 
involving children (Pandolfini et al., 2009).  
The main limitation of this review is felt to be the dependence on just the 
literature as many aspects of the reporting quality of the paediatric RCTs were found 
to be wanting. There was no attempt to contact the study authors. This was not felt to 
be feasible mainly due to the large number of trials contained in the database.  
203 
 
Furthermore an earlier stated goal of the study was to examine reporting 
quality of paediatric RCTs. The rationale is that although contacting authors is a 
luxury afforded to systematic reviewers, it would not be a realistic proposition for 
busy clinicians and policymakers. It is felt that the onus should be on the trial 
investigators or authors themselves to accurately and transparently describe paediatric 
RCTs conducted. Also important is the role of peer reviewers and journal editors, 
especially with the availability of guidelines such as the CONSORT statement. 
Another limitation is the restriction of this review to the English language 
literature. Some information has been extracted from the 22 non-English RCT reports. 
However there are large gaps in the data that could not be analysed. Both the search 
strategies and the medical literature databases are heavily focussed on English 
language scientific reports, therefore it is plausible that many paediatric RCTs 
conducted in non-English speaking settings and reported in languages other than 
English would be missed by this review. Furthermore, existing non-English, local or 
country-specific trial databases were not included in the search. Future collaborative 
studies should provide more insights on non-English RCTs and thus more clearly 
describe the overall situation of paediatric RCTs.  
Another factor that cannot be discounted is human error. All abstracts yielded 
by the search strategies were reviewed by me in regards to the suitability for 
inclusion. Most of the trial characteristics were also reviewed and designated to the 
relevant categories by myself. However, both my supervisors were closely involved in 
reviewing the reports that contained serious adverse events. Hence in effect, more 
than one-third of the RCTs in the database were reviewed by both supervisors. 
Moreover, I kept in close contact with both supervisors over the period of data 
collection and referred any unclear items to them during the supervisory meetings. 
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It is acknowledged that many types of nonrandomised studies also involve the 
paediatric population (Martinez-Castaldi et al., 2008) as well as non-drug studies. 
Future collaborations should shed more light on the overall situation with clinical 
studies involving children. Although RCTs are regarded by many as the highest 
quality of evidence, there are also those who question the hierarchical approach to 
evidence for medical interventions (Rawlins, 2008). It is acknowledged that this thesis 
has not looked at any alternative study types (observational studies in particular) for 
paediatric medicines that are perhaps equally relevant. Nevertheless, it is hoped that 
the insights offered by this thesis into the characteristics of paediatric drug RCTs may 
lead to useful discussions, as well as improvements, regarding the conduct and 
reporting of paediatric RCTs on a global level. 
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3. CLOSING WORDS 
 In closing, paediatric RCTs are seen to be increasingly globalised. Such a shift 
brings with it the potential for causing harm especially exploitation contrary to the 
principles outlined in the Declaration of Helsinki (Ahmad, 2001, Goodyear et al., 
2008, Kimmelman et al., 2009), and especially vulnerable children. However these 
RCTs can also bring direct and ancillary benefits to the health of the paediatric 
populace of such locales. 
In LMIC, the greatest benefits can be obtained from improving access to basic 
health interventions such as vaccines, clean water, perinatal care, but RCTs can and 
should go hand-in-hand with such measures. Benefits include allowing assessments of 
treatment efficacy specific to the health needs of the population thereby allowing the 
most cost-effective treatments to be delivered, the development of safe and effective 
treatments for diseases causing heavy morbidity and mortality as well as ancillary 
benefits. These include providing basic standards of care, improvements to local 
health facilities as well as expertise, and building collaborations between researchers 
from both rich and poor regions (Yusuf, 2002). 
The argument is not merely advocating RCTs involving paediatric populations 
in poor countries. It is the wider argument that healthcare research should focus more 
on the health needs of the global children, and thus must attempt to shrug off the 
underlying influence of financial rewards and profits as the primary motivator. After 
significant advancements seen recently, yet another paradigm shift of paediatric 
clinical research is required, towards being motivated by altruistic and beneficient 
reasons, rather than driven ultimately by the pursuit of returns denominated in 
FXUUHQF\7KHPDLQLVVXHVKRXOGEHWKHKHDOWKRIWKHZRUOG¶VFKLOGUHQ 
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APPENDICES 
 
1. COUNTRY SETTINGS OF SINGLE COUNTRY RCTS 
Country 
 
No of RCTs 
 
Country 
 
No of RCTs 
USA 115 Guatemala 2 
India 32 South Africa 2 
Turkey  27 Pakistan 2 
Iran  25 Sudan 2 
Germany 21 Tanzania 2 
Canada 20 Benin 2 
United Kingdom  19 Switzerland 1 
Italy 17 Greece 1 
Brazil  16 Singapore 1 
Australia  14 Qatar 1 
Netherlands  13 Czech Republic 1 
France 11 Hungary 1 
Japan 10 Poland 1 
Israel 9 Chile 1 
Thailand 8 Lithuania 1 
South Korea 8 Argentina 1 
Egypt  8 Cuba 1 
Nigeria  8 Kazakhstan 1 
China 8 Colombia 1 
Taiwan 6 Jordan 1 
Denmark 6 Gabon 1 
Belgium 5 Indonesia 1 
Mexico 5 Cambodia 1 
Vietnam 4 Madagascar 1 
Sweden 4 Senegal 1 
Hong Kong 4 Gambia 1 
Saudi Arabia 4 Guinea 1 
Uganda  4 Guinea-Bissau 1 
Austria 4 Mali 1 
Spain 3 Congo 1 
Croatia 3 TOTAL 508 
Lebanon 3 
Ghana 3 
Nepal 3 
Bangladesh 3 
Burkina Faso 3 
Afghanistan 3 
Mozambique 3 
Finland 2 
New Zealand 2 
Russia 2 
Tunisia 2 
Philippines 2 
  
 
 
 
 
 
  
2. ALL RCTS THAT REPORTED A SERIOUS ADVERSE EVENT (SAE) 
Ref Drug Control/ 
Comparator 
 
Disease Age N Country SAEs Comments 
18 Vancomycin 
 
Teicoplanin Cardiac surgery 
-post op MRSA 
prophylaxis 
0-28 
months 
11 vs 
11 
Japan 1 death 
Post-op Cr increase 2xVan 
 
44 IFN-Beta 
 
Azathioprine Multiple 
Sclerosis 
13-48 
years 
47 vs 
47 
?paed 
Iran 1xsevere depression GI Ses 
Flu-like Sx 
78 Deferiprone PO 
Desferrioxamine 
IV 
Deferiprone PO Thalassemia 
major 
5-24.5 
Years 
12 vs 
12 
Turkey 1 death arrhythmia-CHF 
1 agranulocytosis 
Neutropaenia - 3xDFO, 
2xDFP 
Aseptic meningitis 
Acute cerebellar syndrome 
 
Nausea 
Arthralgia grade 2 
 
109 IV methylpred 
 
Nebulised budesonide 
OR untreated control 
Meconium 
Aspiration 
Syndrome 
Neonate
s 
34 v 
32 v 
33 
India Death x2 ± pneumothorax, 
DIC (both control group) 
Hypotension req. inotropes: 
4 v 3 v ? (control) 
 
128 SP-Artesunate 
 
CQ vs  
SP vs SP-AS 
Malaria 6-59 
Months 
79 vs 
77 vs 
81 
Benin Convulsions 
Severe anaemia 
ARIs 
Pyomyositis 
 
161 Levetiracetam 
 
Placebo Idiopathic 
generalised 
epilepsy 
4 to 65 
years 
 
80 v 
84 
Eu,NA,Mex,
Aus/NZ 
Agression, depression, suicide 
attempt 
 
?paed SAE 
Hypotension 
206 
 
 
Mannitol 
 
Placebo Cerebral 
Malaria 
6-60 
months 
80 vs 
76 
Uganda 22 deaths + 1 lost to f/up 
10 vs 13 (not sig) 
 
No other AEs 
227 Fexofenadine 15mg OR 
30mg 
 
Placebo Allergic rhinitis 6 mo ± 2 
years 
85 v 
108 v 
199 
US RSV x 1 ± placebo group GI sx 
  
228 Levalbuterol 
 
Racemic albuterol Asthma 12 and 
above 
496 v 
250 
US SAEs 18v13 ±no details  
288 Triethyl citrate + ethyl 
linoleate lotion 
 
Vehicle Acne 16-45 
?paed 
20 vs 
20 
UK 1 depression  
(unrelated) 
?paed 
298 Venlafaxine ER 
 
Placebo Paed Social  
Anxiety 
Disorder 
8-18 
years 
148 
vs 
137 
US Suicidal ideation  
3 Ven vs 0 plc 
Multiple TEAEs 
Behavioural AEs 
317 Liposomal AmB 
+ Caspofungin 
Lipo AmB 
(hi-dose) 
Invasive 
Aspergillosis ± 
haem. 
Malignancies 
16-75 15 vs 
15 
France 3 deaths (unrelated) 
Renal disorder (related) 
 
 
410 
 
 
Recombinant Factor 
VIIa 
Bolus 
Continuous 
Vs control 
Haemophilia 
undergoing 
surgery 
10-67 
years 
12 vs 
12 vs 
12 
US Haemorrhage/ haematoma (Rx 
failure) 
Deep thrombophlebitis 
Multiple other AEs 
429 Methylphenidate 
(crossover placebo, 5, 
10, 15 mg ± 6 dosing 
orders) 
Placebo Bipolar disorder 
& ADHD 
5-17 yrs 20 US Hospitalisation for mood sx ± 
before any Rx 
Discont x2 ± 
elevated liver 
enzymes, urticaria 
& vomiting 
438 Azithromycin PO 4.5g 
OR 6.0g OR 7.5g 
 
3 doses Acne 16-37 
years 
36 v 
34 v 
34 
Croatia Ankle fracture Elevated AST 
GI Sx 
469 Botulinum-A Toxin 
Alone (intravesical) 
Botox+ 
anticholinergics 
Neuropathic 
bladder 
2-11 
years 
12 v 
11 
Saudi Arabia Acute pyelonephritis (f/up)  
489 Sibutramine 
 
Placebo 
(crossover) 
Secondary 
Obesity 
7-20 yrs 45 Sweden 2 depression ± plc 
3 tumour recurrence 
Type 2 DM - plc 
 
 
518 Dexamethasone 
 
Placebo Bacterial 
meningitis 
15-91 
yrs 
217 
vs 
238 
Vietnam 49 deaths (22 vs 27 not sig)  
GI bleeding (p=0.2) 
 
Herpes (p=0.69) 
?paed 
521 IV Valproate 
 
 
 
IV Diazepam Status 
epilepticus 
5-144 
months 
20 vs 
20 
India 7 deaths (4 vs 3) 
Resp depress 0 vs 12 
Hypotension 0 vs 10 
Breakthrough seiz 
8 vs 8 
  
557 
 
 
Ketoconazole Topical Placebo vehicle Seborrhoeic 
dermatitis 
12 and 
older 
1162 US 1% SAEs ± 13. Diverticulitis, 
CVA, CHF, CAD ± all rated 
unrelated 
 
?paed 
Local sx 
562 Ciclesonide inh 80 mic  
160 mic 
 
Fluticasone inh Persistent 
asthma 
12-75 
years 
278 
vs 
270 
vs 
259 
Multi EU  
Countries 
SAEs: 3 vs 4 vs 3 
Not mentioned 
 
574 Quinine rectal 
 
Quinine IV Cerebral 
Malaria 
6 mo ± 5 
years 
56 vs 
54 
Uganda Neuro sequelae 
1 vs 3 
Death 4 vs 5 
No PR bleeds 
No SEs known 
with quinine 
Vomiting 3 vs 10 
575 Nifurtimox-eflornithine 
 
Eflornithine Sleeping 
sickness 
Trypanosoma 
brucei 
gambiense 
15-70 
years 
51 vs 
52 
Congo Death 1 ±  
treatment failure* 
247 drug reactions* 
14 major drug reactions* 
Seizures 4 vs 1 
Arrhythmia 1 vs 1 
Neutropaenia/anaemia 
1 vs 6 
 
576 Valtropin (rhGH) 
 
Humatrope (rhGH) Growth 
Hormone 
Deficiency 
3-11 
years 
98 vs 
49 
Morocco 
Turkey 
S.Africa 
Russia 
Slovakia 
Serbia 
9 SAEs 7 vs 2 
1 gen. urticarial rash 
1 high Alk.phos+vit D def 
1 ALL*** 
 
593 Bupropion 
X 2 doses 
Placebo Smoking 
cessation 
14-17 
yrs 
103 
vs 
105 
vs 
104 
US Jimson weed poisoning 
Suicide attempt 
Pregnancy 
 
607 Amoxicillin PO 
 
Benzylpenicillin IV Comm. Acq. 
Pneumonia 
1.4-5.4 
yrs 
100 
vs 
103 
UK 3 Empyema IV vs 0 PO  
  
617 Early Fixed-dose Insulin 
Rx 
 
 
Std glycaemia 
monitoring 
VLBL neonates 
Hyperglycaemia 
Preterm 
neonates 
8 vs 8 UK 3 deaths  
626 Botulinum toxin A 
 
Different dosing 
regimen 
Cerebral palsy 2-8 yrs 42 Australia Epilepsy 
Shunt malfunction 
Fractures 
All unrelated 
657 Benazepril 
 
Placebo IgA 
nephropathy 
9-35 yrs 32 vs 
34 
EU 1 death ± car accident 
Pregnancy ± interrupted 
 
675 Ibuprofen PO 
 
Indomethacin PO Patent Ductus 
Arteriosus 
Preterms 18 vs 
18 
Iran Death 1 sepsis vs 1 NEC 
NEC 0 vs 3 p=.03 
 
689 Levofloxacin 
 
Amoxiclav/ceftriaxone 
(0.5 - <5) 
Clarith/ceft+clarith or 
erythro) 
>5 
Community-
acquired 
pneumonia 
6 month 
± 16 
years 
529 
vs 
180 
Argentina 
Brazil 
Chile 
Costa Rica 
Mexico 
Panama 
US 
33 vs 8 (6% vs 4%) 
Respiratory 13 vs 4 
1 Hepatomegaly (possible) 
Probable/very likely: 
Hepatitis 
Rash 
Aggravated pneumo. 
 
2 deaths*** 
1 bronchoscopy procedure 
1 severe bronchospasm 
 
693 Infliximab 
 
Placebo Juvenile RA 4-17 yrs 60 NA,SA,Eu 2 deaths 
Serious infections + inf. 
reactions 
+ SAEs higher in Ix 3mg/kg 
group 
6mg/kg group 
better 
710 IV Valproate 
 
IV Phenytoin Status 
epilepticus 
2-17 (22 
pts ) 
22 India 8 deaths ?paed 
Diazepam ± hypotension, resp. 
depression 
 
Valproate-elevated 
liver enzymes 
 
716 Ciclesonide 
 
 
 
Fluticasone Asthma 12-74 233 
vs 
239 
Eu, S.Africa SAEs not described ± 
unrelated 
 
  
720 Caffeine citrate 
 
Placebo Apnoea of 
prematurity 
Preterm 
neonates 
1006 
vs 
1000 
US Death + 
Neurodevelopmental disability 
Caffeine sig. better 
than plc ± death & 
neurodevelopment
al disability 
723 Dexa. IV vs 
Dexa+Glycerol PO vs 
Glycerol PO 
 
Vs Placebo IV + PO 
4 arms 
Double dummy for all 
Bacterial 
meningitis 
2-184 
months 
166 
vs 
156 
vs 
166 
vs 
163 
Latin 
America 
Dominica 
Ecuador 
Argentina 
Venezuela 
Brazil 
Death 
23v20v17v26 p=.3 
Neuro seq 
10v8v7v19 p=.02* 
Hearing loss 
10v9v12v12 
PR blood 
6v5v1v2 p=.03* 
 
 
754 Fluoxetine 
 
Placebo Adolescent 
depression 
12-17 
yrs 
439 US Suicidal ideation! TADS study ± 
multiple papers 
Suicidal ideation 
prominent 
 
766 Olanzapine 
 
Placebo Bipolar Mania 13-17 
yrs 
107 
vs 54 
(plc) 
US Exacerbation of bipolar 
Neutropaenia? 
Suicidal ideation ± TEAE  
?blood dyscrasia ± 
not discussed 
771 Idebenone 
X 3 doses 
Placebo )ULHGUHLFK¶V
Ataxia 
9-17 yrs 48 US Chest pain 
GI symptoms 
Neutropaenia- related 
 
784 Ceftriaxone + amikacin 
 
 
 
 
 
 
 
 
 
 
Imipenem Febrile 
neutropaenia 
18 and 
below 
66 vs 
63 
Egypt 4 Deaths (2 vs 2) 
  
Reversible 
cholestasis ±C+A, 
p=0.02 
GI symptoms ±
Imipenem, p=0.05 
  
798 Carvedilol 
Low & high dose 
 
Placebo 
 
Heart failure Below 
18 
161 US 11 deaths (5 vs 3 vs 3  -not 
sig) 
Worsening heart failure 
 
Favouring 
carvedilol but not 
sig. 
Underpowered?! 
799 Continuous SC Insulin 
Inj. 
(Aspart/Lispro Insulin ± 
quick acting) 
Multiple Daily Inj.  
(Glargine OD + 
human Insulin) 
Type 1 DM 9-18 
years 
18 vs 
18 
Italy Severe hypo 
(similar in both groups) 
No description of 
AEs 
815 Salmeterol/fluticatisone 
 
 
 
3 doses Persistent 
asthma 
12 -76 
yrs 
325 Canada Multiple SAEs 
None related 
Candidiasis 
Hoarseness 
Throat irritation 
823 Growth Hormone 
 
No Treatment  Turner 
Syndrome 
9 mo ± 4 
years 
45 vs 
44 
US 4 vs 4 
Gastro 
Bac. Pneumonia 
Bleeding post-tonsillectomy 
Hypoxaemia post 
adenoidectomy 
All Unrelated 
828 Atomoxetine 
 
Placebo ADHD + Major 
depression 
12-18 
years 
72 vs 
70 
US 1 worsening depression ± 
placebo group 
 
Discont ± Atx grp. 
Mod.nausea 
Aggression ± 2 in 
placebo 
No mania 
Mild Aes more in 
Atx grp 
873 Ibuprofen high-dose  
 
Placebo Cystic Fibrosis 6-18 yrs 142 Canada GI bleed x 1 ± significant SMC 
recommended H2-
antagonists post 
event 
 
894 Amifostine 
 
No treatment Chemo for 
Osteosarcoma 
(toxicity 
protection) 
7-15 
years 
15 vs 
13 
Mexico Death x 1 ± relapse 
Renal tox ± 20%v30% 
Audio tox-100%v80% 
Cardiotox- 
0v2 
Grade 3 vomiting 
93%v7% p=0.000 
  
903 Miglustat 
 
No Rx Niemann-Pick 
C disease 
4-11 
yrs, 
12 
above 
12, 
29 
US,UK Severe confusion 
Salivary hypersecretion 
Severe dehydration 
RSV infection 
depression 
None related 
 
 
921 Budesonide + 
Formoterol 
 
 
 
 
 
Budesonide & 
Formoterol alone, 
placebo 
Asthma 12 -78 
yrs 
480 US Lobar pneumonia 
Facial fracture 
Intestinal obstruction 
None related 
Mild arrhythmias 
Upper airway Sx 
No cardiac SAEs 
929 Budesonide inh 
suspension 
4 doses 
 
Budesonide dry-
powder inh 
Asthma 12-65 
yrs 
57 
paed  
US 8 SAEs 
Asthma x 2, others unrelated 
Mild AEs ± upper 
resp. tract mainly 
931 Ertapenem 
 
Ticarcillin/clavulanate Intra-
abdo/pelvic 
Infections 
2-17 yrs 84 vs 
28 
US,Mex, 
Brazil 
14 SAEs 11 vs 3 
Abdo abscess (Er) 
Diarrhoea ±
C.difficile negative 
(Er) 
Rated as severe 
ADR 
Rash (T/c) 
Rated ADRs 10 
(Er) vs 6 (T/c) 
 
943 Recombinant factor VIII 
 
 
 
 
 
 
 
Regular vs episodic 
infusions 
Severe 
haemophilia A 
6-30 
months 
32 vs 
33 
US Life-threatening bleeding  
3 (episodic) vs 0 
High titer inhibitor  
0 vs 2 
 
  
946 Doxo,Bleo,Vinb,Dacarb
azine 
+ RT 
 
 
 
No Rx 
RT only 
Hodgkin¶V
Lymphoma 
16-
75yrs 
recruited 
? paed 
16 
below 
20 
?paed 
Eu 51 deaths 
Multiple toxicity 
Onco 
957 Amphotericin B 
 
 
1mg/kg OR 
0.75mg/kg alt day OR 
1mg/kg OR 
0.75mg/kg daily  
Indian visceral 
leishmaniasis 
2-65 yrs 245 v 
244 v 
500 v 
496 
India 14 deaths  
13 discont d/t toxicity 
- vomiting&diarrhoea 
- hepatotoxicity 
- nephrotoxicity 
- severe thrombocytopaenia 
- recurrent hypothermia 
Increased fever and 
rigours 
965 Levocetirizine 
 
Placebo Atopic children 12-24 
months 
255 v 
255 
10 Euro 
countries, 
Aus, 
S.Africa 
SAEs 12.2v14.5% 
ALL x1 ± judged unlikely 
**Febrile convulsion 4v0-
judged unlikely 
Bronchopneumonia 4v1 
Cough 4v2 
Pneumonia 2v0 
(see table of SAEs) 
Discont 2v1.2%  
- unrelated to med 
976 Denufosol tetrasodium 
20mg OR 40mg OR 
60mg 
Placebo Cystic fibrosis 8-45yrs 
(62<18 
years) 
23 v 
22 v 
23 v 
21 
US Hodgkins lymphoma 
Pulm oedema ± both 
considered unrelated 
5 disconts ± 0v2v1v2  
Haemoptysis, pulm fx test 
decrease, lung infiltration, 
cough 
Cough 
Lung fx test 
decrease-  
resolving later 
OxyHb sat 
decrease- 
Not clinically sig 
977 Inactivated Polio vax 
 
 
 
 
 
 
Both OR 
Oral polio vax 
Prophylaxis of 
polio 
6-11 
week 
infants 
166 v 
168 v 
166 
Guatemala 1 death ± PDA 
26 SAEs ± hosp. d/t diarrhoea, 
resp diseases 
All rated unrelated 
 
Fever 
Mild sx 
Local reactions 
  
1001 Invasive chemo with 
high-dose cytarabine & 
methotrexate 
(ONCO) 
Std post-remission rx ALL  12 
months 
or 
younger 
infants 
95 v 
96 
22 countries 25 deaths and multiple toxic 
events: 
Infections 
Mucocitis 
Renal 
Liver 
Neuro  
Non-sig diff in 
EFS 
1007 Albuterol neb 
1.25mg OR 0.62mg 
Placebo Moderately 
severe asthma 
6-12 yrs 115 v 
117 v 
117 
US 6 SAES- undescribed, rated 
unrelated 
 
Beta-adrenergic sx 
1013 Dexamethasone  
 
Placebo Mod-severe 
bronchiolitis 
2-12 
months 
305 v 
295 
US Pneumonia 1v2-empyema Vomiting 
5.5v4.7% 
1017 Salmeterol/Fluticasone 
 
Fluticasone Moderate 
asthma 
12-80 
yrs 
182 v 
180 
9 countries 3 SAEs- undescribed, rated 
unrelated 
1 discont- headache 
Upper resp. sx 
Oral candidiasis 
1022 Ciclesonide intranasal 
 
Placebo Perennial 
allergic rhinitis 
12-73 
yrs 
441 v 
222 
US SAEs 16v6 all rated unrelated Epistaxis 
Pharyngolaryngeal 
pain 
Sinusitis higher in 
ciclesonide 
1037 Topiramate 400mg/kg 
maintenance dose 
(titrated) 
Topiramate 50mg/kg 
Maintenance dose 
(titrated) 
Epilepsy 6-15 yrs 77 v 
74 
US, Canada, 
Europe, 
S.America 
Testicular torsion, appendicitis 
(rated unrelated) 
7 disconts in higher dose-
neurobehavioural AEs 
Dose related: 
Wt loss, 
paraesthesia, mood 
problems, non-
specific cognitive 
dysfunction 
1123 Ciclesonide 
 
 
 
 
 
 
 
 
Budesonide Asthma 6-11 yrs 416v 
205 
8 countries 
6 Euro, Aus, 
S.Africa 
SAEs 4v4 ±all rated unrelated 
Disconts 2.9v1.0% - asthma 
exacerbations 
URT sx 
Oral candidiasis 
dysphonia 
  
1125 Recomb. Growth 
hormone 
 
No treatment Juvenile 
idiopathic 
arthritis on 
steroid rx 
18mo-
9yrs 
(girls), 
11yrs 
(boys) 
15v15 France Deaths x2- post-op for spinal 
cord compression 
Discont x4 incl. deaths ± 
BMTx2 
Fasting 
hyperinsulinaemia 
47v7%,p=0.03 
Elevated HbA1C 
7v1,p=0.03 
Asymp DM 1v0 ± 
resolved 
?steroid-related 
1165 Olanzapine  
 
 
 
 
 
 
 
Quetiapine AND 
risperidone 
Early psychosis 16-40 
yrs 
133 v 
134 v 
133 
USA SAEs 4v7v7 
Olanzapine-2 suicide attempts 
+ 1 alleged homicide 
Quetiapine-2 suicides + 1 
suicidal ideation 
Risperidone ± 1 suicide 
attempt 
Extrapyramidal sx 
???Paed 
1169 Seq high-dose chemo  
(ONCO) 
Single. high-dose 
chemo 
 
Relapse/ 
refractory germ 
cell tumours 
16-59 
yrs 
108v 
103 
Germany ***Terminated ± excess 
toxicity in arm B 
Mortality 4v16%,p<.01 
Multiple rx-related toxicities 
TERMINATED 
?paed 
1228 Paromomycin 
 
Amphotericin B Visceral 
leishmaniasis 
5-55 yrs 
 
502 v 
165 
Paed 
188v6
4 
India 4 deaths ± before rx, alcoholic 
(rated poss. related), 
septicaemia (unrelated), gastro 
(prob. related to 
amphotericin). 
2 more SAEs: 
Elevated LFTs 
Bacterial pneumonia 
???ages 
 
Inj-site pain, 
ototoxicity, 
elevated LFTs in 
paro. 
Pyrexia,rigors, 
Vomiting, 
nephrotoxicity in 
amphotericin 
 
 
1238 Intensified maintenance 
chemo. 
(ONCO) 
 
No treatment Post-remission 
Acute 
Promyelocytic 
Leukaemia 
 
15-
70yrs 
89 v 
86 
Japan ***Relapses 28v10% 
Deaths 15v3% 
?ages 
***Treatment 
more toxic 
  
1253 IV Terbutaline 
 
Placebo (NSaline) Status 
asthmaticus 
2-17 yrs 25 v 
21 
US Cardiac arrhythmia x1 
Hypotension 8v9 
 
Hyperglycaemiax1 
Chest pain x1 
1262 Anidulafungin 
 
Fluconazole Invasive 
candidiasis 
16-91 
yrs 
127 v 
118 
US SAEs 2v2 
Anidula-AF,seizures 
Fluconazole-DVT, el. LFTs 
Disconts 15v27 
 
1286 ChemoRT with 
carboplatin 
(ONCO) 
ChemoRT with 
cisplatin 
Locoregionally 
advanced Ca 
nasopharyngeal 
16-70 
yrs 
106 v 
101 
Thailand Deaths 18.1v15.8% 
Toxic death 0v1 (sepsis) 
?paed 
 
1327 Recomb. Growth 
hormone 0.07mg/kg OR 
0.039mg/kg 
 
Placebo  CF 9-20 yrs 20 v 
22 v 
21 
Germany SAEs equal 4v5v4 
-resp infection req antibiotics 
(see table 3) 
 
 
 
Pulm 
exacerbations 
7v6v4 
1330 Prednisolone PO daily 
 
IV methypred monthly Infantile 
haemangioma 
1-4 
months 
10 v 
10 
Canada Growth retardation@1 yr in 
PO group, wt&ht lower 
(p=0.003&0.001) 
Resp distress 1v1 
HPTx1 in PO grp,req rx 
 
 
1351 Tobramycin neb 
 
Placebo CF and 
P.aeruginosa 
6-45 yrs 161v 
86 
Hungary, 
Poland, 
Russia 
SAEs 20v27 
Worsening of CF + pulm 
infections (table IV) 
Deaths 1(cardiomyopathy) v 
2(resp failure) 
 
 
Tobra: 
Bronchospasmx1 
Voice alterationx1 
 
1352 Tobramycin neb. 
 
 
 
 
 
Placebo CF and 
P.aeruginosa 
6-30 yrs 29v30 France, 
Italy, 
Ukraine, 
Moldova 
SAE 1v3 ±undescribed 
1 death ± placebo 
 
Discontx3 ± CF 
exacerbation 
 
  
1369 IV Paricalcitol 
 
Placebo Secondary 
hyperparathyroi
dism on 
haemodialysis 
5-19 yrs 15 v 
14 
US 10 subjects with SAEs 
All rated unrelated 
 
1389 Daunorubicin 1-hr 
infusion 
(ONCO) 
24-hr infusion Chemo for 
newly 
diagnosed ALL 
1-18 
years 
43 v 
58 
Germany Death in remission?2nd malig? 
 
³QRVSHFLILF
analysis of 
WR[LFLW\´ 
1396 Ibuprofen PO 
 
Indomethacin IV PDA <35 
weeks 
gest 
9v12 Egypt Pulm haemorrhage 0v2  
1401 Inhaled nitric oxide 
 
Placebo Preterms with 
severe resp 
failure 
<34 
weeks 
gest 
14 v 
15 
US Gd3/4  IVH 0v2  
Death 5v4 
BPD 3v5 
 
****STOPPED 
BY DSMB 
1405 IFN based chemo 
(ONCO) 
 
Primary 
haematopoietic stem 
cell transplantation 
(HSCT) 
Chronic 
Myeloid 
leukaemia 
11-59 
yrs 
219 v 
135 
Germany Multiple deaths  ?drug toxicity not 
reported 
µ«RUDGYHUVHGUXJ
effects). No 
differences were 
found between the 
JURXSV¶ 
1409 Amodiaquine+SP OR 
Amo+artesunate 
 
Artemether-
lumefantrine 
Uncomplicated 
falciparum 
malaria 
1-10 yrs 111 v 
113 v 
105 
Uganda 45 SAEs 
9 seizures possibly related 
El. LFTs ± all rated unrelated 
 
Anorexia+ 
weakness in 
Amo+SP  
1447 Fluticasone 100mic bd 
OR Montelukast 5-10mg 
nocte 
 
 
 
 
 
 
 
OR Fluticasone + 
salmeterol nocte 
Mild persistent 
asthma 
6 yrs 
and 
older 
169 v 
166 v 
165 
USA SAEs 6v4v4 
Def. Related : 1 burning in 
mouth and tightening of throat 
Poss related: 2 asthma 
Unrelated: 11 
Unclear: 1 depression 
Monte: less URTI 
and viral resp. 
Fluti: more N+V, 
fever 
  
1470 Reformulation of 
Recomb. Factor IX  
 
Original form Mod.severe to 
severe 
Haemophilia B 
12-61 
yrs 
34 
(cross
over) 
US 3 SAEs: cellulitis, pyogenic 
arthritis ± both rated unrelated, 
Haematuria-rated unrelated  
Headache, nausea, 
dizziness, 
unpleasant taste-at 
least possibly 
related 
1493 Different chemo regimes 
(ONCO) 
 
As noted B-cell non-
Hodgkin 
lymphoma 
2.5-20.5 
yrs 
657 
to 4 
arms 
France, 
Belgium, 
Netherlands, 
US, Can, 
Aus, UK 
Multiple deaths 
Lower toxicity with half dose 
of cyclophosphamide 
 
1494 8-course CHOP regimen 
(ONCO) 
 
6-course intensified 
CHOP regimen  
Agressive non-
Hodgkin 
lymphoma 
16-65 
yrs 
239 v 
238 
Netherlands  
Belgium 
Treatment-related mortality 
4v6 
Cardiotoxic deaths 5v2 
Second malign. deaths 2v3 + 7 
other second malig 
 
1496 Reduced intensity chemo 
(ONCO) 
 
Standard intensity 
FAB chemo 
High-risk CNS 
non-Hodgkin B 
lymphoma and 
B acute 
lymphoblastic 
leukaemia 
6 mo ± 
21 yrs 
52+ 
44 v 
51+ 
43 
France  
USA 
UK 
11 non-disease progression 
deaths 
Haemorrhage 3 
Pneumonia 2 
Thrombosis 1 
Infection 2 
Prior to rx 1 
Post intensification of stem 
cell transplant 2 
 
1497 Heat shock protein 
peptide (DiaPep277) 
Sc inj 
 
Mannitol as placebo Type I DM 7-14 
years 
15 v 
15 
Israel Acute gastro req. adm 2v0 ± 
considered unrelated 
Optic neuritis ± 2yrs post 
study 
 
1498 Heat shock protein 
peptide (DiaPep277) 
 
Mannitol placebo Type 1 DM 16-58 
yrs 
17 v 
18 
Israel SAEs 2v2 all rated unrelated Local sx 
1520 Beclomethasone PO 
(related to ONCO) 
 
Placebo Prednisone-
sparing in 
GI graft-vs-host 
disease 
6-70 yrs 62 v 
67 
US Deaths 29%v42% p=0.04 
SAEs, ADRs, disconts. all 
higher in placebo 
 
  
1541 IV paracetamol 
 
Proparacetamol Acute fever d/t 
infection 
1 mo ± 
12 years 
33 v 
32 
France 1 overdose/admin error- 2yo 
given 2g instead of 420mg, no 
toxicity 
TEAE 5v13 
Vomiting 1v2 
Rigor 0v1 
Pain 1v0 
Inc lfts 0v1 
Rash 1v0 
1543 Trimethoprim/ 
Sulfamethoxazole 
Placebo Acute otitis 
media 
12-143 
months 
50v51 Netherlands Mastoiditis 1v1 req.  
mastoidectomy & IV abs 
Rash ± discont. Rx + req 
cetirizine 
Vomiting+ 
Diarrhoea 9v2% 
1544 Botulinum toxin a inj 
 
No rx Hemiplegic 
cerebral palsy 
3-16 yrs 21v22 Australia SAEs 1(seizure)v5 (2 seizures 
in 1 child+3 hosp. adm) 
Anxiety 1 
Depression 1 
 
Vomiting and 
cough 
Excessive 
weakness 
Headache 
Flulike sx 
 
1633 Fosmidomycin-
Clindamycin 
 
 
 
Sulfadoxine-
pyrimethamine 
Falciparum 
malaria 
3-14 yrs 54 v 
51 
Gabon 1 SAE ± convulsion in FC 
group 
All AEs 64v100 
p=0.05 
Vomiting 
1v13,p=0.002 
1648 Azithromycin eye drops 
for 2/7 OR 3/7 
 
Azith single oral dose Trachoma 1-10 yrs 224 v 
225 v 
221 
Guinea-
Conakry, 
Pakistan 
1 death ± head injury ± 
unrelated 
Ocular AEs 
10.8v8.9v13.1 
1661 Liposomal Amphotericin 
B high-loading dose 
10mg/kg 
(ONCO) 
Std dosing 
3mg/kg 
Invasive mold 
in immuno 
compromised 
patients 
2-78yrs 107 v 
94 
10 countries Deaths, survival 88%v93% 
p>.05 
Nephrotoxicity 31v14%,p<.01 
hypoK 30v16%,p=.015 
Multiple disconts 
-elevated creat 
-abnormal LFTs 
-hypoK 
1662 Rupatadine 10mg OR 
20mg 
 
 
 
 
Placebo Chronic 
idiopathic 
urticaria 
12-65 
yrs 
113 v 
112 v 
109 
Spain, 
Poland, 
Romania, 
Argentina, 
Germany 
Deterioration of arterial hpt 
and metrorrhagia, rated 
unrelated 
 
Headache and 
somnolence both 
similar to placebo 
  
1733 Sibutramine 
 
Placebo Obesity 12-17 
yrs 
12 v 
12 
Netherlands 1 clinical depression Abdo complaints 
sig higher in 
sibutramine 
1772 Glimepiride 
 
Metformin Type 2 DM 8-17 yrs 143 v 
142 
USA SAE 1(DKA)v1(convulsion) 
Severe hypo 1v1 
 
Hyperglycaemia 
Upper abdo pain 
Abdo pain 
Diarrhoea 
Nausea 
Headache 
1793 Lamotrigine OR 
Topiramate 
(SANAD trial) 
Valproate Gen and 
unclassifiable 
epilepsy 
5 years 
and 
above 
239 v 
239 v 
238 
UK Multiple  stated SAEs eg MI, 
status epilepticus etc. No 
further details 
 
1794 Carbamazepine OR 
Gabapentin OR 
Lamotrigine 
(SANAD trial) 
Oxcarbazepine OR 
Topiramate 
Partial epilepsy 5 yrs 
above 
378 v 
377 v 
378 v 
210 v 
378 
UK Multiple stated SAEs 
No specific details 
 
1798 Infliximab 
Every 8 weeks 
Infliximab every 12 
weeks 
Crohns disease 6-17 yrs 52  v 
51 
N. America, 
W. Europe 
and Israel 
SAE 8v7 
Serious infection 3v4 
Pneumonia 2v1 
Intes stenosis 1v0 
Inf. Reactions 9v9 
Discount 2v4 
El. AST 0v3 
 
1838 Antibiotic 
Clarithromycin + 
rifabutin 
 
Surgical excision Nontuberculous 
mycobacterial 
cervicofacial 
lymphadenitis 
0-15 
years 
50 v 
50 
Netherlands Permanent facial nerve 
dysfunction x1 ± surgery grp 
µVHYHUH¶$(V± jaundice 
Gen. rash 
74%v20% AEs 
Multiple AEs-no 
disconts. 
1865 Drotrecogin alfa 
 
 
 
 
 
 
Placebo Severe sepsis 38weeks 
to 17 
years 
237 v 
240 
18 countries CNS bleeding 11v5, p=.13 
Mortality 41v41 
Drug SAEs >placebo! 
SAEs in <4yos 
***paed vs adult 
PROWESS v 
RESOLVE 
  
1897 ABX-CBL hybridoma-
gen. murine IgM 
monoclocal antibody 
(ONCO-type) 
Antithymocyte 
globulin 
Steroid-resistant 
acute graft-vs-
host disease 
2-65 yrs 48 v 
47 
US Deaths + multiple SAEs 
similar between groups 
Pneumonia 15v30, p=.002 
 
1908 Artemether-lumefantrine 
 
Dihydroartemisin-
piperaquine 
Drug resistant 
falciparum and 
vivax malaria 
1-60 
years 
387 v 
387 
Indonesia Sudden death -32yo,NAD in 
blood, no further details 
Rash 3yo-rx with 
antihistamines 
1909 Recombinant human 
epidermal growth factor 
1-48 
 
Placebo Severe NEC Below 
12 
weeks 
4 v 4  Hong Kong Deaths 1v1 ± unrelated 
Intraab abscess 2v1 
 
**CANCELLED 
d/t admin reasons, 
Targeted 20 
1921 IV Oestradiol + 
Progesterone 
 
Placebo Broncho 
pulmonary 
dysplasia  
Extreme
ly 
preterm 
infants 
<29 wks 
gest 
43 v 
42 
Germany Multiple SAEs related to 
disease (table 2) 
Cholestasis 3v6 
Cirrhosis 0v1 
Thrombosis 4v4 
 
Hypertriglyceridae
mia 16v7 p=.05 
1935 Growth Hormone 
 
 
No Rx Prader-Willi 
syndrome 
4-37 
months 
25 US Scoliosis progression ± GH 
treated 3yo 
 
1956 Etoposide-Ifosfamide 
+ HD MTX 
(ONCO) 
Doxorubicin + 
HD MTX 
Osteosarcoma 3.1-19.5 
yrs 
120 v 
119 
France Severe neutropaenia 74v59% 
p=.02 
Non-haemato toxicity 63v79% 
p=.005 (hepatotoxicity) 
Neurotoxicity x2 
Nephrotoxicity x6 
 
Second malig. 2v4 
Deaths d/t disease 
 
 
1966 Dapsone gel  
 
 
 
 
Vehicle Acne 12 and 
older 
1506 
v 
1504 
US 9 hospitalisations ± all rated 
unrelated 
2 discont in 
Dapsone group ± 
skin sx 
  
1988 GM-CSF 
(ONCO) 
No Rx Priming for 
Induction 
regime for ALL 
15-50 
yrs 
124 v 
135 
France Multiple chemo related 
toxicities and deaths 
 
1996 Clindamycin+Benzoyl 
peroxide LA 
 
Erythromycin+Zn 
Acetate LA 
Acne 12-39 
yrs 
73 v 
75 
Poland EtOH intoxication 
Discont. 2 skin reactions 
 
2001 Idursulfase 
 
Placebo Mucopolysacch
aridosis II 
(Hunter 
Syndrome) 
6-20 yrs 12 US Life-threatening resp. distress 
in 20yo ± x3 episodes ±
anaphylaxis? 
Infusion reactions 
in high-dose 
2031 IV methylpred 
 
Placebo Kawasaki 
Disease 
6 mo 
above 
101 v 
98 
US, Canada SAE 2v2 
Shock& resp. 
failure/sensorineural hearing 
loss/coronary art 
thrombus/anaphylaxis to IVIG 
Hypotension 5v1,p=.21 
*hypotension 
?severity 
2066 Artemether-lumefantrine 
 
Amodiaquine + Sulfa-
pyrimethamine 
Uncomplicated 
falciparum 
malaria 
6 mo 
above 
261 v 
260 
Burkina 
Faso 
2-anaemia hb<50 g/l pruritus 
2076 Mometasone inh 400mic 
OR 800 mic 
 
Placebo Severe 
persistent 
asthma 
13-83 
yrs 
42 v 
43 v 
38 
US 2v4v2 
Pneumonia, adr insuff, intest 
perf, diverticulitis, ca pros, 
atrial fib, cad ± all rated 
unrelated 
1 death ± pneumonia 
?paed 
Pred withdrawal sx 
2078 Dexrazoxane 
 
No Dexrazoxane Prevention of 
cardio-
pulmonary 
toxicity during 
chemo of paed 
Hodgkins 
21 yrs 
and 
younger 
239 v 
239 
US Excess risk of second malig. 
Neoplasm 3.43%v0.85% 
p=.06 
 
2119 Montelukast 
 
 
 
Placebo Intermittent 
Asthma 
2-14 yrs 107 v 
113 
Australia SAEs 24 v 21 ± all rated 
unrelated 
 
  
2130 Venlafaxine 
 
Placebo Generalised 
Anxiety 
Disorder 
6-17 yrs 157 v 
163 
US Suicidal ideation-10yo in ven 
group* 
Withdrawal syndrome with 
agitation and confusion ± 
10yo ven group* 
Anorexia 13%v3% 
Somnolence adol. 
11%v0% 
 
2138 Ofloxacin 
 
Ceftriaxone Multidrug-
Resistant 
Typhoid fever 
Up to 12 
yrs 
93  India Hepatitis 
Intestinal perf. 
Pleural effusion 
Intestinal perforationx1 
Disease-related 
2175 Dihydroartemisin supp + 
Sulfadoxine-
pyrimethamine PO 
IM artemeter + 
Sulfadoxine-
pyrimethamine PO 
Moderately 
severe malaria 
6 mo ± 
10 yrs 
37 v 
35 
Nigeria Cerebral malariax1 Perianal redness 
Mild sx 
2178 Posaconazole 
 
Fluconazole/Itraconaz
ole OR Fluconazole 
OR Itraconazole 
Prophylaxis of 
fungal infection 
in neutropaenic 
patients 
13-82 
yrs 
304 v 
298 v 
240 v 
58 
Worldwide Death 49v67 (p=.048) 
SAEs 19v6 p=.02 
QT prolongation 12v9 
Atrial fib, decreased EF, 
torsades - posaconazole 
?paed 
*MORE SAEs in 
Posa* 
2179 Posaconazole 
 
Fluconazole Prophylaxis of 
fungal infection 
in graft-v-host 
disease 
13-72 
yrs 
301 v 
299 
Worldwide 40 v 29 SAEs 
Deaths 156 v 167 
1 death rated poss related ±
ITP 
Increased liver enz+GGT 
11v4* 
Hepatocellular dmg 4v0* 
 
?paed 
*Hepatotoxicity* 
2180 High Dose Methotrexate 
Intrathecal 
(ONCO) 
Low dose 
Methotrexate 
intrathecal 
Chemotherapy 
for acute 
lymphoblastic 
leukaemia 
1.5-15 
yrs 
316+
77 v 
290 
81 
France Neurotoxicity 3+15 v 0+17 
Seizures 
Neuropathy 
Encephalopathy 
 
2181 Omalizumab 
 
 
 
 
 
Placebo Allergic asthma 
with risk of 
helminth 
infection 
12-30 
yrs 
68 v 
69 
Brazil SAE 1 v 2 ± all rated unrelated 
(2xabortion,severe asthma) 
 
  
2189 G-CSF 
(ONCO) 
No G-CSF Infection 
prophylaxis 
after induction 
Rx 
0-18 156 v 
161 
Germany, 
Austria 
Infectious mortality 4 v 9 
Sepsis 9 v 2  
Febrile neutropaenia 
(all non-sig) 
No sig diff in 
Diarrhoea 
Nausea 
Vomiting 
Hepatic and CVS 
2192 Fenofibrate 
 
Placebo Burn injury 4-16 yrs 21 US Death x1-sepsis (Fen grp)  
2211 Metoprolol 
0.2mg/kg OR 1.0mg/kg 
OR 2.0mg/kg 
Placebo Hypertension 6-16 yrs 45 v 
23 v 
49 v 
23 
US SAE x2-pneumonia  
-menometrorrhagia 
Mild sx 
2217 Sitaxsentan 50mg 
 
Sitaxsentan 100mg Pulm arterial 
hpt 
12-75 
yrs 
Safet
y: 
4v9 
Effica
cy: 
20v15 
US, Canada, 
Australia 
1 death-disease deterioration 
No SAE related to sitaxsentan 
 
2222 Isoniazid 
 
 
Placebo Prophylaxis of 
TB in HIV 
8 weeks 
above 
132 v 
131 
South Africa Deaths 8%v16% p=0.015 
-multiple infectious 
causes+unknown 
Gd 3/4  toxicity 5v8 
± increased LFTs 
-11 haem events  
 
No disconts 
2233 Chemo regimen 
(ONCO) 
 
Chemo regimen Osteosarcoma 4-41 yrs 250 v 
254 
Multi 
country 
12 treatment related deaths  
2237 Insulin detemir 
 
NPH insulin Type 1 DM 6-17 yrs 232v 
115 
16 countries 
in Europe & 
Israel 
DKA 1.7%v1.7% URTI, headache, 
pharyngitis, gastro, 
flu-like 
Inj site reactions 
2245 Vincristine pulses + 
dexamethasone 
(ONCO) 
 
Untreated controls ALL 
continuation rx 
Younger 
than 18 
1325 
v 
1293 
10 countries Mortalities 10v5 
and second malignancies 5v9 
 
 
  
2315 Erythromycin 
 
Placebo Feeding 
intolerance in 
preterm 
neonates 
Preterms 30 v 
30 
Egypt Sepsis, Cholestatic jaundice, 
NEC, Mortality all similar 
with placebo 
 
2328 Magnesium sulphate 
 
Placebo Neuroprotection 
after traumatic 
brain injury  
14 
above 
250 v 
249 
US Mortality high conc 2x 
mortality vs placebo 
Other major medical 
complications comparable 
Slight excess of pulm. 
Oedema and resp failure in 
lower Mg group 
?paed 
2332 Allupurinol 
 
Placebo Cerebral injury 
following birth 
asphyxia 
Neonate
s 
30 v 
30 
Turkey 6 deaths 
20 severe impairment or 
microcephaly 
Severe adverse outcome 
39%v54%, p<0.05 
 
9992 Azithromycin Placebo Prevention of 
BPD 
ELBW 
<1000g 
preterm 
neonates 
19v16 US Death 4v5 
 
No SEs attrib to 
drug 
 
88851 Anti-D immunoglobulin 
 
Placebo Thrombo 
cytopaenic 
dengue  
27 
children 
 
25v22 
 
Philippines 2 deaths ± 1 child ±  
rated dengue related 
 
 
99912 Chemo regimens 
(ONCO) 
Other chemo regimens  Early-stage 
Hodgkins 
15-70 
yrs 
542 
and 
996 
pts 
8 Euro 
countries 
Second malignancy 55 pts 
Cardiotoxicity 
?paed 
99924 Fluconazole 6mg AND 
3mg 
 
Placebo Prophylaxis of 
fungal infection 
in VLBW inf 
Preterm 
neonates 
225 v 
111 
Italy Deaths 8%v8.7%v9.4% p=1 
Sepsis 
NEC 
Retinopathy 
Elevated LFTs ±no 
Rx 
99929 Fluconazole 
 
 
 
Placebo Prophylaxis of 
fungal infection 
in VLBW 
Preterm 
neonates 
60 v 
60 
India Deaths 17v17 
Fungal inf 1v3 
No other AEs 
mentioned 
  
99934 
 
 
 
       
99935 Ciclesonide inh 
 
Budesonide inh Persistent 
asthma 
12-75 
yrs 
198 v 
201 
Germany 3 SAEs ±all rated unrelated Oral candidiasisx1 
4x0 Aes 
Dyspnoea, voice 
alteration, cough, 
headache 
99938 Propanolol 
 
No treatment Severely burned 
patients 
Below 
18 yrs 
102 v 
143 
US Death 5%v6% 
Multi organ failure 6%v9% 
Sepsis 7%v10% 
All non-sig 
?ADRs not looked 
for 
888147 Gatifloxacin 
 
 
Cefixime Uncomplicated 
Enteric fever 
2-65 yrs 203 v 
187 
Nepal Death 1 -?disease related 
Rash 1 req rx 
Excessive vomiting x2 in gati 
group  
N&vomiting ± 23 
2 req rx 
888217 Steroid for 3 days + 
Tacrolimus, 
mycophenolate, 
basiliximab induction 
 
Steroid maintenance  Immuno 
Suppression for 
live-donor renal 
transplant  
5-60 
years 
50v50 Egypt Avascular bone necrosis x 1 Experimental< 
Control  
DM,p=.037 
Bone/joint pain, 
p=.04 
Acne, p=.001 
Infections p=.02 
Admissions p=.02 
888256 Strain-spec serogrp B 
meningo vax 
(2 cohorts) 
 
 
 
 
 
 
 
 
Norwegian parent vax 
strain 
Prophylaxis of 
meningococcal 
disease 
8-12 yrs A-
241 v 
61 
B- 
250 v 
63 
 
New 
Zealand 
9 SAEs ± all judged unrelated 
 
Local rx 
Headache 
  
888335 Indacaterol 400mic OR 
800 mic 
 
Placebo Asthma 12-65 
yrs 
59 v 
59 v 
26 
Belgium 
Canada 
Czech 
Slovakia 
 
5 SAEs- bronchospasm 1v1v0 
-thought related to study drug 
Hyperventilation 
Acute asthma 
Ectopic  
AEs all similar % 
?paed 
888430 Indian Hep B vax 
 
European Hep B vax Prophylaxis of 
hep B 
Infants 180 v 
180 
India SAEs- pneumonia x2 
UTI, bronchiolitis, gastro ±
rated unrelated 
Fever 
888476 Budesonide/formoterol 
 
Salmeterol/fluticasone Uncontrolled 
asthma 
12 
above 
1154 
v 
1155 
17 countries 1 death-severe typhoid fever 
SAEs 3%v3% 
Discont 11v20 
Beta-adr effects 8v1 
 
888507 Human rotavirus vaccine 
 
Placebo Rotavirus 
gastroenteritis 
6-14 
weeks 
2646 
v 
1348 
6 Euro 
countries 
SAEs 11%v13% 
1 intussusception 8 days post 
vaccine 
2 cases 2nd rota season 
Safety data not 
described? 
888582 Combined vax DTPa-
HBV-IPV/Hib 
 
Separate admin Prophylaxis Infants 
11-17 
weeks 
75 v 
75 
Singapore 7 SAEs- bronchitisx2,UTI, 
gastrox2,brochiolitis,head inj 
All rated unrelated 
Pain,redness, 
swelling 
Irritability 
888649 Frozen live att flu vax 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Refrigerated cold-
adapted flu vax 
Prophylaxis of 
influenza 
5-49 yrs 190+
281 v 
186+
285 
US 2 SAEs ± gastro in 24yo and 
lymphadenitis in 7yo ± both 
unrelated 
Disconts x3 
Reactive airway 
disease 
Runny nose and 
cough 
Tooth abscess 
Others: 
Asthma, adhd, 
reactive airway 
disease 
Kidney stones 
Hpt 
Sleep apnoea 
Gallstones,migrain
es 
  
888671 Sulfadoxine-
pyrimethamine 
 
Placebo Intermittent 
preventative 
treatment in 
infancy 
Infants 
from 3 
months 
600 v 
600 
Ghana Deaths 29v30 (all unrelated) 
 
9022 AEs ± GI and 
Resp 
Scabies 
1 child with severe 
rash-poss related 
888702 RTS,S/AS02D malaria 
vax 
 
Hep B vaccine Malaria Infants 107 v 
107 
Mozambique SAEs 31v30 
4 deaths ± septic shock,gastro. 
& dehydration 
Pain,swelling,fever
, loss of 
appetite,drowsines
s ± vaccine related 
sx 
888704 Hep A vax 
 
Immune globulin Prophylaxis 
post exposure 
2-40 yrs 2272 
v  
2252 
Kazakhstan 28 SAEs 25 Hep A, 
appendicitis, rubella, 
bronchitis ± all rated unrelated 
 
888729 Chemo 
(ONCO) 
 
Allogeneic OR 
Autologous stem-cell 
transplantation 
Very high risk 
Acute LL 
Infant-
17 yrs 
38 v 
24 v 
38 
Spain 2 transplantation related 
deaths 
 
?chemo related 
toxicity not 
mentioned 
888737 Combined DTP-IPV 
booster 
 
Separate vax Prophylaxis 4-8 yrs 779 v 
126 
Germany 2 SAEs ± extensive local 
reaction to vax + hospitalised 
2/7 
Forearm fracture 
Local and systemic 
mild vax reactions 
888839 Hep A vax + hexavalent 
combi vax 
 
Hep A vax + separate 
vax 
Prophylaxis Infants 311 
v308 
Belgium & 
Germany 
74 SAEs 36v38 
Gastro, pneumonia, 
bronchiolitis, URTI 
All rated unrelated 
2 SAEs reported: 
Resp apnoea/missed SIDS ±
probably not related 
Serum sickness related to 
amoxiclav acid ±probably not 
related 
Local & systemic 
mild reactions 
Fever  
888855 Peribulbar block OR 
Topical lidocaine  
+ GA 
 
GA alone Paed strabismus 
surgery 
2-13 yrs 15 v 
15 v 
15 
India Ventricular bigeminy 2 pts 
Asystole 1 pts  
All 3 in control group 
Oculocardiac reflex req 
atropine 1v1v3 
 
  
888913 Fully liq vax ±dpt-ipv-
hib 
 
Reconstituted hib with 
dtp-ipv 
Prophylaxis Infants 339 
infant
s 
Canada 1 SAE ± afebrile seizure 3 
occasions-on phenobarb rx 
 
Mild systemic& 
local inj site rx 
888928 Dexa OR glycerol OR 
dexa+glycerol 
 
Placebo Bacterial 
meningitis 
2mo ± 
12 yrs 
12 v 
13 v 
20 v 
13 
India 3 deaths 0v1v1v1 
GI bleed 1v0v1v1 
Neuro+hearing sequelae ±
disease related 
 
888949 New combined DTPw-
HBV vax 
 
Separate vax or 
combined vax 
Prophylaxis Infants Prima
ry 
239 
Boost
er 
215 
Czech 
Slovakia 
10 pts had SAEs 
1 rated related ± gastritis in 
new combi. Grp 
All other SAEs rated unrelated 
Fever 
Drowsiness 
irritability 
888950 Inhaled Zanamivir 
 
Placebo Prophylaxis of 
influenza 
12 yrs 
and 
above 
1678 
v 
1685 
Canada 
Czech 
France 
Germany  
Latvia 
US 
SAEs 17v16 
1 death-MI rated unrelated 
Rated drug related(?)  
Acute asthmatic bronchitis v 2 
in placebo-arrhythmia and 
dyspnoea/cough 
Chest tightness 
2v2 
Mod&severe in rx 
grp 
8881099 Virosome-adjuvanted 
Hep. A vaccine 
(Epaxal) 
0.25ml v 0.5 ml 
Havrix Junior (hep A 
vax) 
Prophylaxis 1-16 
years 
123 v 
123 v 
62 
Belgium SAE 7v3v3 
All rated unrelated 
Fever 
Local inj reaction 
8881104 Hib vax (Hiberix) ±DTP 
 
Hib vax ±DTP OR 
Hib vax ± DTP 
(Tritanrix) 
Prophylaxis 6-12 
week 
120 v 
120 v 
120 
Thailand 8 SAEs- undescribed ± all 
rated unrelated 
Local inj Rx 
Grade 3 fever = all 
groups 
8881141 Morphine iv 
 
Codeine im Intraop 
analgesia for 
cleft palate 
repair 
Infants 
mean = 
7 mo 
22 v 
22 
UK µYRPLWHGEORRG¶[± codeine Morphine 
-vomiting 
-retching 
-facial itching 
8881235 Virosomal hep. A vax 
concomitantly admin. 
with DTPH-IPV-OPV-
MMR 
 
Hep. A vax alone OR 
Alum adjuvanted Hep. 
A vax-DTPH-IPV-
OPV-MMR 
Prophylaxis 12-15 
month 
old 
109 v 
105 v 
108 
Israel 29 SAE-all rated unrelated Fever 
Local inj rx 
  
8881295 IV immune globulin 
IHN-A21 
 
Placebo Prevention of 
Late Onset 
Sepsis in 
VLBW 
neonates 
Prem. 
Neonate
s 
994 v 
989 
US  
Canada 
NEC 
Gastro. Perf 
Retinopathy 
Pneumothorax 
Sepsis 
Hydrocephalus 
Bradycardia 
All = Placebo + rated possibly 
related 2v4 SAEs 
 
8881334 Growth hormone 
 
Untreated (treated 
after 12 months) 
Small for gest. 
Age  
2-5 
years 
39 v 
37 
Spain Fever+convulsions+hosp. 1v1 
Rated unrelated 
All AEs rated 
unrelated 
8881335 Growth hormone Untreated controls Juvenile 
idiopathic 
arthritis 
Pre 
pubertal 
Mean= 
10+/-2 
13v18 Germany Deathx1 ± undescribed No safety section 
Mean obs time=8.4 
years!*** 
8881428 Atomoxetine 
 
Methylphenidate ADHD 6-16 
years 
164 v 
166 
China, 
Korea, 
Mexico 
Simple partial seizure x 1 
 
TEAEs: atx>mph 
Anorexia,nausea,s
omnolence, 
Dizziness,vomiting
: atx>mph p<0.05  
8881448 4 groups 
Choroquine (CQ) 50mg 
v 
Amodiaquine (AQ) 
15mg v 
AQ 30 mg v 
CQ 25 mg 
 
 Uncomplicated 
malaria 
2-177 
months 
184 v 
181 v 
182 v 
182 
Guinea-
Bissau 
2x convulsions ± hospitalised Vomiting 
itching 
8881466 Fluticasone 
 
 
 
 
 
 
Budesonide inh. Growth velocity 
in asthma 
6-9 
years 
114 v 
119 
11 countries SAE 1v4 ± undescribed 
 
Candidiasis 2v1 
  
8881482 Live Att. rotavirus 
vaccine 
 
3 different virus 
concentrations VS 
placebo 
Prophylaxis 6-12 
weeks 
101 v 
101 v 
102 v 
101 
Mexico 2 deaths ± SIDS, Road 
accident 
31 SAEs 
1 intussusception ± rated 
unrelated 
All SAEs rated unrelated 
 
All sx = 3 group = 
PLACEBO 
8881543 P.aeruginosa flagella 
vaccine 
 
Placebo Prophylaxis in 
Cystic Fibrosis 
patients 
2 ± 18 
years 
239 v 
244 
Germany 
France 
Italy 
Austria 
Death x 1 ± rated unrelated 
SAE =5  
1 definite related ± pers. 
Severe pain 
4 no/improbable 
- atelectasis 
-epilepsy 
- Acute L. leukaemia 
- meningitis 
Local inj. Sx 
Fever 
Nausea 
Headache 
8881694 MMRV vax co-admin 
with 
DPTH  
 
MMRV alone OR 
DPTH alone 
Prophylaxis 12-23 
months 
150 v 
150 v 
150 
Germany 11 SAEs- all rated unrelated 
Febrile convulsionx1- 
unrelated 
Fever No diff 
Rash No diff 
Parotid gland 
swelling ± not 
mumps 
Local inj. sx 
8881735 Attenuated Flu vax 
 
Placebo Prophylaxis 12-<36 
months  
1653 
v 
1111 
8 Asian 
countries 
2 deaths ± unknown cause 
(placebo), drowning 
Bronchospasm 7 v 3 
Bronchitis 3v2 
Rhinitis 3v0 
Discont ± 1 
persistent fever 
Fever > in vax 
Local inj. Sx 
8881788 HPV vaccine 
 
 
 
 
 
 
 
Hep A vax Prophylaxis 15-25 
years 
9319 
v 
9325 
14 countries 5 deaths ± all unrelated 
SAEs related to infectious 
events and abnormal preg. 
Outcomes (no sig. diff) 
Local inj. Sx 
  
8881837 Low-dose 
hydrocortisone 
 
Placebo Prevention of 
chronic lung 
disease in 
preterms 
Preterms 
24-30 
weeks 
25 v 
25 
Italy Death 4v10 p<0.05 
GI perf. 2v1, HPT, 
hyperglycaemia, 
Hyperkalaemia, 
Sepsis, fungal inf. All Non-
sig. 
 
***STOPPED BY 
SAFETY COMT 
± RISK OF GI 
PERF*** 
8881847 Artemether-lumefantrine 
 
Dihydroartemisin-
piperaquine 
Malaria 6 
months- 
10 years 
256 v 
253 
Uganda SAE = 6 
3 x febrile convulsion 
1 AOM, 1 asthma, 1 
pyomyositis 
All rated unrelated 
Malaria sx 
8881944 Fridge-stable 
MMR+Varicella vax 
 
Frozen formulation 
vax 
Prophylaxis 12-23 
months 
1006 
v 513 
US 
Sweden 
7 v 2 
RSV infection,pneumonia, 
dehydration, pharyngitis, 
gastro, accidental exposure  
Gastro, pneumonia, 
neuroblastoma 
 
Insomnia/dermatiti
s> in fridge 
Viral URTI < in 
fridge 
Fever 
Local inj sx 
8881965 Topical Vitamin E  
 
Placebo Prophylaxis for 
chemo-induced 
oral mucositis 
(N-of-1 trial) 
6.4-15.1 
years 
16 
kids 
45 
cycles 
22v23 
Canada 2xBacteraemia ±both placebo ***N-OF-1*** 
8882011 Beclomethasone aerosol  
 
Fluticasone inh Asthma 5-12 
years 
139 v 
141 
Belgium, 
Netherlands, 
UK 
Severe stomatitis - unrelated 
Arm fracture ± unrelated 
 
Dysphonia 
coughing 
8882072 Pneumovax booster at 15 
mo 
At 18 mo Prophylaxis 12-15 
months 
168 v 
167 
Canada SAEs = 4, not mentioned Local inj sx 
8882108 Cyclophosphamide + 
antithymocyte globulin 
 
 
 
 
Cyclo alone Conditioning 
regimen for 
bone marrow 
transplant 
***chemo*** 
<10-60 
years 
70 v 
60 
US, Swiss, 
France 
Graft-v-host disease (Rx 
failure?) 
Infections-55/68v40/60 p=.07 
Deaths-no sig diff 
***CHEMO*** 
  
8882114 Quadrivalent HPV vax  
 
Placebo Prophylaxis 16-24 
years 
2723 
v 
2732 
16 countries SAEs 48v45 ± no sig diff 
Bronchospasm Rx-related 
 
Local inj sx 
*SAEs in supp 
table 
8882120 Hib-MenC-TT vax 
(novel) 
 
 
3 other formulations + 
1 control group 
Prophylaxis Infants 
8-16 
weeks 
102 v 
104 v 
101 v 
104 v 
109 
Germany No deaths  
13 SAEs- all unrelated 
Local inj sx 
8882123 Sildenafil 
 
No treatment Pulm Hpt after 
congenital heart 
surgery 
1-16 
years 
20 vs 
22 
Iran Postop complications 
Haemothorax,pneumonia,pleu
ral eff.,gastric 
haemorrhage,aborted cardiac 
arrest+pulm. Hpt crisis 
Erections 
Nasal stuffiness 
GI upset 
8882193 Erythromycin 
 
Placebo Parenteral 
nutrition-assoc 
cholestasis 
Preterms 91 vs 
91 
Hong Kong Death 2v4 (2v4%) 
NEC 0v1 
Sepsis 9v11 
 
8882342 Inactivated Polio 
Vaccine 
(together with DTPHib) 
No treatment Prophylaxis Full 
term 
infants 
82 vs 
84 
Cuba Transient hypotonia 
Persistent crying x5 
Substantial 
attrition due to 
hypotonia 
8882343 Budesonide/formoterol Salmeterol/fluticasone 
fixed dose 
Budesonide/formo. 
Fixed maintenance 
dose 
Asthma 12 
above 
1107 
vs 
1123 
vs 
1105 
16 countries 2 deaths ± resp.failure,cardiac 
failure ± unrelated 
4 SAEs ± 
pneumonia,gastritis,asthma 
asthma 
URT sx 
?paed 
8882412 Malaria vaccine 
RTS S/ASO2A 
 
Malaria vaccine 
RTS S/ASO2D 
Malaria 3-5 
years 
100 
vs 
100 
Mozambique 11SAEs ±all unrelated 
1 death due to AIDS 
 
8882418 Propofol-remifentanil 
 
Sevoflurane-fentanyl Anaesthesia 4-6 
month 
17 vs 
22 
Denmark 2nd op due to bleeding  
8882448 Tick-borne encephalitis 
vaccine 
 
 
 
 
3 schedules Prophylaxis of 
TBE 
1-11 
years 
82 vs 
73  vs 
139 
Germany 
Hungary 
25 SAEs ± all unrelated Arthralgia 
Nausea 
Fever 
  
8882502 Ketamine (iv ketamine 
through surg, iv 
ketamine end of surgery) 
 
placebo Preventive 
analgesia during 
tonsillectomy 
5-15 
years 
30 vs 
30 vs 
30 
Turkey Resp distress re:postop 
bleeding 
1v3 
 
Erythema in 
ketamine p=.045 
Emesis p=.06 
8882546 Hep B vax 
2-dose 
 
Hep B vax 
3-dose 
Prophylaxis 11-15 
years 
258 v 
126 
Australia 
Belgium 
Ukraine 
4v1 
Septic 
arth./fracture/Crohns/RTA/den
tal surg 
All unrelated 
General + inj site 
8882568 Rotavirus vaccine 
 
Placebo Prophylaxis  
(gastro) 
6-12 
weeks 
old 
651 
vs 
661 
US 
Finland 
1 death Rx group ± SIDS 
SAEs 21vs27 
*fever 2v0 
*pneumo 3v1  
No intussusception 
8882641 HPV vaccine Placebo Prophylaxis 9-15 
years 
1184 
vs 
597 
10 countries 5v0-all rated unrelated 
ARF,type 1 
DM,infection,anaemia, 
Appendicitis 
Discont. 2v0 
Inj. Site sx 
8882686 Tetracaine 4% gel 
 
Placebo Venepuncture 
pain 
Infants 
Incl 
preterms 
71 vs 
71 
Canada 1 death ± placebo NEC 
 
Erythema 7v4 
8882699 DTPPolioHib liquid 
 
 
 
DTPPolio at different 
sites (IM) 
Prophylaxis Infants 2 
months 
above 
100 
vs 
100  
Taiwan 13v8 
All unrelated 
No withdrawals 
 
8882748 Adapalene gel 0.1% 
 
 
 
 
 
 
 
 
 
 
Placebo vehicle Acne 12-30 
years 
73 vs 
63 
Europe Wisdom teeth extraction Local reactions 
2 discont 
Skin infection 
Erythema+desqua
mation 
  
8882755 Live attenuated flu vax 
 
Inactivated flu vax Prophylaxis 6-59 
months 
4179 
vs 
4173 
US 136v128 
Death 1v1: 
Foreign body aspiration 
House fire 
Live-vax: 
Bronchiolitis x2 
Asthma 
Wheezing 
Gastro 
Inactivated vax: 
Pneumonia 
Wheezing 
Febrile convulsion+pneumo 
Viral gastro 
No difference in 
hospitalisation rate 
8882867 DTPH + polio + 
pneumo. + Hib vaccine 
 
Same vax but 
separately 
Prophylaxis 6-12 
weeks 
667 
vs 
333 
US 23 vs 16 SAEs 
Fever+hospitalisation 
All unrelated 
 
8883021 Growth hormone 
 
No treatment Short stature 3-12.3 
years 
27 vs 
25 
US Scoliosis x2 
Clavicle fracture 
? group 
Arthralgia 3v2 
Gyneco 1v0 
Cutaneous nevi 
2v0 
OM 1v1 
Scoliosis 1v0 
8883033 Deferasirox Deferoxamine Transfusional 
iron overload 
with sickle cell 
disease 
3-54 
years 
132 
vs 63 
US 46.2%v42.9% 
Sickle cell anaemia with crisis 
33.3%vs31.7% 
 
Elevated ALT 5v0 
8883073 Malaria vaccine 
 
 
 
 
 
 
 
Hep B vaccine Malaria 
prophylaxis 
1-4 
years 
30 vs 
30 
Mozambique 2v2 
Malaria+febrile convulsion 
Bronchopneumonia 
Glomerulonephritis 
All full recovery 
Elevated ALT due 
to hepatitis A 
  
8883098 DPT vaccine 
Adolescent-adult 
formulation 
 
DPT vaccine 
Paed. formulation 
Prophylaxis 
DPT 
4-<7 
years 
299 
vs 
294 
Canada 1 SAE ± circumsicion for 
phimosis 
Local + fever 
*Where available, group nos. follow group description order 
 
